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Abstract 
 
Penile cancer is a rare urogenital malignancy associated with an unusual geographical 
variability. Unifying hypotheses to explain this diversity include variations in human 
papilloma virus (HPV) infection and distinct socioeconomic influences. However, our 
understanding of the molecular drivers for penile carcinogenesis remains deficient. 
Furthermore, current prognostic and predictive tools for the clinical management of 
men with penile cancer have limited discriminatory roles. Radical surgery remains the 
cornerstone of treatment and effective adjuvant treatments are lacking.  Despite 
improvements in surgical techniques and diagnostic methods, clinical outcomes 
appear to have plateaued in recent times. The DNA replication licensing factors are 
important cell cycle regulatory proteins which are showing promise as novel 
biomarkers and therapeutic targets in a broad range of tumour types. It may be 
possible to exploit the unique properties of the replication licensing system; as a relay 
station for upstream, signalling pathways, in order to develop utilitarian biomarkers 
and therapeutic targets for managing men with PeScc. 
 
In this thesis, I show that there is aberrant regulation of the DNA replication licensing 
system in PeScc. Importantly, I demonstrate that the dysregulation of these molecules 
is associated with aggressive, genomically unstable tumour phenotypes, which in turn 
translates into important prognostic information with regards to patient survival. 
Furthermore, I have shown that multiparameter expression analysis of these proteins 
allows assessment of cell cycle kinetics in individual pathological specimens, 
parameters linked to the biological behaviour of these tumours. This novel form of 
cell cycle biomarker analysis may also be of value as a predictive test for assessing  
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the therapeutic effect of cell cycle phase specific anti-cancer agents or mechanistic 
drugs targeting the cell cycle machinery. Collectively, these studies highlight the 
prognostic, predictive and therapeutic utility of the DNA replication licensing system 
in PeScc. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.1. Purpose and Objectives of the Thesis 
Penile cancer is a rare urogenital malignancy with significant geographical variation 
and indeterminate aetiological factors (Daling et al. 2005; Barnholtz-Sloan et al. 
2007; Curado et al. 2007). Current prognostic and predictive tools for the clinical 
management of men with penile cancer have limited discriminatory roles and radical 
surgery remains the cornerstone of treatment (Pizzocaro et al. 2010).  The molecular 
mechanisms underpinning tumourigenesis and disease progression in penile cancer 
remain poorly understood (Muneer et al. 2009). Recent research in this area has 
focused on understanding the relationship between human papilloma virus (HPV) 
infection and tumour formation. However, this association is not absolute and other 
factors appear to be implicated. Despite improvements in surgical techniques and 
diagnostic methods, clinical outcomes in this difficult patient cohort have reached a 
plateau in recent times (Verhoeven et al. 2013; Djajadiningrat et al. 2013).  
 
The efficacy of DNA replication licensing factors (RLFs) as novel biomarkers of 
diagnosis and prognosis has been described in various different cancer types (Blow 
and Hodgson 2002; Gonzalez et al. 2005; Laskey 2005; Blow and Gillespie 2008; 
Jackson, Laskey, and Coleman 2013).  I have sought to investigate the role of these 
important effectors of cellular proliferation and differentiation in men with penile 
carcinoma (PeScc). Additionally, I examine how the dysregulation of these proteins 
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may contribute to the initiation and progression of this heterogeneous and complex 
malignancy. In Chapter 3, I investigate the histopathological patterns and 
clinicopathological features observed in men with penile cancer. Additionally, I 
correlate these data with tumour DNA content as a marker of genomic instability and 
assess the role of aneuploidy as a novel prognostic marker. In Chapter 4, using in 
vitro and in vivo model systems, I investigate the involvement of these cell cycle 
regulators in the transition from benign to malignant penile tissue. Furthermore, I 
investigate the multiparameter analysis of RLF expression to investigate the cell cycle 
kinetics of individual tumour specimens including penile squamous cell carcinoma 
subtypes. In Chapter 5, I show that the RLFs are intricately linked to the development 
of cell cycle dysregulation, genomic instability and the progression from indolent to 
aggressive phenotypes. Extending on these studies, in Chapter 6, I explore how the 
biological dysregulation of these G1/S regulatory proteins alongside aneuploidy 
impact on prognosis and survival in men with penile cancer.  
 
1.2. Somatic Tissue Systems 
1.2.1. Proliferative states define cellular sub-classes 
Development and maintenance of human tissues in multicellular organisms requires 
precise spatial and temporal control of cellular proliferation. The major role of cell 
division in adult life
 
is to maintain the number of differentiated, functional cells; 
thereby
 
replacing cells that are lost through death or injury. Normal somatic tissue 
types can be broadly subdivided into three classes based on their growth control 
strategies and their ability to respond to mitogenic stimuli. These groups are defined 
as: self-renewing, stable and permanent tissues (Hall and Watt 1989; Potten and 
Loeffler 1990; Stoeber et al. 2001). The ability to arrest growth in quiescence, 
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differentiation and senescence reflects fundamental growth regulatory mechanisms 
that operate stringently in untransformed cells but are defective in tumour cells. In 
stable tissues such as thyroid and liver, all cells are differentiated but retain the ability 
to re-enter the cell division cycle in response to mitogenic cues (“dormant growth 
potential”). In contrast permanent tissues (e.g. neurones, cardiac myocytes) have no 
reserve capacity for growth in adult life  (Leblond 1964). Tissues with the most rapid 
cellular turnover are referred to as self-renewing
 
systems and include: skin, gut, testis 
and the haemopoietic system.
 
These tissues share similar hierarchies of cellular 
development,
 
from stem cells to terminally differentiated mature cells via
 
transit 
amplifying cells (Figure 1.1) (Myster and Duronio 2000; Watt and Hogan 2000). 
Although the general scheme of cellular hierarchies is similar
 
for self-renewing 
systems, differences are observed between
 
those of somatic and germ cell type. In 
somatic self-renewing
 
systems such as skin and gut, cell production occurs in the
 
basal 
proliferative compartment through mitotic cell divisions
 
with migration and 
differentiation of post-mitotic cells into
 
the luminal compartment (Figure 1.2) (Potten 
and Loeffler 1990; Watt and Hogan 2000). In testis, a more complex cellular 
hierarchy is found. Germ
 
cell development occurs in successive mitotic, meiotic and 
post-meiotic
 
phases with germ cells moving from the basal compartment to
 
the lumen 
of seminiferous tubules as cells engage their differentiation
 
programme 
(spermatogenesis) (Potten 1986). 
 
Neoplasia is regarded as disorder of cell growth and its origin is considered to result 
from somatic mutations and clonal selection, with successive collection of cells 
conferring growth advantages (Hanahan and Weinberg 2000). However, tumours can 
demonstrate variations in their patterns of growth and degree of differentiation. They 
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may arise from undifferentiated stem cells or from fully differentiated cells and can 
vary widely in their biological behaviour. It can therefore be postulated that 
abrogation of growth control  
mechanisms in tumours derived from undifferentiated stem-like cells is likely to be 
different from deregulation in tumours derived from stable tissues. Squamous 
epithelium 
appears to represent an appropriate “model system” to investigate tumour progression 
in self-renewing tissues. The specific attributes unique to penile squamous epithelium 
is introduced in more detail in section 1.5.1. 
 
1.2.2. Epidermal organisation and hierarchy 
Epithelial cells show specialised function and a capacity of self-renewal from their 
stem cell population and are organised into multi-layered structures such as the 
stratified epidermis, oesophagus, cervix and the lining of the mouth (Underwood 
J.C.E 1996). It is this organisation that is integral to their function as a protective 
interface between internal and external environments. The proliferative cells, 
including the stem cells that are ultimately responsible for renewing the epithelium, 
are anchored to an underlying basement membrane (Watt 1984). Cells that become 
committed to undergoing terminal differentiation, withdraw from the cell cycle, 
detach from the base membrane and move into the suprabasal layers. The epithelium 
of skin epidermis has a characteristic stratified appearance with keratinisation. As 
cells ascend from basal to apical regions, traversing the trans-amplification 
compartment, they undergo a progressive series of changes acquiring the 
characteristics that are required for their protective role (Figure 1.3). 
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Figure 1.1 
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Figure 1.2 
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Figure 1.3 
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Thus, it has been proposed that strict spatial correlation with regards to the basement 
membrane and also the solar polarity are key determinants in normal differentiation 
programs (Watt 2002). A continued, self-renewal of the cell population is essential as 
terminally differentiated cells eventually die and are shed from the outer surface. It 
has been proposed that epidermal turnover can be achieved over a 60 day period 
(Mackenzie 1997; Barthel and Aberdam 2005; Morasso and Tomic-Canic 2005). 
 
1.2.3. Squamous epithelium: steps to carcinogenesis 
1.2.3.1. Normal 
Cellular proliferation and differentiation are under the influence and control of 
numerous local factors linked to mitogenic signalling pathways. These pathways are 
crucial in normal tissue repair processes and often malfunction in carcinogenesis.  
 
Histologically, the differentiation process has defined three important layers within 
the epidermis (Underwood J.C.E 1996). Stratum basale is the lowest layer and 
contains the proliferative stem cell compartment. The cells located in the middle third 
of the epidermis, are recognisable squamous cells (keratinocytes) and are held 
together by desmosomes. Shrinkage of the cell and the presence of desmosomal 
bridges draw out small spines of cytoplasm from these cells giving them a typical 
prickle appearance from which they derive their name of stratum spinosum. During 
further migration towards the apical zone, these cells become simplified and 
metabolism becomes totally directed to producing the components of an eventually 
horny layer. The stratum corneum contains dead cells and leaves a highly structured 
keratin layer behind. Models have been developed describing the multistep  
progression from normal epithelium to malignancy through know intermediary steps 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  37                                                                          
 
(Chisholm and Greene, Jr. 2011). These processes will be discussed further and the 
potential intermediary conditions highlighted. 
 
1.2.3.2. Benign papilloma and squamous hyperplasia 
A papilloma is defined as a benign tumour of non-glandular or non-secretory 
epithelium typified by squamous epithelium. The development of papillomas has been 
clearly described in other tumour types such colorectal cancer (Vogelstein and 
Kinzler 2004). Human papilloma virus (HPV) infection plays an important role in 
initiation of cutaneous malignancies and is detailed in section 1.5.4. Squamous cell 
hyperplasia is characterised by microscopic findings consisting of elongation, 
widening of the rete ridges and irregular thickening of the Malpighian layer of rete 
ridges (acanthosis), hyperkeratosis and chronic inflammation in the dermis. 
Parakeratosis may also be present. Inflammatory reactions within the dermis consist 
of lymphocytes and a small number of plasma cells.  A number of premalignant 
penile dermatoses may reside under this umbrella term including: male genital lichen 
sclerosus et atrophicus (MGLS), penile cutaneous horn, leukoplakia, and 
pseudoepitheliomatous, keratotic and micaceous balanitis (PKMB) (Kayes, Shabbir, 
and Minhas 2012). 
 
1.2.3.3. Dysplasia 
Dysplasia can be defined as an observable expansion of immature cells in conjunction 
with a decrease in the number and location of mature cells. Dysplasia is often 
indicative of an early neoplastic process. The term dysplasia is typically used when 
the cellular abnormality is restricted to the originating tissue, as in the case of an early 
in-situ neoplasm. Dysplasia, in which cell maturation and differentiation are delayed, 
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can be contrasted with metaplasia, in which cells of one mature, differentiated type 
are replaced by cells of another mature, differentiated type (Underwood J.C.E 1996). 
Carcinoma in situ (Cis) represents a high grade dysplasia exhibiting all the features 
associated with malignancy but without evidence of invasion. Clinical examples 
which represent high risk premalignant, penile conditions include: Erythroplasia of 
Queyrat (EQ), Bowen’s disease (BD) and Bowenoid Papulosis (BP) (Kayes, Shabbir, 
and Minhas 2012). 
 
1.2.3.4. Squamous cell carcinoma  
Squamous cell carcinomas are very common epithelial tumours with variable 
aetiological heritage. These tumours are characterised by focal or extensive loss of the 
basement membrane, an increased number of proliferating cells and a reduced number 
of cells that undergo terminal differentiation. In addition, the spatial organisation of 
cells is disrupted, leading to a loss of the normal multi-layered epidermal structure 
(Underwood J.C.E 1996). These disorganised keratinocytes demonstrate typical 
malignant cytology and also show foci of keratinisation within the tumour. The 
degree of keratinisation is utilised to define the level of differentiation demonstrated 
by these tumours, with well differentiated tumours expressing a greater proportion of 
keratin [Broder’s grading system] (Broders AC. 1921). Integrin expression is often 
altered with focal, extensive integrin loss; especially with regards to basement 
membrane proteins and has been linked to metastatic capabilities (Janes and Watt 
2006). Tumour progression often involves spread to locoregional lymph nodes and 
distant metastases can occur.  
 
  
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  39                                                                          
 
1.3. Cell Cycle Machinery 
1.3.1. Cell cycle: Checkpoints, coordination and control 
The cell cycle control system is the regulatory network that controls the order and 
timing of cell cycle events. The cell cycle consists of four coordinated processes: cell 
growth, DNA replication, distribution of the duplicated chromosomes to daughter 
cells and cell division. The process is essential to the survival and continuing viability 
of all cells. Regulatory factors ensure a tight control and coordination of the distinct 
phases of the cell cycle resulting in the accurate passage of the genome to daughter 
progenies (Underwood J.C.E 1996). Mitosis is the most dramatic stage of the cell 
cycle, corresponding to the separation of daughter chromosomes and resulting in 
cytokinesis. However, mitosis and cytokinesis last approximately one hour; thus 95% 
of the cell cycle is spent in interphase. At the molecular level, interphase is the time 
during which the cell cycle machinery undertakes the enormous task of duplicating 
each of the 3.2 billion base pairs that constitute its DNA (Alberts B, Johnson A, and 
Lewis J 2002).  
 
The cell cycle is divided into four stages: G1, S, G2 and M phases. Cells initially 
begin cycling in the G1 phase, either directly from the M phase of a previous round of 
replication or from a state of quiescence (G0). G0 cells are metabolically active, 
although they cease to grow and have reduced rates of protein synthesis. Cycling cells 
have to pass through important regulatory checkpoints that ensure the successful 
completion of one stage of the cell cycle before being allowed to proceed to the next 
stage (Hartwell and Weinert 1989; Morgan 1997). The central components acting as 
biochemical switches driving phase to phase transition are the cyclin-dependent 
kinases (CDKs) (Nurse 2002). The duration of these cell cycle phases varies 
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considerably in different cell types.  However, for a standard adult mammalian cell, 
the lengths of S-G2-M phases are relatively fixed with the greatest variability in 
periodicity observed during G1 phase. Due to physiological stresses and/or mitogenic 
cues, this stage of cell cycle can last a few minutes or as long as a few days.  
 
A system of checkpoints and feedback controls are crucial in controlling the passage 
of cells through the cell cycle, maintaining high fidelity whilst stabilising replication 
forks and preventing cell cycle progression during replication stress or damage. The 
molecules which govern the G1/S and G2/M transitions are of crucial importance in 
dictating transit through the cell cycle and in preserving genomic integrity.  
Oscillations in the activity of critical ‘cyclin-CDK’ complexes at specific times during 
the cell cycle, govern the progression of cells through each stage (Hartwell and 
Weinert 1989; Morgan 1997). This process ensures that the cell cycle machinery is 
appropriately prepared for the next stage of the cell cycle. The precise timing of 
changes in CDK activity is overseen by multiple mechanisms. Fluctuation in the 
concentrations of corresponding regulatory cyclins is particularly important and is 
achieved through changes in cyclin gene expression and rates of cyclin degradation. 
Further modulation is achieved through the involvement of CDK inhibitory proteins. 
Cyclin D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 drive G1 progression through 
the restriction point (R), which commits the cell to complete the cycle (Planas-Silva 
and Weinberg 1997). S phase is initiated by cyclin A-CDK2, and cyclin B-CDK1 
regulates progression through G2 and entry into mitosis (Nigg 2001). Progression 
through each cell cycle phase and transition from one phase to the next are monitored 
by sensor mechanisms, called checkpoints, which maintain the correct order of events. 
If the sensor mechanisms detect aberrant or incomplete cell cycle events (e.g. DNA 
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damage), checkpoint pathways carry the signal to effectors that can trigger cell cycle 
arrest until the problem is resolved. 
The G1/S, S and M phase specific CDKs are inactive in G1, ensuring that cell cycle 
events are not triggered inappropriately before the cell commits to a new round of 
replication. In particular, a decision point in late G1 (restriction point [‘R’]) defines a 
temporal marker when the cell is committed to proceed through S phase and the rest 
of the cell cycle, even in the absence of further growth factor stimulation (Sclafani 
and Holzen 2007). Induction of molecules controlling this checkpoint is determined 
by increased gene expression through the E2F family of transcription factors. E2F 
function itself is regulated by the inhibitory retinoblastoma (Rb) pathway (Fang and 
Han 2006; Giacinti and Giordano 2006). The G1/S checkpoint defines a temporal 
marker for the cell to determine whether it should: divide, delay division or enter a 
resting stage (G0). For example, G1 arrest can be induced through the action of the 
Ink4 family [INK4A (p16), INK4B (p15), INK4C (p18) and INK4D (p19)] of CDKIs, 
which inhibit CDK4 and CDK6, or, alternatively, via the Cip/Kip family of inhibitors 
(p21, p27, p57), which suppress CDK2 activity (Malumbres and Barbacid 2009).This 
represents a fraction of the signalling pathways involved in cell cycle progression but 
highlight the complexity of the system identified to date.  
These cellular control concepts are clearly illustrated in the elegant cell fusion 
experiments of Rao and Johnson in the 1970s, which provide insight into how cells 
maintain genomic stability with repeated rounds of replication (Rao and Johnson, 
1970). When a G1 nucleus is fused to an S phase cell, the G1 nucleus begins to 
replicate prematurely. Therefore, a G1 nucleus is competent to replicate but lacks 
factors present in S phase that are necessary for DNA synthesis initiation. However, 
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delivering these factors to a G2 nucleus by fusing S and G2 phase cells fails to 
instigate replication in the G2 nucleus; indicating that the cell has some means of 
differentiating between replicated and unreplicated DNA. These observations have led 
to the concept of DNA replication licensing (Nishitani and Lygerou 2002; Blow and 
Hodgson 2002) and will be expanded on in the succeeding section.  
Several other cell cycle checkpoints function to ensure that incomplete or damaged 
chromosomes are not replicated and passed on to daughter cells. One of the most 
clearly defined of these checkpoints occurs in G2 and prevents the initiation of 
mitosis until DNA replication is completed (Foijer and Te 2006; Hook, Lin, and Dutta 
2007). This G2 checkpoint senses unreplicated DNA, which generates a signal that 
leads to cell cycle arrest. Progression through the cell cycle is also arrested at the G2 
checkpoint in response to DNA damage, such as that resulting from irradiation. This 
arrest allows time for the damage to be repaired, rather than being passed on to 
daughter cells. DNA damage not only arrests the cell cycle in G2, but also slows the 
progression of cells through S phase and arrests cell cycle progression at a checkpoint 
in G1. This G1 arrest may allow repair of the damage to take place before the cell 
enters S phase, where the damaged DNA would be replicated. In mammalian cells, 
arrest at the G1 checkpoint is mediated through p53 pathways, which is rapidly 
induced in response to damaged DNA (Sancar et al. 2004). Finally, a third important 
cell cycle checkpoint that maintains the integrity of the genome occurs toward the end 
of mitosis. This checkpoint monitors the alignment of chromosomes on the mitotic 
spindle, thus ensuring that a complete set of chromosomes is distributed accurately to 
the daughter cells (Musacchio and Salmon 2007). For example, the failure of one or 
more chromosomes to align properly on the spindle causes mitosis to arrest at 
metaphase prior to the segregation of the newly replicated chromosomes to daughter 
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nuclei. As a result of this checkpoint, the chromosomes do not separate until a 
complete complement of chromosomes has been organized for distribution to each 
daughter cell. Degradation of cyclin B up-regulates the anaphase-promoting complex 
(APC), leading to the breakdown of securin. Degradation via ubiquitination and 
subsequent proteolysis allows separase to separate sister chromatids. Other factors 
such as the mitotic engine kinases Plk 1, Aurora A and Aurora B are important factors 
in successful mitosis, controlling centrosome maturation and separation, chromosome 
orientation and segregation. (Hook, Lin, and Dutta 2007; Rieder 2011). 
This brief overview of the mechanistic components both driving and regulating cell 
cycle progression in normal somatic cells permits insight into the potential steps in 
normal cell growth and division; which, when dysregulated, may result in genomic 
instability and tumuorigenesis. These areas will be reviewed in more detail in later 
sections and the current understanding of the molecular events driving carcinogenesis 
in PeScc explored. 
1.3.2. Cell cycle: Cancer 
Cancer is a disease in which cells no longer respond to the usual social signals that 
govern their behaviour in a tissue. This results in a new balance between the 
proliferation and survival of these cells, determined by alterations in mitogenic and 
apoptotic regulatory pathways. Tumour evolution is driven by the gradual 
accumulation of genetic mutations as a result of natural errors in the duplication, 
repair or segregation of DNA and chromosomes (Hanahan and Weinberg 2000; 
Hanahan and Weinberg 2011). However, the rate of spontaneous mutation in most 
human cells is insufficient to produce a large number of defects required for 
progression to malignant cancer. Therefore, tumourigenesis is thought to depend on 
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the acquisition of genetic instability: an increase in the rate at which genes and 
chromosomes are mutated, lost, amplified or re-arranged. This cellular phenotype will 
permit a significant growth and survival advantage over neighbouring somatic cells 
(Rajagopalan and Lengauer 2004; Storchova and Pellman 2004). 
 
The cytogenic hallmarks of neoplastic change include: increased number of cells, 
abnormal cell size/shape, unusual cellular arrangement, increased nuclear content, 
abnormal chromosomes and mitotic figures.  It is proposed that tumours escaping 
normal growth restraints and entering a hyperproliferative state with clonal expansion 
of neoplastic cellular populations, will do so through a multi-step process, whereby 
cells acquire numerous genetic mutations (Nowell 1976). Ultimately, the timing and 
combination of these defects in pathway regulation and gene expression can differ 
between tumour types. Colorectal cancer is a well-studied model for tumourigenesis 
that supports this hypothesis (Fearon and Vogelstein 1990; Jass 2006) and can be 
defined by a three step process: initiation, promotion and progression. Each stage 
reflects changes in either early or late molecular events which drive tumours to grow 
and spread. These events include: altered oncogene and tumour suppressor gene 
expression, epigenetic events, point mutations, checkpoint dysfunction, chromosomal 
abnormalities and telomere shortening. 
 
Defects in mitogenic signalling lie at the heart of uncontrolled proliferation of tumour 
cells, through the activation of G1 and G1/S CDKs that drive entry into the cell cycle. 
Dominant oncogene mutations have been identified at nearly every step in these 
pathways in cancer cells. These steps include mutations in genes for mitogens 
establishing autocrine signalling pathways, cell surface receptors, downstream 
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effector molecules (i.e. Ras within the MAP kinase pathway) and transcriptional 
regulators (myc, E2F) (Massague 2004; Vogelstein and Kinzler 2004). Deregulation 
of the cell cycle engine underlies the uncontrolled cell proliferation that characterizes 
the malignant phenotype. Mitogens release the brakes of cell cycle progression by 
stimulating G1–S CDK activities, which trigger the phosphorylation of pRB proteins, 
leading to disruption of their interaction with the E2F family of transcription factors. 
In cancer cells, the pRB brakes are often defective, resulting in E2F dependent G1–S 
gene expression even in the absence of mitogens. This may arise as a result of 
activating tumourigenic mutations which have been identified in diverse tumours at 
all levels in the mitogenic signalling pathways from ligands and receptors (e.g. 
HER2/ErbB2/neu receptor mutations or HER2 gene amplification) to downstream 
signalling networks (e.g. Ras–Raf–MAPK or PI3K–Akt signalling pathways) and also 
for the cell cycle-regulated genes themselves (e.g. CYCLIND1 and CDK4 gene 
amplification) (Huang et al. 2002; Freier et al. 2003; Zhang, Yang, and Gray 2009). 
Aberrant signalling promotes activation of CDK–cyclin complexes, which 
phosphorylate Rb and attenuate its capacity to induce transcriptional repression. The 
notion that Rb phosphorylation is a convergence point for these oncogenic signalling 
pathways is consistent with the fact that inactivation of the RB gene by mutation or 
methylation is a common occurrence in cancer (Malumbres and Barbacid 2001). The 
inactivation of tumour suppressor genes that encode CDKIs (e.g. p15, p16 and p27) 
are also common events in diverse tumour types. This releases the brakes on cell 
cycle progression and further abrogation of checkpoint control mechanisms leads to 
the acquisition of genomic instability which drives tumour evolution (Malumbres and 
Barbacid 2001).  
 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  46                                                                          
 
Genomic instability is defined by the loss of DNA repair mechanisms, chromosome 
instability (numerical and structural) and micro-satellite instability (MSI). It is 
imperative in normal, cycling cells undergoing DNA synthesis that tight control exists 
to ensure that re-replication of the genome does not occur. It is well understood that 
the CDK activity is central to this process (Storchova and Pellman 2004). Aneuploidy 
is a common finding in tumour cells and represents one of the hallmarks of cancer 
development. Whether aneuploidy is a ‘cause or consequence’ of cancer remains to be 
elucidated (Weaver and Cleveland 2007); however chromosomal instability can result 
through numerous aberrant mechanisms.  Defective DNA damage response systems 
are central to the development of chromosomal instability, through large losses, 
amplifications or exchange of chromosomal segments. This is thought to occur as a 
result of abnormal mitosis or cytokinesis checkpoints leading to structural changes in 
parent DNA being passed to daughter cells (Kops, Weaver, and Cleveland 2005). 
Alternative mechanisms, resulting in imbalanced duplication of DNA, also include 
over-replication of single stranded DNA segments during S-phase (Hook, Lin, and 
Dutta 2007) and degeneration in telomere length and function in the presence of 
defective DNA damage repair systems (ATM/p53 and Akt/Bcl-2) (Feldser, Hackett, 
and Greider 2003).  The key role of DNA replication licensing and the coordinated 
process of DNA replication in maintaining genomic stability will be discussed in the 
next section. 
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1.4. The DNA Replication Licensing Pathway 
1.4.1. Background 
The error-free duplication of the entire human genome, alongside its stable 
maintenance, is fundamental for normal cellular proliferation and survival. For this to 
occur, mammalian systems have developed a series of highly coordinated cellular 
pathways which behave in a strictly monitored fashion in order to regulate DNA 
replication. The initiation of DNA replication is a crucial decision point; lying at a 
convergent target of all mitogenic signalling transduction pathways that drive 
proliferation (Figure 1.4). In this respect, the DNA replication licensing pathway can 
be regarded as a “relay station” providing a molecular switch to couple growth 
regulatory pathways with the initiation of chromosomal replication (Stoeber et al. 
2001; Blow and Hodgson 2002; Bell and Dutta 2002; Gonzalez et al. 2005; Barry and 
Bell 2006; Blow and Gillespie 2008). Furthermore, the dysregulation of this intricate 
replication apparatus has been shown to be linked to the development and progression 
of a diverse range of tumour states (Freeman et al. 1999; Meng et al. 2001; Stoeber et 
al. 2002a; Going et al. 2002; Gonzalez et al. 2003; Chatrath et al. 2003; Williams et 
al. 2004; Wharton et al. 2004; Shetty et al. 2005; Dudderidge et al. 2005; Obermann 
et al. 2005; Mehrotra et al. 2006; Scott et al. 2006; Kulkarni et al. 2007; Dudderidge 
et al. 2007; Mukherjee et al. 2007; Scarpini et al. 2008; Saeb-Parsy et al. 2012). 
 
The current understanding of the molecular mechanisms involved in carcinogenesis 
includes a variety of mutations in key signalling pathways through mechanisms 
including: codon mismatch, gene silencing and point mutations leading to over-
activity of oncogenic systems or the loss of regulatory tumour suppressor molecules 
(Knudson 2002). Tumours acquire a growth advantage over normal tissues through a 
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variety of mechanisms, including acquisition of aneuploidy and dysregulation of the 
mechanisms that control cellular proliferation. The DNA replication licensing 
pathway has emerged as a powerful downstream mechanism for controlling the 
proliferative state of cells and ensures that DNA is replicated once and only once per 
cell cycle; thus maintaining genomic fidelity (Blow and Hodgson 2002; Blow and 
Dutta 2005). 
 
The initiation of DNA replication may provide an attractive therapeutic anti-cancer 
target by virtue of its position at the convergence of multiple signalling systems and 
since the mutational status of upstream signalling components should have no 
implication on the action of agents targeting this highly evolutionary conserved 
process. Studies demonstrating the exploitation of these proteins as prognostic, 
diagnostic and therapeutic targets will be reviewed in the subsequent sections. 
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Figure 1.4 
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1.4.2. Replication origins and DNA licensing initiation 
In order to maintain eukaryotic genomic integrity, precise duplication of DNA must 
occur once, and only once, during each cell division cycle. This is achieved, during 
the G1-S transition, through tightly regulated initiation events at multiple replication 
origins scattered along each chromosome (Machida, Hamlin, and Dutta 2005). The 
basic mechanism of initiation occurs in several steps and results in the establishment 
of bidirectional replication forks at DNA origins:  
 
(i)     Origin recognition: label the origin with ORC. 
(ii)  Assembly of the pre-replicative initiation complex: load the DNA 
helicase to form the pre-RC. 
(iii)  DNA unwinding: activate the DNA helicase. 
(iv)  Elongative assembly: load the replisome including DNA polymerase 
and single stranded DNA binding protein. 
 
A replication origin is a specific site on the chromosome where initiative proteins 
bind and open the DNA helix to allow DNA synthesis to begin (Figure 1.5). These 
sites on the DNA are commonly called the origin recognition complex (ORC) (Bell 
and Stillman 1992). Usually, replication begins at an origin and proceeds in a 
bidirectional manner to complete a single replicon.  
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The replication origins in mammalian cells are not distributed at regular intervals 
throughout the chromosomes but tend to be organised into clusters and are all 
activated simultaneously (Prasanth et al. 2004; Siddiqui and Stillman 2007). 
Approximately thirty thousand origins are postulated to exist in the mammalian 
genome; however, the number of licensed origins exceeds the number of origins 
activated in each cell cycle due to the assembly of pre-RCs at both active and silent 
origins. This acts to ensure that the entire genome is replicated even if some origins 
fail to initiate (Bell and Dutta 2002).  
 
In higher eukaryotes the organisation of origins appears more complex and difficult to 
define compared to the models constructed in yeast. Human ORC is capable of 
binding functionally to any DNA sequence, which is consistent with the observation 
that replication can occur at multiple sites. Although the mechanism of ORC 
recruitment varies between eukaryotes, the subsequent steps involved in assembling 
the pre-RC after ORC binding are conserved among all eukaryotes. The replication 
origin forms the foundation on to which the pre-replicative complexes are assembled 
during late M and early G1 phases. Replication licensing factors: ORC, Cdc6, Cdt1 
and Mcm2-7 assemble into pre-RCs, which render replication origins “licensed” for 
DNA synthesis (Blow and Hodgson 2002). This is a highly coordinated process with 
sequential loading of each factor onto the ORC subunit under the control of ATPase 
activity (Siddiqui and Stillman 2007).   
 
Six paralogous proteins constitute the MCM complex, with Mcm2 to Mcm7 first 
identified in budding yeast; where defects in both initiation and elongation phases in  
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Figure 1.5 
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DNA replication were noted in mutated forms (Lei et al. 1997; Tye 1999; Forsburg 
2004). Studies show that the six subunit MCM complex lacks helicase activity in 
vitro, suggesting that Mcm4/6/7 constitutes the core helicase while Mcm2/3/5 are 
regulatory subunits (Ishimi 1997; You, Komamura, and Ishimi 1999; Ishimi and 
Komamura-Kohno 2001). The model is supported by studies showing that the ATPase 
activity of the Mcm2-7 complex requires the coordinated action of all six subunits 
with Mcm4/6/7 involved in ATP hydrolysis and Mcm2/3/5 regulating its activity 
(Schwacha and Bell 2001). Consequently, the activation of MCM helicase activity, 
probably involves the re-arrangement of some of the units to form a ring-like 
molecule that encircles and unwinds the DNA (Davey et al. 2002). Each pre-RC 
constituent is essential for the initiation of DNA replication with reduced levels of any 
component leading to the loss of replicative capacity and an inability to progress into 
S-phase. Once MCM complexes are loaded onto chromatin, the other components of 
the pre-RC are dispensable for replication initiation. Therefore, the primary function 
of ORC, Cdc6 and Cdt1 in replication is to load the Mcm2-7 complex (Donovan et al. 
1997; Hua and Newport 1998; Harvey and Newport 2003). 
 
The transition from G1 to S phase involves the conversion of pre-RCs into replication 
forks. Initiation requires origin unwinding, stabilisation of single stranded DNA and 
loading of the replicative polymerases. These processes require the function of a 
second set of replication factors and the activity of at least two kinases – cyclin 
dependent kinases (CDKs) and Dbf4 dependent kinase (DDK); also termed Cdc7 
kinase (Jiang et al. 1999; Grishina and Lattes 2005). These factors are temporally 
regulated throughout S phase and induce a conformational change in the pre-RC, 
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resulting in the recruitment of additional initiator proteins which collectively promote 
origin unwinding and recruitment of DNA polymerases.  
 
The earliest initiation factor recruited to pre-RCs is Mcm10, which is involved in 
several critical functions. Mcm10 interacts with Mcm2-7, as well as ORC2 and Cdc7-
Dbf4, and has been suggested to facilitate phosphorylation of Mcm7 by Cdc7-Dbf4 
(Mendez and Stillman 2003; Takeda and Dutta 2005). The formation of an active 
helicase leads to the recruitment of additional factors, including Cdc45 and the four 
subunit GINS complex, which is also dependent on Cdc7 kinase activity (Gambus et 
al. 2006). Phosphorylation of the MCM complex by CDKs and DDK results in the 
recruitment of Cdc45 to the origin (Wohlschlegel et al. 2002a; Sawyer et al. 2004). In 
addition Mcm10 is required for the loading of Cdc45 onto the chromatin and like 
Mcm2-7 is essential for elongation of DNA synthesis. As well as activating the MCM 
complex the pre-initiation complex acts on the final part of DNA replication initiation 
by loading polymerase-alpha-primase and the other DNA polymerases delta and 
epsilon onto the DNA (Mimura and Takisawa 1998; Aparicio, Stout, and Bell 1999). 
 
Once activated, the MCM helicase unwinds double-stranded DNA at origins to 
generate a single-stranded DNA template required to recruit the DNA synthesis 
machinery containing RPA, PCNA and DNA polymerase α-primase (Sclafani and 
Holzen 2007). Following entry into S phase, the licensing system is shut down to 
prevent re-initiation events at origins that have already been ‘fired’. The key event in 
suppressing relicensing of origins is the inactivation of the MCM loading factor Cdt1 
through two mechanisms (Blow and Dutta 2005). First, Cdt1 undergoes cell cycle 
dependent proteolysis during S and G2 (Li et al. 2003). Second, residual Cdt1 is 
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inhibited by the binding of a small regulatory protein called geminin, which is 
expressed at high levels during the S, G2 and M phases (Tada et al. 2001; 
Wohlschlegel et al. 2002b).  
 
1.4.3. Preventing re-replication errors through licence control 
Cells have developed several mechanisms for avoiding re-replication of the genome 
through the control of DNA replication licensing and DNA synthesis. This is 
important for normal cell survival and may play a critical role in the generation and 
progression of abnormal neoplastic events. In mammalian cells these mechanisms 
impinge on the replication initiation factors Cdt1 and Cdc6 with the negative 
regulatory protein geminin. The interaction between geminin and Cdt1 in mammalian 
cells has been shown to prevent re-licensing of origins during S-G2-M (Blow and 
Dutta 2005; Li and Blow 2004a; Li and Blow 2005; Saxena and Dutta 2005). Both 
Cdt1 and ORC1 are subjected to phosphorylation dependent proteolysis in 
mammalian cells whilst phosphorylation decreases their affinity for chromatin and 
helicase activity. These processes are influenced by specific CDKs. 
 
Geminin was initially identified in two independent functional screens in Xenopus 
(McGarry and Kirschner 1998; Maiorano, Rul, and Mechali 2004). It retains the 
ability to regulate DNA replication via its central Cdt1-binding coil domain and to 
modulate neural cell fate. The geminin molecule is a tetramer formed by two dimers 
with monomers interacting via coiled-coiled domains determined by both X-ray 
crystallography and electron microscopy studies (Okorokov et al. 2004). Geminin 
does not affect Cdt1 loading but rather inhibits recruitment of Mcm2-7 by Cdt1 on to 
chromatin by steric hindrance (Cook, Chasse, and Nevins 2004; Saxena et al. 2004). 
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Levels of geminin rise during S phase with Cdt1 binding during S, G2 and M phases 
to prevent the re-initiation of DNA replication. Geminin binds to Cdt1 and inhibits its 
activity until late M phase (Arias and Walter 2007) when geminin is degraded by the 
anaphase promoting complex (APC) via CDK-dependent ubiquitination and 
proteolysis (McGarry and Kirschner 1998; Li and Blow 2004b).  A new round of 
DNA replication is initiated through inactivation of APC in late G1 and entry into the 
subsequent S phase (Benjamin et al. 2004). 
 
The importance of geminin in regulating licensing and maintaining genomic stability 
has been demonstrated by knockdown experiments in Drosophila and mammalian cell 
lines, where geminin reduction results in re-replication and checkpoint activation that 
prevents entry into mitosis (Mihaylov et al. 2002; Melixetian and Helin 2004; Zhu, 
Chen, and Dutta 2004). Inappropriate replication licensing and initiation is linked to 
re-replication in cancer cells through the over-expression of Cdt1 and Cdc6 (Vaziri et 
al. 2003). The re-replicated regions are predominately enriched in segments of the 
chromosomes that replicate early in S phase and are accompanied by ATM/ATR and 
Chk2 dependent activation of p53 which is characteristic of DNA damage. The 
phenomenon is selectively observed in p53 negative cancer cells. This indicates that 
replication licensing is the main system that prevents the re-replication of DNA in a 
single cell cycle. Over-expression of Cdt1 or depletion of geminin results in the 
activation of various checkpoints, including the upstream ATM and ATR kinases and 
downstream Chk1 and Chk2 kinases leading to an arrest of the cell cycle and/or 
apoptosis (Melixetian and Helin 2004; Zhu, Chen, and Dutta 2004; Saxena and Dutta 
2005).  
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1.4.4. DNA replication licensing, proliferation and cancer 
As alluded to in previous sections (1.4.1 & 1.4.2); the DNA replication initiation 
machinery can be regarded as a final and critical step in growth control which is 
positioned at the convergence point of multiple, complex and branched upstream 
signalling pathways. This component of the cell cycle machinery therefore acts as a 
relay station, connecting growth signalling networks with the initiation of DNA 
synthesis, and is therefore a potentially attractive diagnostic and therapeutic target in 
the context of cancer (Gonzalez et al. 2005; Williams and Stoeber 2007; Williams and 
Stoeber 2012).  
 
1.4.4.1. Defining the proliferative state 
Investigation of the DNA replication initiation machinery in different organisms, 
tissues and cell types has revealed that cell cycle withdrawal and loss of proliferative 
capacity are linked to the shutdown of the licensing system (Blow and Hodgson 2002; 
Barkley et al. 2007; Kingsbury et al. 2005). It has been shown that during the 
proliferation differentiation switch, the MCM loading factors Cdc6 and Cdt1 are 
rapidly downregulated, as cells migrate from the transit amplifying compartment 
(TAC) to the functionally differentiated compartment of self-renewing tissues 
(Stoeber et al. 2001). This is coupled to a more gradual downregulation of the Mcm2-
7 RLFs, as cells mature and adopt a fully differentiated phenotype. The conversion of 
replication origins into an unlicensed state also occurs during withdrawal from the cell 
division cycle into G0 quiescent and senescent “out-of-cycle” states as described in 
section 1.2.1. The repression of the DNA replication licensing machinery therefore 
appears to represent a ubiquitous and powerful downstream mechanism to restrain the 
proliferative capacity of cells in multicellular organisms and tissues following 
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withdrawal from the mitotic division cycle. It is interesting to note that many 
components of the DNA replication initiation machinery are under E2F transcriptional 
control (e.g. Cdc6, Cdt1, Mcm2-7, Mcm10 and Dbf4) and thus co-ordinates their 
downregulation during cell cycle withdrawal via the Rb-E2F pathway (Yan et al. 
1998; Yoshida and Inoue 2004). 
 
Proliferating cells have been shown to express high levels of the Mcm2-7 proteins 
throughout the cell division cycle [G1-S-G2-M]; with cyclical binding to origins 
occurring in late M/early G1 and displacement from chromatin during S phase 
(Stillman 1996).  Consequently, Mcm2-7 proteins have emerged as novel biomarkers 
of proliferation.  Unlicensed replication origins and absence of CDK activity, on the 
contrary, characterise the differentiated and G0 out-of-cycle states and therefore allow 
such cells to be clearly distinguished from cycling cells in complex and dynamic 
heterogeneous cell populations (Stoeber et al. 2001; Eward et al. 2004; Gonzalez et al. 
2005; Williams and Stoeber 2012; Jackson, Laskey, and Coleman 2013).  
 
1.4.4.2. DNA replication licensing factors and cancer  
RLFs represent novel biomarkers of growth and have emerged as powerful cancer 
biomarkers with clinical utility is a wide range of settings including cancer detection 
and screening, monitoring of therapeutic response, tumour surveillance and 
prognostication (Williams and Stoeber 2007). Notably it has been shown that 
dysregulation of the DNA replication licensing machinery is an early event in 
multistep tumourigenesis occurring at the precursor premalignant stage of cancer 
development (Freeman et al. 1999; Williams et al. 1998; Kodani et al. 2001; Going et 
al. 2002; Williams and Stoeber 2012; Jackson, Laskey, and Coleman 2013). 
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Identification of MCM proteins in pathological specimens using immunodetection 
methods has been shown to be an accurate and simple method for determining the 
growth fraction in dynamic tumour cell populations (Williams et al. 1998; Freeman et 
al. 1999; Going et al. 2002; Alison, Hunt, and Forbes 2002). Moreover, Mcm2–7 
expression levels are powerful prognostic indicators in diverse tumour types, 
including cancers of the lung, breast, kidney, bladder, prostate and ovary (Meng et al. 
2001; Gonzalez et al. 2003; Shetty et al. 2005; Dudderidge et al. 2005; Korkolopoulou 
et al. 2005; Kulkarni et al. 2007). This finding is consistent with large-scale meta-
analysis of cancer microarray data, which identified up-regulation of the MCM2–6 
genes as a component of poor prognostic signatures (Rhodes et al. 2004). In most 
tumour types, the up-regulation of MCM and other licensing proteins is likely to 
reflect oncogene-driven engagement of the cell division cycle. However, deregulation 
of the licensing system may also be a primary driver of oncogenesis, at least in some 
tumour types. For example, over-expression of Cdc6 or Cdt1 have been shown to be 
oncogenic, and deregulated Mcm7 expression has been linked to tumour formation, 
progression and malignant transformation in animal models (Arentson et al. 2002; Seo 
et al. 2005; Liontos et al. 2007; Shima et al. 2007; Pruitt, Bailey, and Freeland 2007). 
Oncogenic mutations in genes upstream of the licensing machinery (e.g. RAS, 
CYCLINE and CYCLIND1) can also impact on tumourigenesis by causing 
deregulation of the licensing machinery. This may either result in relicensing events 
or allow cells to enter S phase with insufficient licensed origins, both of which can 
lead to genomic instability (Blow and Gillespie 2008). 
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1.4.4.3. Tumour cell cycle phase analysis  
Tumour cell cycle kinetics has been shown to impact on not only prognostic 
assessment but also response to cell cycle phase specific chemotherapeutic agents. 
Indeed prognostic algorithms for many tumour types include parameters which are 
linked to the proliferative potential of the tumour. Such parameters include the 
assessment of the mitotic index and/or Ki67 labelling index. Prognostic algorithms 
used in common practice which incorporate a measurement of proliferative potential 
include: the Nottingham Prognostic Index (NPI) for breast cancer (Elston and Ellis 
1991) and the Federal Nationale Des Centresde Lute le Cancer Grading System for 
Soft Tissue Sarcoma (Coindre 2006). However, these biomarkers represent crude 
measurements of proliferation and are compromised. For example fixation delay of 
tissue can influence the assessment of mitotic index.  Although Ki67 has emerged as a 
promising prognostic marker, its routine introduction into clinical practice has been 
vitiated by conflicting data from meta-analysis studies (Yerushalmi et al. 2010). 
Moreover, harmonization in methods used to quantify Ki67 levels between 
laboratories has proven problematic and reported cut-points vary widely. 
Additionally, although Ki67 has now been utilised for over 30 years as a proliferation 
marker, its function remains poorly defined (Scholzen and Gerdes 2000). In contrast 
the function of the RLFs has been extensively studied in a wide variety of species and, 
therefore, offers a new class of biomarkers for the assessment of proliferation in 
human biopsy material.  
 
The analysis of core constituents of the cell cycle machinery now provides an 
alternative method to assess the proliferative state of dynamic tumour cell 
populations. As discussed above expression of the Mcm2-7 proteins allows tumour 
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cells engaged in the mitotic cycle to be clearly distinguished from cells residing in 
terminally differentiated, quiescent (G0) and senescent “out-of-cycle” states. MCMs 
are expressed at high levels during the G1-S-G2-M phases of the cell division cycle 
contrasting with their tight downregulation in terminally differentiated/G0 cells. The 
expression of geminin in contrast is restricted to the S-G2-M phases of the cell 
division cycle and importantly is indicative of cell cycle progression (Wharton et al. 
2004). As discussed above Ki67, a 345 kDa protein is expressed in actively 
proliferating cells in all proliferating cells in all cell-cycle phases (G1, S, G2, and M). 
It has been shown in multiple tumour types and tissues that combinatorial analysis of 
these cell cycle biomarkers (i.e. Mcm2-7, geminin and Ki67) and more recently with 
the M phase marker phosphohistone H3(H3S10ph) can provide more detailed 
information regarding the cell cycle kinetics of complex dynamic cell populations in 
vivo (Kulkarni et al. 2007; Loddo et al. 2009). 
  
Multiparameter analysis using this set of biomarkers has revealed new insights to 
proliferation control in stable, self-renewing and permanent tissues and the tumours 
arising from these tissues. For example immunostaining of colonic epithelium and 
other self-renewing tissues such as cervical and oesophageal epithelium has revealed 
an inverse relationship between DNA replication licensing and differentiation in these 
tissues (Stoeber et al. 2001). Mcm2-7 levels are expressed at high levels in the transit 
amplifying compartments of these tissues indicating a high proportion of these cells 
are engaged in the cell division cycle. In contrast surface terminally differentiated 
cells are MCM negative in keeping with in vitro studies that the removal of the 
replication licence is a common pathway by which proliferation is restrained (Musahl 
et al. 1998; Kingsbury et al. 2005; Barkley et al. 2007; Williams and Stoeber 2012). 
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The MCM negative status is indicative that these cells have withdrawn from the 
proliferative cycle. Notably the high proportion of the MCM positive cells in the 
transit amplifying compartments of these tissues are associated with high levels of 
geminin, indicating that the cells are actively progressing through cycle (S-G2-M) 
fraction. Intriguingly resting mammary epithelium and ovary have been shown to 
demonstrate high levels of expression of the Mcm2-7 proteins but lacks expression of 
either geminin or Ki67 indicating these cells reside in a G1 state (Stoeber et al. 2001; 
Eward et al. 2004). In contrast pregnant, proliferating breast epithelium expresses 
high levels of all three biomarkers indicative of active cell proliferation. In contrast, 
secretory- differentiated, lactating breast tissues show a marked downregulation of 
Mcm2-7, geminin and Ki67 indicating withdrawal from the cell division cycle. 
Interestingly, the licensed G1 arrested/delayed state observed in normal resting 
mammary epithelium has been observed in precursor dysplastic lesions of self-
renewing epithelia including: cervix, bladder and oesophagus (Williams et al. 1998; 
Going et al. 2002; Stoeber et al. 2002b; Williams and Stoeber 2012). The arrested 
differentiation in these precursor lesions is associated with high Mcm2-7 expression 
but expression levels of Ki67 and geminin are very low indicating the majority of 
these cells reside in a G1 arrested/delayed state. It has also been shown that the 
majority of tumour cells in more advanced invasive cancers arising from these tissues 
also reside in this licensed G1 arrested state. The added sensitivity of Mcm2-7 
biomarkers over Ki67 has been exploited in the development of Mcm2-7 cancer 
detection tests for a number of organ systems including: cervix, bladder and prostate 
(Williams et al. 1998; Meng et al. 2001; Stoeber et al. 2002a; Dudderidge et al. 2010; 
Kelly et al. 2012). The clinical utility of these Mcm2-7 biomarkers has now reached 
the advanced stage of commercialisation including validation studies for FDA 
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approval. For example, Tripath/Beckton Dickinson have developed the ProEx C test 
for improved detection of abnormal cells in the cervical Pap smear test 
[http:www.bd.com/tripath/products/proexc]. This exploits the use of MCM 
biomarkers for the improved detection of precursor malignant cells using an 
immunocytology approach. Similarly, Cytosystems Ltd [http:www.cytosystems.com] 
and Urosens Ltd [http:www.urosens.com] have developed Mcm2-7 assays for the 
detection of bladder and prostate cancer.  It is interesting to speculate that the 
persistence of Mcm2-7 in non-proliferating breast may be an evolutionary relic from 
times when women spent most of their fertile years either pregnant or lactating and 
consequently, it was therefore unnecessary for these cells to be able to withdraw from 
the G1 state. An important question raised by this finding is whether licensed but 
slowly proliferating cells such as these have a higher risk of undergoing malignant 
transformation. Since the lack of origin licensing may be an important mechanism 
restraining the proliferation of G0 cells, it is possible that failure to down-regulate the 
licensing system (as in these breast cells) may make transition to uncontrolled 
proliferation significantly easier to achieve. Taken together these extensive 
clinicopathological studies have revealed that multiparameter analysis with these 
novel cell cycle biomarkers can be used to identify three discrete cell cycle states in 
complex  dynamic tissues: (i) an “out-of-cycle”, unlicensed state characterized by an 
absence of expression  of Mcm2-7, geminin and Ki67, (ii) an actively cycling state 
characterized by high expression levels of the Mcm2-7 proteins, geminin and Ki67 
and (iii) G1 arrested/delayed state characterized by high Mcm2-7 expression levels 
but low geminin and Ki67 levels. This latter cell population has been referred to as 
“licensed cells with proliferative potential” (reviewed in Figure 1.6). 
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Figure 1.6 
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Additional cell cycle parameters have also been identified using combinatorial 
analysis of these three cell cycle biomarkers in relation to tumour cell cycle kinetics 
(Wharton et al. 2004; Dudderidge et al. 2005; Kulkarni et al. 2007; Loddo et al. 
2009). As discussed above, the Ki67 labelling index identifies all phases of the 
proliferative cell cycle (G1, S, G2, M) and the geminin labelling index identifies the 
fraction of cells in S–G2–M. The geminin/Ki67 ratio is therefore an indicator of the 
relative length of the G1 phase. Proliferating cells with a short G1 phase will 
approximate to a geminin/Ki67 ratio of  ̴ 1; whereas cells with a prolonged G1 phase 
will approximate to a geminin/Ki67 ratio   ̴0. Studies have shown that tumours with a 
more aggressive phenotype are associated with high geminin/Ki67 ratios. 
Alternatively, the Mcm2-7/Ki67 ratio can be used to define the proportion of cells that 
are licensed to proliferate, representing a ratio of licensed to actively proliferating 
cells. Thus, the higher the Mcm2/Ki67 ratio then the greater the proportion of cells 
that reside in a licensed, non-cycling state. This has been shown to be an important 
parameter of biological and prognostic significance in a range of different tumour 
types as described above. Moreover the difference in the labelling index between 
Ki67 and geminin [Ki67-geminin] can be used to estimate the percentage of cells that 
are transiting G1 (i.e. G1 growth fraction). Overall, this information is of potential 
value in determining the cell cycle kinetics of dynamic tumour cell populations in 
normal and malignant penile epithelium.  I investigate RLF expression and associated 
multiparameter tumour cell cycle phases kinetic analysis in benign and malignant 
penile tissues in section four. Furthermore, in later chapters, I link these data to 
clinical and prognostic information to determine their utility as novel biomarkers in 
men with penile cancer.  
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1.5. Penile Squamous Cell Carcinoma (PeScc)  
1.5.1. Penile anatomy: relevance to staging and surgery in PeScc 
The penis consists of three separate cylindrical structures and originates from the 
genital tubercle at the cranial end of the cloacal membrane in utero. Normal 
development is under the direct control of androgenic hormonal stimulation. The 
penis is composed of three parts: the shaft/body, anterior (glans, corona, foreskin) and 
posterior (perineal attachments). The corpora cavernosa join beneath the pubis to form 
the major portion of the body of the penis. These two cylinders of the penis are 
separated by a septum which allows the vascular spaces to freely communicate. They 
are enclosed by the tough tunica albuginea, which is predominantly collagenous and 
meets distally to separate the heads of the copora cavernosa from the corpus 
spongiosum of the glans. It completely encases the copora cavernosa and appears to 
constitute an important biological barrier to the dissemination of PeScc (Velazquez et 
al. 2004; Leijte et al. 2008; Heyns, Mendoza-Valdes, and Pompeo 2010). 
The corpus spongiosum tapers and runs on the underside of the corpora cavernosa and 
then expands to cap them as the glans penis. The corona separates the base of the 
glans from the shaft of the penis. The spongiosum is traversed throughout its length 
by the anterior urethra, which begins at the perineal membrane. Proximally, it is lined 
by stratified and pseudostratified columnar epithelium, distally by stratified squamous 
epithelium. The mucus-secreting glands may be seen as small outpouchings of the 
mucosa. 
Buck's fascia surrounds both cavernosal bodies dorsally and splits to surround the 
spongiosum ventrally. This important layer can clearly be defined on MRI and 
provides crucial information for surgeons pre-operatively, when planning 
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conservative surgical techniques (Kayes et al. 2007). In the perineum, Buck's fascia 
fuses with the tunica albuginea deep to the muscles of the erectile bodies. Distally, it 
fuses with the base of the glans at the corona. 
The skin of the penile shaft is highly elastic and without appendages (hair or glandular 
elements), except for the smegma-producing glands at the base of the corona. 
Distally, it folds over the glans as the foreskin (double-membrane) and attaches firmly 
below the corona. Its blood supply is independent of the erectile bodies and is derived 
from the external pudendal branches of the femoral vessels. These vessels enter the 
base of the penis to run longitudinally in the dartos fascia as a richly anastomotic 
network. The skin of the glans is immobile as a result of its direct attachment to the 
underlying, thin tunica albuginea (Heitz, Pottek, and Schreiter 1998; Velazquez et al. 
2003).  
A rich network of lymphatics of the glans and the copora cavernosa courses along the 
dorsal vein to the symphysis pubis and drains into superficial and deep inguinal 
lymph nodes which are anatomically separated by the deep fascia of the thigh (fascia 
lata). The superficial group of nodes (12 to 15 nodes) are situated in the deep 
membranous layer of the superficial fascia of the thigh (Camper's fascia). The sentinel 
lymph node group (1 to 3 nodes) can be identified by their anatomical location at the 
anterior or medial aspect of the superficial epigastric vein (Cabanas 1977; Cabanas 
2000). The node of Cloquet is the most cephalad of the deep group and is situated 
within the femoral canal (Shen et al. 2000). The external iliac lymph nodes receive 
drainage from the deep inguinal, obturator, and hypogastric groups. In turn, drainage 
progresses to the common iliac and para-aortic nodes. The earliest route of 
dissemination in penile carcinoma is to loco-regional lymphatics. Penile carcinomas 
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have a predictable pattern of local, regional and systemic spread (Cabanas 1992; 
Horenblas et al. 1993). Locally invasive tumours initially penetrate the lamina 
propria, supeficial dartos or superficial corpus spongiosum layers (Figure 1.8). Later 
invasion involves deep corpus spongiosum, tunica albuginea, corpora cavernosa and 
preputial skin (Figure 1.9). Urethral invasion is not unusual in early or late stages 
depending on the site of origin of the initial tumour. Advanced tumour with local 
tissue destruction often represent higher staged and aggressive disease states (Figure 
1.10), Intrapenile satellitosis (nodules of carcinoma separated from the main tumour 
mass) is a late phenomenon related to aggressive tumour behaviour (Velazquez et al. 
2005).  
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Figure 1.7 
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Figure 1.8 
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Figure 1.9 
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Subsequently, loco-regional involvement occurs in a step-wise fashion, involving 
initially the superficial inguinal nodes before spread occurs to the deeper inguinal 
layer and finally onto pelvic and distant sites. It is extremely rare to observe disease 
‘skipping’ nodal stations. The presence of lymphatic metastases strongly impacts on 
prognosis.  
Patients with locally controlled disease have five year overall survival rates of greater 
than 90%; decreasing dramatically to approximately 30-50% if lymph node positive. 
There is a striking deterioration in survival outcomes with the increasing number of 
nodes involved and also the level of nodal involvement. Currently, 5 year survival is 
0-38% from pelvic metastases in published series (Ravi 1993; Ornellas et al. 2008).  
 
It has been shown that early lymph node clearance compared to delayed/therapeutic 
dissection, conveys a clear survival advantage (Kroon et al. 2005a; McDougal 2005). 
However, patient selection is notoriously difficult, as current staging techniques lack 
the required accuracy (section 1.5.3).  Additionally, radical regional lymph node 
dissection carries high rates of mortality (3%) and morbidity (50-90%) (Horenblas et 
al. 1993; Pizzocaro, Piva, and Nicolai 1996; Sanchez-Ortiz and Pettaway 2004). 
Complications encountered may include: wound infections, wound dehiscence, flap 
necrosis, disabling lymphoedema and seroma formation. 
 
This clinical paradigm highlights the current limitations that clinicians and scientists 
face when treating men with PeScc. Novel management algorithms should aim to 
stratify patients appropriately to: (i) surveillance programmes, (ii) aggressive surgical 
protocols and (iii) adjuvant chemotherapeutic treatments. It is important that novel 
biomarkers accurately reflect the biological status of the disease and predict disease 
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progression for high risk patients.  Overall, future discoveries should ultimately 
minimise unnecessary co-morbidity and impairment to the patient’s quality of life 
whilst improving overall survival.  
 
1.5.2. Epidemiology and aetiology  
Penile cancer is a rare neoplasm with approximately 400-500 new cases and 80-100 
deaths annually in the United Kingdom. In Western countries, primary malignant 
penile cancer is uncommon, with an incidence of less than 1.00 per 100,000 males in 
Europe and the United States (Barnholtz-Sloan et al. 2007; Cancer Incidence in Five 
Continents. Vol. IX. IARC Scientific Publication, No. 1602009). However, there are 
significant geographical variations, with some centres in Europe reporting an 
incidence greater than 1.00 per 100,000 men (Parkin et al. 2005). In contrast, in the 
non-Western world, the incidence of penile cancer is much higher and can represent 
10-20% of malignant diseases in men ranging from an age-adjusted incidence of 0.7-3 
per 100,000 people in India to 8.3 per 100,000 men in Brazil, and even higher in 
Uganda, where it is the most commonly diagnosed male cancer (Owor 1984; Wabinga 
et al. 2000). Important risk factors include social and cultural habits alongside 
hygienic and religious practices.  
 
Squamous cell carcinoma (PeScc) is the predominant tumour variant accounting for 
95% of cases (Burgers, Badalament, and Drago 1992). Other malignant tumour types 
described in the literature include: adenocarcinoma, lymphoma, melanoma and 
various mesenchymal tumours such as Kaposi sarcoma and leiomyosarcoma. Initial 
presentation usually occurs in the sixth decade of life, often with areas of ulceration 
on the distal penis. Associated infection can present with offensive discharge and 
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cases of auto-amputation have also been reported (Rajaian, Gopalakrishnan, and 
Kekre 2010). Despite the fact that causation has yet to be fully delineated, a number 
of risk factors have been identified. It is well known that neonatal circumcision 
appears protective (Schoen 1996; Daling et al. 2005), as denoted by the extremely low 
incidence of penile cancer in Jewish populations. The protective mechanisms of 
circumcision are lost if surgery is delayed, thus establishing the hypothesis that 
factors within the inner preputial environment promote carcinogenesis. This 
hypothesis is supported by the increased frequency of preputial stenosis (phimosis) 
witnessed in uncircumcised patients presenting with penile cancer.  
 
Other important risk factors include: inflammatory conditions (balanitis xerotica 
obliterans), human papilloma virus (HPV) infection and smoking (Moore et al. 2001; 
Pietrzak et al. 2006; Kayes, Shabbir, and Minhas 2012). The combination of these 
factors suggests that this malignant process involves multiple molecular pathways, 
which may be altered by the presence of chronic inflammation, oncogenic viral 
products and carcinogenic cofactors. Two core studies conducted by the IARC have 
reviewed the prevalence of HPV infection and cancer developments between stable 
couples. Their findings support a decreased prevalence of HPV infection in 
circumcised men (Castellsague et al. 2002) and that the incidence of cervical cancer 
was increased in uncircumcised men with a history of multiple sexual partners 
(Franceschi et al. 2002). These studies failed to elucidate on the long infective latency 
times that are observed in cancer development and evaluating time of HPV 
transmission. The various pathways involved in tumourigenesis and progression in 
PeScc are discussed in detail throughout this section and a hypothetical model for 
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carcinogenesis in penile cancer through HPV dependent and independent mechanisms 
is proposed (Figures 1.10 and 1.11).  
 
1.5.3. Diagnosis, staging and prognostic factors 
Patients should be examined to evaluate clinically advanced tumours; recording the 
location of the primary tumour, tumour size, involvement of penile/adjacent structures 
and the presence of inguinal lymphadenopathy. Confirmation of PeScc on biopsy 
material is mandatory and patients are staged through the routine use of pre-operative 
CT scanning. Penile MRI can help to delineate local staging of the primary tumour 
(see section 1.5.1) and assist in planning surgical strategies. These measures are 
important in contemporary surgical practice as radical penile amputation carries 
significant psychological and physical morbidity. In appropriate cases, where tumours 
are located distally and superficially on the penis (Ta, T1 & T2 without cavernosal 
involvement), the implementation of conservative surgical techniques have been 
successfully employed thus preserving phallus length and function in these patients 
(Minhas et al. 2005).  
 
As discussed in the previous section, disease progression is in a loco-regional fashion, 
with sequential involvement of inguinal and pelvic lymph nodes; before distant 
metastases develop. Common sites for distant spread include: lung, brain and bone. 
Tumour recurrence can develop locally, within the lymphatic basins, subcutaneously 
with discrete nodules or at the distant sites already alluded to. Death is usually from 
inanition and sepsis; although catastrophic bleeding as a result of erosion of the 
femoral vessels caused by fungating, inguinal metastases can occur. 
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Figure 1.10 
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Figure 1.11 
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Recent studies have suggested that in the presence of palpable inguinal 
lymphadenopathy, the probability of inguinal metastases is approximately 80% 
(Hegarty et al. 2006). This supports recent changes in clinical practice and guidance 
(Pizzocaro et al. 2010), such that patients should be counselled for immediate 
modified or radical inguinal lymphadenectomy rather than delaying surgical 
intervention for a period of antibiotic therapy to exclude infective or inflammatory 
lymphadenopathy.  Improvement in the five year survival rates following early 
surgical clearance of positive nodal disease provides strong evidence to support the 
implementation of radical surgery in this clinical setting (Kroon et al. 2005a; 
McDougal 1995). 
 
However, treatment protocols for patients with clinically negative examination 
findings remains controversial; as up to 20% of these patients will harbour micro-
metastatic disease that will be missed should the patients be entered into a 
surveillance program (Kroon, Horenblas, and Nieweg 2005). In order to improve 
patient selection to either surveillance, surgical and/or chemotherapeutic regimes 
important predictive information can be gained from primary tumour histology 
(Cubilla 2009). The single most important prognostic factor for overall outcome is 
nodal status; with 5 year survival figures of 90-100%, 80-90%, 40-50% and 0-30% 
for N0 (negative nodes), N1 (single superficial, inguinal lymph node), N2 (multiple or 
bilateral superficial inguinal lymph nodes) and N3 (deep inguinal or pelvic lymph 
node[s], unilateral or bilateral) respectively (Ravi 1993; Horenblas et al. 1993). 
Current histopathological features with prognostic significance for predicting loco-
regional spread and overall survival include: grade, stage, subtype, depth of invasion, 
lymphovascular invasion and tumour size (Ficarra et al. 2006; Kattan et al. 2006; 
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Lopes et al. 1996; Ornellas et al. 2008). This information has helped shape European 
guidelines for the management of suspected inguinal metastases by identifying 
patients at high risk of developing regional spread (Pizzocaro et al. 2010). Patients 
can be stratified into risk groups; with higher risk patients selected for radical surgical 
treatment based on tumour grade and stage. Lower risk groups can be entered into 
surveillance programs with clinical and radiological examination at regular intervals.  
 
Alternative approaches for staging include the use of sentinel node biopsy techniques 
with improving expertise in larger centres with greater experience (Hadway et al. 
2007; Kroon et al. 2005b). The technique involves injection of nanocolliod 
radionuclide solution 24 hours prior to surgery and “hot spots” noted using a gamma 
camera and probe. The use of toludine blue dye injected peri-tumourally aid in the 
guidance and mapping out of lymphatics at the time of surgery to help isolate the 
sentinel node (i.e. first draining node in the primary lymphatic echelon). Removal of 
the lymph node for histopathological analysis is performed and if metastasis 
discovered, then formal radical lymphadenectomy is performed. Current sensitivities 
for this technique are variable with UK experience around 80% (Hadway et al. 2007), 
however Dutch 10 year experience is higher at 90% (Kroon et al. 2005b).  
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1.5.4. Human papilloma virus: Cause or cofactor?  
Human Papilloma Virus (HPV) is a family of small double-stranded DNA viruses 
(8000 bp) with distinct pathogenetic types. Sexual transmission is the most common 
route for viral propagation, although both oral and vertical transmission has been 
described. High risk HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, 58, 
59, 66, 68 and 69 whilst low risk types are 6, 11, 26, 30, 34, 40, 42, 43, 44, 53, 55, 57, 
61, 62, 64, 67, 70, 71, 73, 74, 79, 81-84 (zur 1990; zur 2000). Viral genotypes have 
conserved genetic, transcriptional and functional organisation, with early (E) regions 
encoding proteins for replication, regulation, and modification of the host cytoplasm 
and nucleus and a late (L) region encoding capsid proteins.  
 
HPV has a strong correlation with the carcinogenic processes involved in anogenital 
tumour formation (zur 1990). Studies assessing the prevalence of high risk types and 
the association of oncogenic proteins E6 and E7 in the pathways controlling cellular 
differentiation, proliferation and apoptosis have provided evidence that HPV infection 
is a key player in the generation of in-situ and invasive cancers of epithelial tumours 
(Kamath et al. 2000; Palmer et al. 1989; Walboomers et al. 1999). Squamous cell 
carcinoma of the uterine cervix has provided the most convincing model for 
understanding the molecular alterations seen with HPV infection and HPV DNA 
integration into the human genome. Recent advances have led to the manufacture of 
the first HPV specific, bivalent and quadrivalent vaccines, which in clinical trials has 
demonstrated efficacy in preventing infection (Harper et al. 2006; Villa et al. 2006). 
The benefits of this vaccine for other anogenital and aerodigestive HPV-related 
malignancies are yet to be evaluated. 
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Fundamental understanding of HPV mechanisms during infection and viral 
replication has been extensively reviewed (Hebner and Laimins 2006). The overall 
prevalence of HPV DNA in penile carcinoma ranges from 20-80%, dependent on 
methodological approaches and geographical variance (Wiener et al. 1992; Villa and 
Lopes 1986; Lam et al. 1995; Picconi et al. 2000; Rubin et al. 2001; Daling et al. 
2005; Senba et al. 2006). Implementation of advanced PCR techniques has generated 
a reference figure of approximately 40-45%, which is similar to the detection rates 
seen in vulval cancer (Della et al. 1992). Notably, the prevalence of HPV DNA 
detection in cervical neoplasia is 100% for in-situ disease and 99.7% for invasive 
tumours (Walboomers et al. 1999).  
 
Distinct pathological variants have been identified which are associated with indolent 
behaviour (verrucous, warty, Buschke-Lowenstein condyloma) and others with more 
aggressive phenotype (Squamous cell carcinoma of usual type [NOS], basaloid, 
papillary) (Cubilla et al. 1993; Cubilla 1995). It has been demonstrated that there is a 
correlation between tumour subtype and HPV infection. Basaloid and warty variants 
are regularly HPV-associated (80-100%), demonstrating koilocytic changes on 
standard microscopy; whereas only a third of keratinising and verrucous tumours have 
such a relationship (Gross and Pfister 2004). It appears that carcinoma in-situ is 
strongly related to high risk HPV infection (90%) (Gross and Pfister 2004). HPV 16 
and 18 are the most common types isolated in specimens of carcinoma in-situ and 
invasive PeScc (60-75%) whilst HPV 6 and 11 are most frequently seen in lower risk 
condylomas and Buschke-Lowenstein tumours. Verrucous tumours appear negative 
for HPV involvement, with only individual isolated cases showing positivity for the 
virus (Dianzani et al. 1998). This has led to the hypothesis that only a subset of 
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tumours is HPV-dependent with the remainder subject to other genetic and molecular 
alterations.  
 
Two viral genes, E6 and E7, are continuously expressed in high risk types of the HPV 
transformed cells. E6-E7 gene products cooperate in disturbing cellular 
differentiation, proliferation and apoptosis through their involvement with the 
retinoblastoma Rb/E2F and p53 tumour suppressor pathways. Certainly, their 
expression is required to induce and maintain the neoplastic phenotype of cervical 
cancer cells and similar mechanisms seem to exist in penile cancer. Such alterations in 
these pathways which have been described in HPV positive and negative patients with 
penile cancer are reviewed subsequently. 
 
The prognostic influence of HPV infection in patients with PeScc is controversial 
owing to contradictory evidence. Traditionally, it has been proposed that high risk 
HPV types, particularly HPV-16 and 18 are associated with aggressive variants and 
therefore give rise to poorer survival. Chan et al reviewed HPV 16/18 infection in a 
cohort of men with PeScc from Hong Kong (Chan et al. 1994). The data suggested 
that verrucous and well differentiated tumours were not associated with high risk 
HPV types. However, the specific impact of high risk HPV types in higher grade 
tumours was not commented upon. Gregoire and colleagues have supported the 
hypothesis that HPV 16/18 infections are highly associated with specific tumour types 
(basaloid/warty) which have been identified as aggressive variants (Gregoire et al. 
1995). They also demonstrated that HPV-infected tumours are linked to higher grade 
and aggressive growth patterns. These results are confirmed by the presence of HPV 
16 and 18 types in a number of cases with positive inguinal metastases (Wiener et al. 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  83                                                                          
 
1992; Scinicariello et al. 1992; Leis et al. 1998).
 
 Weiner et al have demonstrated in a 
retrospective study the potential link of HPV 16 infection to disease progression 
(Wiener et al. 1992). However, they were unable to demonstrate a survival difference 
in patients with HPV compared to HPV negative cases.  
 
More recent evidence for HPV 18 involvement in the metastatic process in penile 
cancer cases from Thailand has been published. This aggressive phenotype was found 
in 4 out of five cases with metastatic disease (Senba et al. 2006). High HPV 18 
infection rates are witnessed in Brazil and may explain the geographic differences 
seen in South America. Bezerra et al reviewed similar parameters and outcomes 
following primary penile amputation and bilateral lymphadenectomy in 82 patients 
and revealed no correlation to lymph node metastases or survival outcome at 10 years 
(Bezerra et al. 2001). Their data suggest that HPV infection does not influence 
prognosis in invasive PeScc. Interestingly, over half (51.2%) of the patients were 
found to have inguinal metastases, but the series only contained one poorly 
differentiated tumour.  
 
The largest series examining the relationship of HPV infection with prognosis (171 
patients) found no association to lymph node metastases (Lont et al. 2006). On the 
contrary, there seemed to be a positive impact on outcome with high risk HPV 
subtype infection conferring a survival advantage with 5-year survival at 78% versus 
93% in HPV-negative and HPV-positive patients, respectively. These data propose 
that whilst HPV infection can be linked to a distinct subset of carcinogenic events in 
men with penile cancer, the involvement of the viral genome may be protective 
against the development of aggressive variants. Such a correlation with lymph node 
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status and prognosis suggest alternate mechanisms for tumour invasion and 
metastases. Nonetheless, the interaction between HPV and penile cancer development 
is far from straightforward and requires further investigation in preclinical models. 
 
1.5.5. Molecular biology of penile cancer 
1.5.5.1. Karyotype profiling, ploidy status and telomerase activity 
Genetic imbalances and karyotypic findings have been reported in penile cancer 
(Ornellas et al. 1998; Ornellas et al. 1999; Alves et al. 2001b), through cytogenetic 
analysis and genomic hybridization techniques. The rarity of penile cancer alongside 
technical difficulties inherent in this tumour due to the presence of inflammation, 
necrosis and poor growth characteristics in culture have led to a relative paucity of 
data linking chromosomal abnormalities to biological behaviour and outcome. Alves 
et al noted that DNA sequence copy number alterations (CNAs) were detected with 
distinct similarity to oral Scc and oesophageal Scc. In 23 cases analysed, common 
copy number gains included 8q24, 16p11-12, 20q11-13, 22q, 19q13 and 5p15. 
Deletions were found in 13q21-22, 4q21-32 and along the X chromosome. No 
association to grade or stage was detected, but there was a tentative link between 
lower CNA numbers and lower survival rates. Three studies have investigated the 
relevance of ploidy status in the onset and progression of PeScc. Masih et al 
demonstrated a diploid population in verrucous carcinomas (Masih et al. 1992). 
Ornellas et al performed flow cytometry in 90 cases of PeScc, establishing diploid 
status in all verrucous cancers, although aneuploid cases varied according to grade: 
well differentiated (5.5%), moderately differentiated (28.8%) and poorly 
differentiated (66.6%) (Ornellas et al. 2000). Even so, there were only 3 poorly 
differentiated tumours in this study, preventing formal analysis of aneuploidy as a 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  85                                                                          
 
prognostic factor. Nonetheless, there was a tendency towards high DNA index 
correlating with increased metastatic risk.  
 
Telomerase activity has been briefly studied in penile cancer (Ikeda et al. 2000; 
Melsheimer et al. 2004; Alves et al. 2001a). Telomerase is an enzyme that adds 
specific DNA sequence repeats (TTAGGG) to the 3' end of DNA strands in the 
telomere regions which are found at the ends of eukaryotic chromosomes. The 
telomeres contain condensed DNA material that confers stability to chromosomes. In 
cancer, it is proposed that increased telomerase activity can overcome programmed 
cell death, immortalising the cell and leading to indefinite replicative capacity. This 
may be linked to increased probability of developing chromosomal alterations and 
aneuploid populations. Alves et al describes detectable telomerase activity in 85.4% 
(41/48) of invasive PeScc. Increased levels were also identified in adjacent skin and 
corpus cavernosal tissue. Similar samples from patients with prostatic carcinoma were 
telomerase negative. The prognostic significance of these findings requires further 
clarification, although the changes in surrounding normal tissue suggest a field effect 
(Alves et al. 2001a).   
 
1.5.5.2. Dysregulation of oncogenes and tumour suppressor genes 
It is now accepted that alternative pathways exist to promote tumourigenesis between 
HPV-dependent and HPV-independent neoplasms. Additional cellular changes are 
required in HPV negative epithelium to induce full malignant transformation. 
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1.5.5.2.1. ‘p53’ 
A primary target for researchers evaluating these mechanisms has been the tumour 
suppressor pathway involving TP53 gene and its functional protein product, p53. A 
number of studies have investigated the relationship of p53 expression with HPV 
infection and prognosis (Lam et al. 1995; Castren et al. 1998; Levi et al. 1998; Lam 
and Chan 1999; Lopes et al. 2002; Martins et al. 2002; Humbey et al. 2003). It is 
known that the HPV oncogenic product E6 interferes with this pathway by binding to 
the oligomerisation region of wild type p53 causing suppression of normal inhibitory 
function at the G1/S junction of the cell cycle. This leads to uncontrolled cellular 
proliferation, loss of cellular differentiation and decreased apoptotic control through 
Bcl-2 and Bax imbalance (Camus et al. 2007). Blanton et al demonstrated an in vitro 
model in which foreskin and ectocervical epithelial cells were infected with retroviral 
vectors expressing HPV 16 oncogenes (Blanton et al. 1992). Expression of HPV 16 
E7 caused persistent proliferation in the suprabasal domain, but no effect on terminal 
differentiation. E7 expressing cells were positive for p53 but those cells co-expressing 
E6 and E7 were negative for p53, yet still proliferating suprabasally. The authors 
concluded that E7-induced suprabasal proliferation is independent of baseline p53 
levels. Additionally, recent results have demonstrated that oral keratinocytes infected 
with E6 deletion mutants in vitro showed that increased telomerase activity was 
closely associated with cell immortalization by BMI-1 and HPV-16 E6, whereas p53 
degradation was not (Kim et al. 2007). 
 
The evidence linking p53 expression and presence of HPV DNA in PeScc is 
contradictory. A study by Lam  demonstrated that 100% of HPV infected cells also 
showed positive p53 staining (Lam et al. 1995). However, several reports have shown 
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an inverse or negative relationship (Pilotti et al. 1993; Ranki, Lassus, and Niemi 1995; 
Castren et al. 1998). Castren et al reviewed the expression profile in premalignant 
conditions (treatment resistant genital warts, bowenoid papulosis, Queyrat’s 
erythroplasia and carcinoma in situ) and compared this to profiles in invasive 
tumours. The authors concluded that there was no correlation between p53 and HPV 
status. Over expression of p53 does not indicate a p53 mutation in pre-malignant 
disease.  This infers that TP53 gene mutations may occur in the later events of male 
genital carcinogenesis and thus describe a subset of patients with alternate disease 
progression.  
 
The TP53 gene is situated on chromosome 17p13 and mutation may lead to either 
expression of a mutant protein (90%) or absence of protein (10%).  Intracellular p53 
levels are controlled through a negative feedback loop with its regulatory protein 
Mdm2. It has been shown that mutant p53 will fail to bind to Mdm2, thus resulting in 
the accumulation of the oncogenic protein in cells. Ouban et al have proposed that 
over expression of Mdm2 is important in aberrant p53 down-regulation in PeScc 
(Ouban et al. 2003). 
 
Studies exploring the expression of p53 in invasive PeScc have shown that overall 
expression of the protein varies between 40-89%, with expression localised to the 
periphery of the tumour cell nests in poorly differentiated tumours.  No study has 
shown a correlation with grade or stage of disease. The p53 protein has not been 
detected in verrucous tumours and shows a difference in expression between 
histological types (Rubin et al. 2001; Martins et al. 2002)
 
. A strong association 
between polymorphisms at codon 72 of TP53 with cancer development and 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  88                                                                          
 
progression has been shown in several Squamous cell carcinoma models. It is 
proposed that the arginine (Arg) homozygous genotype presents an increased risk to 
disease progression in cervical cancer. However, contradictory evidence in other 
studies refute these data; which has also been reproduced in Ugandan and Italian men 
with penile cancer (Tornesello et al. 2008). A link between HPV infection and PeScc 
was confirmed, but this study concluded that the Arg/Arg genotype was not a risk 
factor in this series. There was no correlation found between the TP53 polymorphism 
at codon 72 and the presence of HPV DNA.  
 
The utility of p53 as an independent prognostic marker in patients with penile cancer 
has been examined by Lopes (Lopes et al. 2002) in 82 patients treated with penile 
amputation and bilateral lymphadenectomy. The authors were able to demonstrate 
nuclear accumulation of p53 in 34 of 82 samples analysed (41.5%). The 
immunoreactivity of p53 was studied alongside other clinicopathological factors, 
lymph node status and survival. The relationship between p53 expression and HPV 
infection was also analysed. The results from this study showed that p53 staining was 
an independent predictor of lymph node metastases on multivariate analysis. Patients 
with negative p53 had significantly better 5 and 10 year overall survival. Overall 
outcome was significantly worse if tumours were p53 and HPV DNA positive. 
Patients who were HPV positive but p53 negative had the best survival figures thus 
supporting the work performed by Lont. Martins reviewed the outcome in 50 patients 
and explored the relationship between p53 and proliferating cell nuclear antigen 
(PCNA) (Martins et al. 2002). The data supported the findings above, but was unable 
to show that PCNA was of prognostic significance in this disease. Further work is 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  89                                                                          
 
necessary to help delineate the initiation and progression of these alternate pathways 
in men with penile cancer. 
 
1.5.5.2.2. ‘p21’ 
Lam and Chan developed their initial findings of p53 expression in PeScc to include 
p21 expression data in order to investigate the interplay between these two proteins 
(Lam and Chan 1999). The p21 protein is a primary target for p53 by negatively 
regulating cell cycle progression through its interaction with cyclin-dependent kinases 
(CDK) at the G1/S and G2/M checkpoints of the cell cycle. Nuclear staining for p21 
protein was achieved in 40% of tumours with suprabasal localisation. This staining 
was also observed in adjacent dysplastic areas. There was no correlation with grade or 
stage. There was a strong association between HPV 16 positive cases and positive p21 
immunostaining (100%). The authors suggest that in penile cancer p21 expression is 
controlled by p53 dependent and independent mechanisms. 
 
1.5.5.2.3. ‘Bax and Bcl-2’ 
The complex interplay between the pro-apoptotic protein (Bax), anti-apoptotic protein 
family (Bcl-2) and p53 dysregulation is well described for various tumours. Recent 
studies have reviewed this area in penile cancer (Nascimento et al. 2004; Saeed et al. 
2005). Both studies revealed an imbalance in Bax/Bcl-2 ratios between benign, pre-
malignant and invasive disease. Bcl-2 levels were significantly elevated in low grade 
disease compared to verrucous cancers, whilst Bax levels were comparable. 
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1.5.5.2.4. ‘ p16INKA/cyclin D/Rb’ 
The p16
INKA
/cyclin D/Rb pathway is of significant interest in the pathogenesis of 
penile cancer. This pathway has been shown to be dysregulated in many human 
carcinomas with inactivation of single or multiple steps within the pathway. The 
retinoblastoma (Rb) protein is a target for the viral oncoprotein E7, thus its 
inactivation may contribute to carcinogenic events in HPV-dependent tumours.  
 
This pathway may be disrupted by three independent mechanisms in penile cancer 
(Ferreux et al. 2003). Analysis of 52 cases of invasive PeScc were scrutinised for 
p16
INKA 
and BMI-1 using immunohistochemical techniques. HPV 16 E6/E7 mRNA 
and p16
INKA
 methylation were evaluated using polymerase chain reaction. HPV 
presence was also compared using in-situ hybridisation. The authors described HPV-
dependent and independent mechanisms affecting the normal functioning of this 
important signalling pathway. These mechanisms include: (1) blocking of Rb function 
by the E7 oncoprotein with upregulation of p16
INKA
; (2) silencing of the p16
INKA
 gene 
by methylation in the absence of HPV infection 15% of cases with p16 over 
expression; (3) over expression of BMI-1 gene - which targets down-stream factors 
p16
INKA
 and p14
ARF
 – was also found in 10% of tumours in the absence of HPV 
infection.  The authors postulated that p16
INKA
 may act as a potential prognostic 
marker and that these results have strong implications on the potential effectiveness of 
prophylatic HPV vaccines in this tumour, with only a quarter of patients with PeScc 
potentially benefiting from this treatment directly. 
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1.5.5.2.5.   ‘c-ras, myc’ 
Proto-oncogene activity in penile cancer have been analysed through c-ras
Ha  
(Leis et 
al. 1998) and myc (Couturier et al. 1991; Sastre-Garau et al. 2000)
 
mutations and their 
relationship to HPV involvement. The 21 kDa ras protein has intrinsic GTPase 
activity, that is regulated by other protein factors, and acts as a focal point for several 
signal transduction pathways.  It is located on the cytoplasmic side of the cell 
membrane. The codons responsible for inter-protein reactivity are located at codons 
32 to 40. Point mutations have been identified that result in constitutive Ras activity. 
Leis et al examined two cases of PeScc, with one developing late relapse from 
inguinal metastases in the fifth year (Leis et al. 1998). HPV 18 was isolated in the 
primary tumour and nodal metastasis which was linked to mutations in TP53 and c-
ras
Ha
. Whilst HPV infection may be involved in early carcinogenesis, mutation in ras 
genes occur later and are linked to disease progression. Two studies (Couturier et al. 
1991; Sastre-Garau et al. 2000) from the same French institution investigated the 
pattern of genomic integration of HPV DNA in a small number of cases of penile 
cancer. They highlighted that the integration of HPV types 16 and 18 was localised to 
sites containing c-myc (8q24.1) and n-myc (2p24) proto-oncogenes. They also 
demonstrated genetic rearrangements in 3 out of 4 cases. Unfortunately, only one cell 
line was derived from a primary PeScc; however, these results warrant further 
validation.  
 
1.5.5.3. Cell cycle control 
The importance of cell cycle regulation is a cornerstone for normal cellular 
proliferation and genomic stability. As alluded to in previous sections, the cell cycle is 
under the tight influence of numerous signalling pathways involving different proto-
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oncogenes and tumour suppressor genes. The influence of p53 on cell cycle control 
and how the loss of the normal genotype can promote carcinogenic events has been 
previously described. Alternative factors involved in cell cycle regulation investigated 
in penile cancer include PCNA, which was shown not to have any prognostic benefit. 
In addition, the nuclear protein Ki67 which helps to identify the growth fraction 
within tumours has also been investigated.  
 
Ki67 is expressed in all phases of the cell cycle (G1/S/G2/M) but is absent from cells 
which have exited the cell cycle to reside in the G0 state (senescence, terminal 
differentiation or quiescence). This biological attribute allows Ki67 to identify the 
cells which are actively cycling. In normal squamous epithelium this growth fraction 
with positive immunohistochemical staining is restricted to the basal compartment. 
Medina et al investigated the localisation of Ki67 protein in verrucous tumours of the 
penis and demonstrated that proliferative activity was detected at the growing edge of 
the tumour (Medina, Valero, and Martinez Igarzabal 1999). This reflects the well 
differentiated nature of these tumours and the hypothesis that relative increased 
cellular activity is at the invasive edge of PeScc. p53 staining was negative in this 
study, in keeping with previous reports in verrucous cancers. Berdjis et al performed 
an analysis in 44 patients with penile cancer studying the relationship of Ki67 
expression to grade, stage and nodal status (Berdjis et al. 2005). The mean labelling 
index (LI) was 40.5% (6.4 to 93%) for all tumours analysed with the wide range of 
expression reflecting the strong correlation of Ki67 staining to tumour grade 
(p<0.005). There was no significant association with tumour stage or lymph node 
metastases (p=0.07). No survival data was available, so it was not possible to 
comment on the potential of Ki67 as a prognostic marker in this study.  A recent 
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report by Gentile et al investigated HPV, p53 and Ki67 associations in 11 PeScc 
specimens; with ten out of eleven tumours demonstrating positive expression for Ki67 
and p53 proteins. HPV positive cases also had high levels of p53 (80%) and Ki67 
(70%) (Gentile et al. 2006). 
 
1.5.5.4. Cyclo-oxygenase pathway 
Prostaglandin production via the cyclo-oxygenase pathway has been implicated as an 
important regulator and effector influencing multiple events in carcinogenesis and 
tumour invasion. Prostaglandin E2 (PGE2) has been identified as a bioactive product 
shown to stimulate cell proliferation, inhibit apoptosis, modulate angiogenesis, cell to 
cell signalling and suppress immune surveillance. Induction of the pathway has been 
linked to several carcinogenic promoters including polycyclic aromatic hydrocarbons 
produced by smoking. The pathway is also regulated by a number of molecules 
including growth factors, glucocorticoids, cytokines and inflammatory proteins.  
 
Two distinct cyclo-oxygenase isoforms (Cox-1 and Cox-2) exist which convert 
arachidonic acid into the intermediaries PGG2 and PGH2, both of which undergo 
further enzymatic change to produce the final PG products. Prostaglandin E synthase-
1 is responsible for the production of PGE2. In general, Cox-1 (“house-keeping”) is 
constitutively expressed, whilst Cox-2 (“inducible”) is not expressed in normal 
epithelium but induced through the factors described above. Over expression of Cox-2 
has been detected in various pre-malignant and malignant tissues; including 
oesophageal, lung and head/neck Scc (Shamma et al. 2000; Kim et al. 2002; Chang et 
al. 2004).   
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Golijanin et al have investigated the expression of Cox-2 and PGE synthase-1 in a 
small cohort of patients with PeScc (Golijanin et al. 2004). The authors clearly 
demonstrated an up-regulation of both factors in dysplastic and invasive cancer 
specimens with granular cytoplasmic staining compared to no expression in normal 
epithelium. Due to the small numbers of specimens analysed (n=7), it was not 
possible to draw definitive conclusions with respect to the potential utility of these 
factors as prognostic markers. Larger scale studies expanding on the interesting 
findings from this study may identify Cox-2 and associated proteins as both novel 
diagnostic, prognostic and therapeutic targets for future clinical trials. 
 
1.5.5.5. Invasion, metastasis and angiogenesis 
These events have been well described as essential in the progression of confined, 
local disease to stromal and lymphovascular invasion (Bissell and Radisky 2001). The 
first study analysing this important area in penile cancer was recently published, 
analysing E-cadherin (involved in intercell adhesion) and matrix metalloproteinases 
(MMP-2 and MMP-9) (involved in breakdown of extracellular matrix) in 125 patients 
with PeScc (Campos et al. 2006). The authors provided good evidence that low E-
cadherin immunoreactivity is associated with a greater risk of lymph node metastases 
and high MMP-9 expression was an independent risk factor for disease recurrence. 
These markers should be analysed further in prospective, multi-institutional studies. 
 
1.5.5.6. Squamous cell carcinoma antigen (Scc-Ag) 
Two genes (SCC Ag-1 and SCC Ag-2) have been identified that have highly 
homologous protein products which have been classified as serine protease inhibitors. 
The utility of these serological markers have been evaluated in several studies 
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involving penile cancer (Wishnow, Johnson, and Fritsche 1989; Wishnow, Johnson, 
and Fritsche 1990; Laniado et al. 2003)
 
revealing that they may provide information 
for detecting lymph node metastases in penile cancer, either at diagnosis (sensitivity 
57%; specificity 100%) or for patients entered into surveillance programs. Larger 
studies, perhaps focusing on Scc-Ag transcripts, are needed to fully evaluate the 
impact of this marker on clinical management in these patients.  
 
1.6. Chapter Summary 
Penile cancer is a rare malignancy associated with poor survival outcomes for patients 
with advanced disease states. Improving Outcomes in Urological Cancers Guidance 
(IOG) was released in 2002 (National Institute for Clinical Excellence 2002), and may 
have had an effect on mortality as more appropriate treatment is offered, and multi-
disciplinary teams (MDTs) have been formed to discuss treatment options. However, 
identifying patients who will benefit from aggressive therapeutic strategies remains 
problematic. The delineation of novel effective molecular targets capable of 
delivering powerful prognostic information as well as defining new therapeutic targets 
in this clinical setting is challenging. There is clear evidence of a fascinating, mixed 
heritage for tumourigenesis in penile cancer involving virological, inflammatory and 
genetic factors; all of which may act on various molecular pathways to induce and 
promote cancer states.  
 
In light of the important biological, prognostic, and therapeutic implications of RLFs 
as cell cycle regulators in normal cell proliferation and tumourigenesis, I have 
investigated their role in penile carcinoma. I have evaluated the multiparameter 
analysis of Mcm2, geminin, and Ki67 to study the cell cycle kinetics of this tumour 
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type in vivo and how deregulation of the replication licensing pathway may be linked 
to acquisition of aneuploidy.  
 
Using this panel of cell cycle biomarkers, I aim to identify key “proliferation 
signatures” that reflect aggressive cell cycle phenotypes linked to poorer clinical 
outcomes. Integration of these biomarkers with conventional clinicopathologic 
parameters in a novel predictive model has the potential to facilitate identification of 
those patients most likely to benefit from radical surgical and chemotherapeutic 
interventions.  
 
My findings will provide new insights into the biological mechanisms involved in 
tumour progression of penile carcinoma and how these novel biomarkers of growth 
might be exploited to predict the in vivo behaviour of this rare tumour type. 
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CHAPTER TWO 
MATERIALS & METHODS 
 
2.1. General 
2.1.1. Chemicals and reagents 
All chemicals were obtained from Sigma (St. Louis, MO, USA) unless specifically 
referenced by source.  
 
20x TRIS BUFFERED SALINE 
 60.6g   Trizma Hydrochloride  
 13.9g    Trizma base  
 87.6g    Sodium chloride  
 500ml    Distilled water 
 
5X PHOSPHATE BUFFERED SALINE (TABLETS) 
 42.5g    Sodium chloride 
32.4g   Disodium hydrogen phosphate 
0.78g   Sodium dihydrogen phosphate 
Make up to 1 litre with distilled water; pH 7.3 
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4X LAEMLLI SAMPLE BUFFER 
 33 mM  Tris-Cl (pH 6.8) 
 3.3% (w/v)  SDS 
 30% (v/v)  Glycerol 
 17% (v/v)  β-mercaptoethanol 
 0.02% (w/v)  Bromophenol blue 
 
5X TRIS-GLYCINE ELECTROPHORESIS BUFFER 
 125 Mm  Tris-base 
 1.25 M   Glycine 
 0.5% (w/v)  SDS 
 
TRANSFER BUFFER 
 0.3 M   Tris-base 
 10 mM  CAPS 
 0.02% (w/v)  SDS 
 10% (v/v)  Methanol 
 
GEL LOADING BUFFER 
 10% (v/v)  Glycerol 
 0.025% (w/v)  Bromophenol blue 
 
TRIS-EDTA BUFFER 
 10 mM  Tris-HCl 
 1 mM   EDTA (pH to 8.0) 
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FIXATION BUFFER 
 4%    Para-4-aldehyde 
 0.1%   Glutaraldehyde 
 
2% BSA/TBS SOLUTION 
 100mg   BSA 
 5ml   TBS solution 
 
CITRATE BUFFER (0.1 M) 
 80g    Sodium citrate  
 10l    Distilled water (pH to 6.0) 
 
PERMEABILISATION BUFFER 
 0.1%   Triton X-100 
 0.02%   SDS 
 
LYSIS BUFFER 
 50 mM  Tris-Cl (pH 7.5) 
 150 mM   NaCl 
 20 mM  EDTA 
 0.5% (v/v)  NPO4 
 
 
 
 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  102                                                                          
 
2.2. Acquisition of clinical data 
2.2.1 Clinical database 
Clinical and pathologic information was retrieved for 141 patients with squamous cell 
carcinoma of the penis stored on the secure hospital databases. SNOMED searches 
included the terms: penile carcinoma, urethral carcinoma, circumcision and 
penectomy for the period 1988-2007. All patients had been treated within the North 
Thames Cancer Network for penile cancer. The following clinical information was 
sourced directly from patients’ hospital medical records: date of birth, date of 
diagnosis, clinical stage, site, evidence of BXO, smoking status, primary and 
secondary surgery, date of last follow-up, and date and cause of death (Appendix A). 
Information was collated and stored in a clinical database held in the Department of 
Urology (University College London Hospital, London, UK). 
 
Patients who entered into surveillance programs without lymph node surgery were 
classified as negative after 2 years without disease presentation. Twelve patients with 
carcinoma in situ were removed from any formal survival analyses and 11 patients 
were lost to follow-up. Therefore, 118 patients were included in the long-term follow-
up survival study. The median follow up time was 20 months (range, 0.8-162.4 
months). Mean survival time amongst those who had died was 21.4 months (SD=25.6 
months, range 1-138 months). 
 
2.2.2 Tissue specimens 
Ethical approval was obtained from the Joint UCL/UCLH Committees on the Ethics 
of Human Research (Appendix B). Histologic specimens were reviewed by a uro-
oncology pathologist at diagnosis. Paraffin wax–embedded tissue specimens were 
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retrieved from the pathology archives for all patients. Excised tumours were 
histologically staged using the revised tumour-node-metastasis (TNM) system criteria 
2002 (Sobin LH and Wittekind C 2002). Pathologic variables of the primary tumour 
included: grade, local stage, subtype, extent (unifocal/multifocal), tumour size, depth 
of invasion, and lymphovascular invasion. All pathologic parameters were recorded 
by a specialist uro-oncology pathologist and independently reviewed by a second 
pathologist. Tumour grade was defined using Broders' classification (Broders AC. 
1921): well differentiated (grade 1), moderately differentiated (grade 2) and poorly 
differentiated (grade 3). Tumour size was defined as the maximal dimension and 
depth of invasion measured from adjacent normal epithelium to the deepest invasive 
point. Lymphovascular invasion was determined microscopically and confirmed using 
antibodies against endothelial markers CD33 and CD34. Lymph node status was 
confirmed following pathologic review of inguinal and pelvic lymph node specimens 
attained through prophylactic or delayed lymphadenectomy. 
 
2.3. Immunological techniques 
2.3.1. Antibodies  
Affinity-purified rabbit polyclonal antibody against full-length hsgeminin and was 
produced in the host laboratory as described (Wharton et al. 2004). To summarise; 
pET15b-human (hs)Geminin was expressed in Escherichia coli strain BL21(De3) and 
purified by Ni-NTA metal affinity chromatography following the manufacturers’ 
instructions (Qiagen, Crawley, UK). Recombinant hsGeminin was further purified 
using an (HPLC) Hiload Q sepharose 16/10 column in NaPi buffer and eluted with 
varying concentrations of 1 M NaCl. Four rabbits were injected with 125 mg of 
purified hsGeminin protein, and received three boost injections over a period of 80 
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days following a standard protocol (Eurogentech, Seraing, Belgium). The sera were 
collected and affinity-purified on a CNBr column against 10 mg of recombinant 
hsGeminin protein, eluted with 0.1 M glycine (pH 2.5) and dialysed into PBS, 1% 
BSA and 0.1% sodium azide. An equal volume of sterile glycerol was added and 
affinity-purified polyclonal antibodies G92 and G95 were stored at -20
o
C. Antibody 
purification was quality controlled by SDS–PAGE for purity and by ELISA. 
Specificity of the affinity-purified antibodies was demonstrated by immunoblotting of 
cell lysates and by quenching all immunohistochemical staining after incubating 
antibodies diluted at working concentrations with equal or less than molar amount of 
recombinant hsGeminin protein for 1 h prior to a standard immunohistochemical 
staining protocol. The following antibodies were sourced commercially: Ki-67 
monoclonal Ab (clone MIB-1); CD31 monoclonal Ab (clone JC70A) & CD34 
monoclonal Ab (clone QBEnd10) were obtained from DAKO (Glostrup, Denmark), 
Mcm2 monoclonal Ab (clone 46) from BD Transduction Laboratories (Lexington, 
KY) and Cdt1 monoclonal Ab (clone 14676) from Abcam (Cambridge, UK). The 
specificity of Ki67 and Mcm2 monoclonal antibody has been extensively studied and 
validated in previous studies (Dudderidge et al. 2005; Shetty et al. 2005; Kulkarni et 
al. 2007; Loddo et al. 2009).  
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Antibody Immunogen Source WB condition 
IHC 
condition 
Actin MAb 
(clone AC-74) 
β-actin 
N-terminus 
Sigma 
A5316 
5% milk 
1:2500 
- 
CD31 MAb 
(clone JC70A) 
CD31 
N-terminus 
DAKO 
M7240 
- 1:20 
CD34 MAb 
(clone QBEnd10) 
CD34 
N-terminus 
DAKO 
M7240 
- 1:50 
Cdt1 MAb 
Cdt1 
C-terminus 
533-546aa 
Abcam 
Ab14676 
5% milk; 0.1% tween 
1:300 
- 
Geminin PAb 
(#2095) 
geminin 
Full-length 
In-house 
10% milk 1% tween 
1:1000 
1:1500 
dilution 
Ki67 MAb 
(clone MIB-1) 
Ki67 
1002 bp peptide 
DAKO 
M7240 
- 1:70 dilution 
Mcm2 MAb 
(clone46) 
Mcm2 
C-terminus 
725-888aa 
BD Labs 
BM28 
5% milk 0.1% tween 
1:2000 
1:1000 
dilution 
 
Table 2.1 – Antibody specifications 
  
   
2.3.2. Immunoblotting 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed using pre-cast 
Novex 4-20%  Tris-glycine gels with the XCell Surelock
TM
 mini-cell electrophoresis 
system (Invitrogen). Protein samples were mixed with 4x laemlli buffer, heated to 
90
o
C for 3 minutes and pulse centrifuged. 50 µg protein was loaded per well 
according to associated Bradford assay calculations. Samples were run in 1x Tris-
glycine running buffer at 125 mV for approximately 90 minutes. Protein migration 
was confirmed using Ponceau red staining. Protein transfer from polyacrylamide gels 
to nitrocellulose membranes (Amersham Biosciences Buckinghamshire, UK) was 
achieved using semi-dry electroblotting in transfer buffer. Non-specific binding was 
blocked siting the membranes in 5% skimmed milk powder, 0.1% Tween-20 and PBS 
overnight at 4
o
C. Primary antibodies were introduced in the following dilutions and 
conditions and incubated for 2 hours at RT: Mcm2 (1/2000; 5% milk; 0.1% tween), 
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geminin (1/1000; 10% milk; 1% tween), Cdt1 (1/300; 5% milk; 0.1% tween) and 
Actin control. Membranes were washed in PBS/0.1% Tween-20 solution for 5 
minutes and repeated for 6 washes. Secondary antibodies were applied and incubated 
in the above conditions for 1 hour at RT. Finally, membranes were washed again for 6 
washes and immunoreactive bands visualised on photographic film (Kodak) by 
enhanced chemiluminescence (ECL, Amersham Biosciences). 
 
2.3.3.   Immunohistochemistry 
Antibodies used were those described previously (2.3.1). Archival formalin-fixed, 
paraffin-embedded tissues were retrieved as described (2.2.2). Archival formalin-
fixed, paraffin-embedded tissue (PWET) obtained at initial diagnosis was available 
for all patients and for each specimen a block was chosen that contained a 
representative sample of invasive tumour. Consecutive serial sections cut from each 
PWET block were used for immunohistochemistry. Three µm tissue sections were cut 
onto Superfrost Plus slides (Visions Biosystems, UK), dewaxed in xylene and 
rehydrated through graded alcohol to water. For antigen retrieval, slides were pressure 
cooked in 0.1 mol/L citrate buffer (pH 6.0) at 103kPa for 2.5 min. Tissue sections 
were immunostained using the Bond
TM
 Polymer Define Detection kit and
 
Bond
TM
-x 
automated system (Vision Biosystems, Newcastle Upon Tyne, UK) according to the 
manufacturer’s instructions. The following protocol was used for automated staining; 
peroxidase activity was quenched using peroxidase blocking solution for 10 min. 
Sections were washed and incubated with protein block for 10 minutes. Following 
washing, primary antibodies were applied to sections at the dilutions stated (Table 
2.1.) and incubated for 40 min. Sections were washed and post-primary was applied 
for 30 min followed by washing and addition of polymer for a further 30 min. After 
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washing, immunostaining was developed using 3,3 diaminobenzidine 
tetrahydrochloride (DAB) for 10 min followed by Bond
TM
 DAB enhancer (AR9432, 
Vision Biosystems). After washing in dH20, sections were counterstained with 
Meyer’s haematoxylin for 5 min, differentiated in 1% acid alcohol, dehydrated 
through water to alcohol and cleared in xylene.  Coverslips were applied with Pertex 
mounting medium (CellPath Ltd, Newtown Powys, UK). Incubation without the 
primary antibody was used as a negative control and colonic epithelial sections were 
used as positive controls. 
 
2.3.4. Protein expression profiling 
Protein expression analysis was done by determining the labelling index (LI) of the 
markers in each tumour, as previously described (Meng et al. 2001; Shetty et al. 2005; 
Dudderidge et al. 2005; Kulkarni et al. 2007; Loddo et al. 2009).  Consecutive serial 
sections cut from the same formalin-fixed, paraffin-embedded tissue block were used 
to stain for the markers. Slides were evaluated at ×100 magnification to select the 
advancing edge of the tumour. Selected areas at the advancing edge plus three to five 
adjacent fields perpendicular to the advancing front moving progressively towards the 
centre of the tumour were image captured at ×400 magnification with a charge-
coupled device camera and AnalySIS image analysis software (SIS). Images were 
subsequently printed for quantitative analysis, which was undertaken with the 
observer unaware of the clinicopathologic variables. Both positive and negative cells 
within the field were counted and any stromal or inflammatory cells were excluded. A 
minimum of 500 cells was counted for each case. The LI was calculated using the 
following formula: LI = number of positive cells/total number of cells × 100. Normal 
foreskin and colon specimens were used as external controls. Normal adjacent 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  108                                                                          
 
epithelium acted as an additional internal control. Reassessment of 10 randomly 
selected cases by an independent assessor showed high levels of agreement. 
 
2.4. Cell biology techniques 
2.4.1. Cell culture and synchronisation  
HeLa S3 tissue culture cells were cultured in Dulbecco’s modified Eagle’s medium 
(Gibco-BRL) supplemented with 10% foetal calf serum (FCS, Gibco-BRL). SKOV3 
tissue culture cells were maintained in McCoy’s 5A medium (Gibco-BRL) 
supplemented with 15% FCS (Gibco-BRL). For both cell lines growth media also 
contained 100 U/ml penicillin and 0.1 mg/ml streptomycin. HeLa cell cycle 
synchronisation was performed essentially as described (Krude et al 1997). Briefly, 
for preparation of cells in G1/S, cells were synchronised in very early S phase by two 
sequential 25 h blocks in 2.5 mM thymidine separated by a 12 h interval without 
thymidine (Rao and Johnson 1970). For preparation of cells in G2/M phase, cells 
were released from the second thymidine block for 3 h, followed by adding 40 ng/ml 
nocodazole for an additional 12 h to arrest them in mitosis (Johnson et al 1993). For 
SKOV-3 cell cycle synchronisation, cells were synchronised in very early S phase by 
one 25 h block in 2.5 mM thymidine. Cells were released from the thymidine block 
for 3 h, followed by adding 40 ng/ml nocodazole for an additional 12 h to arrest them 
in mitosis. 
 
2.4.2. Preparation of total cell extracts 
HeLa S3 and SKOV3 cells (asynchronous and synchronised time points) were 
harvested by treatment with trypsin, washed in PBS, and resuspended in lysis buffer 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  109                                                                          
 
at 5x10
5
 cells/ml. After incubation on ice for 30 minutes, the lysate was clarified by 
high speed centrifugation (13,000g, 15 min, 4°C) and stored at -80
o
C. 
 
2.4.3. Bivariate flow cytometric analysis 
For cell cycle analysis of DNA content cell samples were fixed in 80% ethanol for a 
minimum of 12 h. After fixation, cells were washed twice in dPBS and incubated for 
20 min with 0.5 ml PI (20 µg/ml) and RNase A (50 µg/ml) (Helmstetter et al 2003) 
and 0.5 ml dPBS at RT. To prevent clumping of cells and loss of sample, 100 µl of 
1% BSA was added at each step and unautoclaved pipette tips were used. Analyses of 
DNA content were performed using a FACSCalibur flow cytometer (BD 
Biosciences). Cell doublets were excluded where necessary by gating on a dot plot of 
the width vs the area of DNA fluorescence intensity (Erlanson and Landberg 1998). In 
most samples, 10
4 
cells were examined and data were analysed using CellQuestTM 
software (BD Biosciences) and WinMDI (V 2.8). 
 
2.5. DNA image cytometric analysis 
For each case, a 40µm section of formalin-fixed, paraffin-embedded tissue obtained 
from the same block as that assessed by immunohistochemistry was used to prepare a 
suspension of nuclei. PWET sections were placed in 50ml falcon tubes and dewaxed 
in xylene followed by rehydration through graded alcohol to water and finally 
suspended in cold PBS. The supernatant was aspirated and excluded between 
solutions. Protease XXIV (2ml) was added to the specimens and incubated for 2h at 
37
o
C in a shaker water bath. Chilled PBS (3ml) was added to quench the enzymatic 
digestion and the samples were filtered through nylon mesh filters. Samples were 
centrifuged at 1500 rpm for 5 minutes and the supernatant discarded. The pellet was 
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re-suspended in 3ml fresh PBS then cytospun in 100 and 200μl aliquots at 1500 rpm 
for 5 minutes to prepare a monolayer of nuclei on Superfrost glass slides (Visions 
Biosystems UK).  The density of the nuclear preparation on the slide was checked 
under a light microscope using toludine blue stain and an adjusted volume of the 
suspension was cytospun if correction of the density was required. The monolayer 
preparations were air dried and fixed overnight in 4% formaldehyde. After washing in 
distilled water, slides were incubated in 5 mol/L HCl for 1h at room temperature for 
hydrolysis. Slides were then rinsed in distilled water and incubated in Feulgen-
Schiff's solution for 2h in the dark. Finally, the slides were washed in running tap 
water for 10 minutes, dehydrated in increasing alcohol gradient, cleared in xylene, 
and coverslipped. 
 
The Fairfield
 
DNA Ploidy System (Fairfield Imaging Ltd, Nottingham, UK) was used 
for image processing, analysis and classification (Figure 2.1). Monolayers were 
analysed with the use of a Zeiss Axioplan II microscope (Zeiss, Oberkochen, 
Germany) that was equipped with a 546nm green filter (plus X40 lens and 0.65 
objective). A modified stage was used linked to a coordinate computer model 
(H152V2, Prior Scientific Instruments, Fulbourn, Cambridge, UK). The microscope 
was also equipped with a single-chip digital camera (model C4742-95, Hamamatsu 
Photonics, Japan.). The final magnification was x1600 at an estimated resolution of 
170nm (0.2μm) per pixel; the visual field measured 1024 by 1024 pixels and had a 10 
bit resolution (1024 gray levels). The nuclei of at least 1000 cells were collated and 
the information stored as a ‘gallery’ in a computerised folder. Lymphocytes and 
plasma
 
cells were included as internal controls, and sections of high-grade bladder 
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tumour and normal foreskin tissue were analysed as external controls for the 
aneuploid and diploid populations, respectively.
  
 
Histograms were classified according to the following previously published criteria 
(Haroske G et al. 1997 ESACP consensus report). The tumour was classified as 
diploid if only one G0-G1 peak (2c) was present, the number of nuclei in the G2 (4c) 
peak did not exceed 10% of the total number of nuclei, and the number of nuclei with 
a DNA content exceeding 5c did not exceed 1%. A tumour was defined as tetraploid 
when a peak in the 4c position was present together with a peak in the 8c position or 
the fraction of nuclei in the 4c region exceeded 10% of the total number of nuclei. A 
tumour was defined as polyploid when a peak in the 8c position was present together 
with a peak in the 16c position. The tumour was defined as aneuploid when 
noneuploid peaks were present or the number of nuclei with a DNA content 
exceeding 5c/9c, not representing euploid populations, exceeded 1%. The histograms 
were classified by two independent assessors with a high level of agreement and 
without knowledge of the clinicopathologic variables. For the purposes of statistical 
analysis, tetraploid and polyploid tumours were grouped together with aneuploid 
tumours (technical figure 2.1). 
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Figure 2.1 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  113                                                                          
 
2.6. Statistical analysis 
Relationships between biomarker expression and other factors were assessed using the 
Mann-Whitney U, Kruskal-Wallis, and Jonckheere-Terpstra tests. Data were 
summarized as the median value and interquartile range of LIs observed across the 
cohort. Multivariable analyses for lymph node status were carried out in three steps 
using logistic regression: (a) all factors were assessed separately and those with P < 
0.05 were retained, (b) remaining pathologic and biomarker factors were entered into 
two separate models and backward elimination was applied with P = 0.05, and (c) 
remaining factors were entered into a single model and backward elimination was 
applied to produce a final model. Multivariable analyses for overall survival were 
carried out in a similar fashion using Cox's proportional hazards model. The 
discriminatory ability of this model was quantified using Harrell's c-index (Harrel 
2001), which is analogous to the receiver operating characteristic area and gives the 
probability that two randomly selected patients have concordant predictions and 
survival times. The c-index takes values between 0.5 (random predictions) and 1 
(perfect concordance). Patients were divided into tertile model-based risk groups and 
labeled as low, medium, and high risk for disease progression. Patients with 
incomplete data were excluded from multivariable analyses. All tests were two sided 
and used a significance level of 0.05 with 95% confidence intervals (95% CI), and no 
allowances were made for multiple hypothesis testing. All analyses were done using 
Stata 10 for Windows (StataCorp).  
 
2.7. Computing and data storage 
Clinical information, including patients’ personal details, was stored in dual electronic 
database formats (MSExcel & MSAccess Microsoft Corporation, USA). This 
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information was made available to the National UK Andrology Database, a SSL 
encrypted web based real-time database (written and developed by Mr. Nim 
Christopher) and linked to the British Association of Urological Surgeons (BAUS) 
cancer registry.  All images were generated using Adobe Illustrator and  Photoshop 
version 7.0 (Adobe Systems Inc, USA) using only standard contrast and brightness 
adjustment functions. The text of this thesis was constructed in MSWord (Microsoft 
Corporation, USA).  
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CHAPTER THREE 
 
INTEGRATED STAGING SYSTEMS IN 
PENILE CANCER: DEVELOPING A 
PREDICTIVE MODEL USING  
TUMOUR PLOIDY INFORMATION 
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CHAPTER THREE 
INTEGRATED STAGING SYSTEMS IN PENILE 
CANCER: DEVELOPING A PREDICTIVE MODEL 
USING TUMOUR PLOIDY INFORMATION 
 
3.1. Introduction 
Therapeutic algorithms in the management of patients with squamous cell carcinoma 
of the penis are currently reliant on risk stratification based on clinical information 
and primary tumour characteristics (Solsona et al. 2004; Ficarra et al. 2006; Kattan et 
al. 2006a). In patients with localized disease, the most relevant prognostic feature is 
the identification of clinical and/or pathologic factors able to predict the presence of 
metastatic disease within regional lymph nodes. Lymph node involvement is the 
strongest predictor of survival in this patient group with data supporting a survival 
benefit following radical surgical resection of involved nodal tissue (Ravi 1993b). 
Patients with palpable inguinal lymphadenopathy (clinically positive; cN+) have a 
high probability of habouring loco-regional disease as reported in several large case 
series with early lympadenectomy advocated. However, some patients may present 
with reactive lymphadenopathy secondary to concomitant infection thus confusing the 
clinical picture. Conversely, in patients with impalpable inguinal lymph nodes 
(clinically negative; cN-); approximately 20% of patients will harbour 
micrometastases who may be disadvantaged if placed into surveillance programmes 
incorrectly (Lont et al. 2003b; Lont et al. 2003a; Kroon et al. 2005).  
 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  119                                                                          
 
The diagnostic and therapeutic dilemma is further complicated given the significant 
morbidity and mortality associated with these surgical techniques which limit their 
routine implementation in all patients (Ravi 1993a; Horenblas 2001). Finally, the role 
of adjuvant and neoadjuvant chemotherapy is poorly understood with limited level 
A/B evidence to support any single agent or regime (Pizzocaro and Piva 1988; 
Yumura et al. 2007; Bermejo et al. 2007; Leijte et al. 2007). Likewise, current 
chemotherapeutic regimes in disseminated disease are linked to poor clinical 
outcomes and high levels of toxicity (Protzel and Hakenberg 2009). Therefore, patient 
identification and selection for aggressive surgical approaches, as well as inclusion for 
neoadjuvant and adjuvant chemotherapeutic programmes remains a challenging 
problem in the management of these patients. 
 
Since the development of this diagnostic and treatment paradigm, numerous studies 
have attempted to identify clinical and pathological factors that may help to predict 
lymph node involvement; as a surrogate marker of survival and outcome. This led to 
the publication of guidelines developed through the European Association of 
Urologists (EAU) consensus group (Solsona et al. 2004), who devised and 
prospectively validated the association of local tumour stage and grade as a predictive 
factor for occult lymph node metastasis in patients with clinically negative (cN-) 
inguinal lymph nodes.  
 
Subsequent studies have further evaluated the impact of these standard pathological 
factors in conjunction with newer pathological parameters. Important factors 
identified with strong associations with lymph node metastases include: depth of 
invasion, size of tumour, tumour thickness, lymphovascular invasion and tumour 
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growth patterns (Ornellas et al. 1994; Cubilla et al. 2001a; Cubilla et al. 2001b; Lopes 
et al. 1996; Slaton et al. 2001).  
 
The lack of diagnostic discriminatory power related to current imaging modalities  
(ultrasound, computed tomography and magnetic resonance imaging) to accurately 
delineate inguinal and pelvic lymphatic involvement (Horenblas et al. 1991; Rubben 
and Lutzeyer 1981; Maiche 1993; Scher et al. 2005; Mueller-Lisse et al. 2008) has 
promoted further development of new nomograms predictive of pathological inguinal 
lymph node involvement and cancer specific survival in patients with PeScc (Ficarra 
et al. 2006; Kattan et al. 2006a). It is hoped that these new integrated staging systems 
will help to diminish the number of unnecessary inguinal and pelvic 
lymphadenectomie. These prognostic tools await crucial prospective application to 
fully understand their clinical utility in this patient population. 
 
In order to determine the importance of clinicopathological features of squamous cell 
carcinoma of the penis in the United Kingdom, I sought to analyse a large, single 
institution, retrospective review of archival penile carcinoma specimens. The 
histopathological information has been linked to clinical data in order to validate this 
database with respect to clinical and demographic information against published case 
series.  Subsequently, I have studied the DNA content of these tumours using image 
cytometry and correlated this variable against known, standard pathological factors. 
Finally, I have evaluated the impact of aneuploidy as a novel predictive factor for 
loco-regional lymph node metastases in men with PeScc. 
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3.2. Materials and Methods 
For Clinical data (2.1.1.2), Antibodies (2.2.1), Immunohistochemistry (2.2.5), DNA 
ploidy analysis: image-based cytometry (2.2.6), Statistical methods (2.2.7.) refer to 
Chapter Two.  All histological techniques were performed as outlined in the review 
by Mikuz -‘Handling and pathology reporting for circumcision and penectomy 
specimens’ (Mikuz et al. 2004). Sections are highlighted for clarity and to reference 
the review process undertaken for all archival specimens. 
 
3.2.1. Patient inclusion 
Clinical and pathological information was retrieved for 141 patients with squamous 
cell carcinoma of the penis stored on the secure hospital databases. SNOMED 
searches included the terms: penile carcinoma, urethral carcinoma, circumcision and 
penectomy for the period 1988-2004. Patients were also recruited prospectively 
though the North Thames Cancer Network for penile cancer referrals from 2004 until 
the end of the study. Archival haematoxylin-eosin stained slides were reviewed and 
the quality of the paraffin wax embedded samples assessed.  Representative tumour 
sections were chosen and processed for immunohistochemistry as described in section 
2.2.6. Primary antibodies were added at dilutions CD31 (1 in 50; Rat Anti-Mouse 
CD31 (PECAM-1); BD Pharmingen) and CD34 (1 in 80;  My10, Mouse anti-Human; 
Becton Dickinson) in order to assess for the presence of invasion by tumour cells into 
vascular spaces. All specimens were reviewed by a single pathologist specialising in 
urogenital pathology. 
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3.2.2. Specimen processing & preparation 
Tissue specimens were handled, fixed and mounted into paraffin wax embedded 
blocks as previously described. Macroscopic findings were recorded in all incidences. 
Specific attention was paid to specimen orientation with longitudinal serial sectioning 
of circumcision specimens. Penectomy specimens were bisected longitudinally with 
reference to the urethra. Histology sections of the tumour, foreskin, transverse section 
through the shaft and longitudinal glans sections were required and the resection 
margin noted (Figure 3.1).  
 
Lymph nodes without overt metastasis greater than 5 mm were cut through the hilus 
in 2 mm thick parallel slices. Lymph nodes smaller than 5 mm along the longitudinal  
axis were entirely processed. Negative lymph nodes are entirely processed (steps of 
250 μm). 
 
3.2.3. Pathology reporting 
Pathology reports were generated with reference to the publication by Mikuz (Mikuz 
et al. 2004) and external validation regarding general histopathology, penile 
carcinoma subtypes including pathology and outcomes sourced from World Health 
Organization of Tumours – tumours of urinary system and male genital organs (Eble 
J.N et al. 2004). 
 
3.2.3.1. Histology of benign & pre-malignant squamous lesions of the   penis 
(a) Normal squamous epithelium 
Control tissues sections were retrieved from the archive involving penile epithelium 
(foreskin +/- glans). Normal epithelial architecture was confirmed such that the 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  123                                                                          
 
basement membrane and lamina propria were intact with normal cellular proliferation 
and maturation from basal layers to apical terminally differentiated keratinocytes. 
Levels of keratin production were noted. Areas of normal epithelium were also 
assessed as internal controls in all cases with atypical or neoplastic changes. 
 
(b) Squamous hyperplasia 
Microscopic findings consisted of elongation, widening of the rete ridges and 
irregular thickening of the Malpighian layer of rete ridges (acanthosis), 
hyperkeratosis, and chronic inflammation in dermis. Inflammatory reactions within 
the dermis consisted of lymphocytes and a small number of plasma cells. Invasive 
malignancy was carefully excluded in all cases. 
 
(c) Balanitis Xerotica Obliterans (BXO) 
Histologically, these lesions demonstrated an atrophic epidermis with the loss of the 
rete pegs and homogenization of collagen in the upper third, combined with a zone of 
lymphocytic and histiocytic infiltration. These changes resemble the lesions of lichen 
sclerosis et atrophicus observed elsewhere in the body. The term is used 
interchangeably with male genital lichen sclerosus (MGLS). 
 
(e) Carcinoma in situ (Cis) 
As seen with cases of intraepithelial neoplasia observed elsewhere, these pre-invasive 
lesions were characterised by atypical hyperplastic cells showing disorientation, 
vacuolation, multiple hyperchromatic nuclei and mitotic figures at all  
Figure 3.1 
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Figure 3.1 
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Figure 3.2 
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levels. The epithelial rete extended into the submucosa and appeared elongated and 
bulbous. The submucosa showed capillary proliferation and ectasia with a 
surrounding inflammatory infiltrate, usually rich in plasma cells. These lesions are 
usually termed erythroplasia of Queryat if involving the glans/shaft penis or prepuce 
and Bowen’s disease if involving the remainder of the genitalia or perineal skin. 
 
3.2.3.2. Histology of squamous cell carcinoma of the penis 
The majority of penile cancers are primary, squamous cell carcinomas (PeScc) 
originating in the epithelium covering the glans, coronal sulcus, and foreskin. Several 
histologic subtypes have been described, each with distinctive clinicopathologic and 
outcome features. Penile verruciform tumours encompass verrucous, warty 
(condylomatous), and papillary carcinomas. As a group, verruciform tumours are low 
grade, with low metastatic and mortality rates. In contrast, basaloid and sarcomatoid 
carcinomas are among the most aggressive penile tumours. Other PeScc variants, such 
as carcinoma cuniculatum and pseudohyperplastic, adenosquamous and acantholytic 
carcinomas are rare.  
 
(a) Squamous cell carcinoma, usual type (NOS) 
PeScc of usual type (NOS) accounts for 48%-65% of penile carcinomas. 
Macroscopically, they range from white-to-grey, irregular exophytic to reddish flat 
and ulcerated endophytic masses. Microscopically, the tumours vary from well-
differentiated keratinizing tumours to solid anaplastic carcinomas with scant 
keratinization. Grading criteria have recently been published and are discussed in 
section 3.2.3.2. Most tumours are highly keratinized with moderate differentiation. 
Poorly differentiated carcinomas can have variable amounts of spindle cell, giant cell, 
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solid, acantholytic, clear cell, small cell, warty, basaloid, or glandular components. 
PeScc (NOS) has a recurrence rate of 28% and lymph node metastases appear in 28%-
39% of cases. The mortality rate is 20%-38% with a 10-year survival rate of 78%. 
 
(b) Verrucous carcinoma 
Verrucous carcinoma represents 3%-8% of penile carcinomas. It is slow-growing and 
extremely well-differentiated, with a papillomatous appearance and broadly based 
limits between the tumour and stroma. Verrucous PeScc is consistently HPV negative. 
It can be confused with other tumours, such as giant condylomas and papillary and 
warty carcinomas. The tumour can be locally aggressive but it is biologically benign 
with negligible threat for metastatic disease. Macroscopically, it exhibits a 
cobblestone to filiform surface and rarely invades beyond the lamina propria, 
superficial dartos, or corpus spongiosum. Microscopically, there is distinct squamous 
differentiation, papillomatosis, hyper- and orthokeratosis, acanthosis, and a broadly 
based interface between the tumour and stroma. Koilocytosis is not present. A 
spectrum of combined tumours exist with focal or significant verrucous features that 
must be distinguished from pure verrucous carcinomas. These mixed or hybrid 
verrucous carcinomas are reported to develop metastases in approximately 25% of 
cases. Associated lesions include: squamous (verrucoid) hyperplasia, differentiated 
penile intraepithelial neoplasia (PeIN), and lichen sclerosus. No inguinal nodal 
metastases have been associated with pure verrucous carcinomas and the mortality 
rate is 0%. 
 
 
 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  128                                                                          
 
(c) Warty (condylomatous) carcinoma 
Warty (condylomatous) carcinomas are slow-growing, low-grade, HPV-related 
verruciform tumours representing 7%-10% of penile carcinomas. HPV DNA has been 
detected in 22%-100% of these tumours. Macroscopically, they are cauliflower-like, 
exophytic, white-to grey tumours. The cut surface shows a papillomatous growth, 
usually penetrating into the corpora cavernosa or corpus spongiosum. The interface 
between the tumour and stroma ranges from broadly based to jagged and irregular. 
Microscopically, the papillae are condylomatous, with a prominent central 
fibrovascular core and koilocytic changes, not restricted to the surface, but also 
present in deep invasive portions of the tumour. Hyper- and parakeratosis, cellular 
pleomorphism, and clear cell features can be observed. A morphologic spectrum of 
condylomatous tumours exists that share koilocytic changes ranging from clearly 
benign (usual condylomas) to frankly malignant (invasive warty carcinoma), passing 
through atypical condylomas and noninvasive warty carcinomas. The biological 
behavior of warty carcinomas is intermediate between that of verrucous/papillary and 
PeScc (NOS). Deeply invasive, high-grade warty carcinomas can be associated with 
inguinal nodal metastases. The differential diagnosis includes verrucous and papillary 
carcinomas and giant condylomas. Warty carcinomas lack the extreme differentiation 
of verrucous carcinomas and show jagged and irregular deep borders. Papillary 
carcinomas lack koilocytosis, and the papillae are more complex, with irregular 
fibrovascular cores and jagged tumour base. The associated precursor lesions of warty 
carcinomas are warty/basaloid PeIN. Local recurrences are observed in 10% of cases, 
and the inguinal metastatic rate is 17%-18%. The cancer-specific mortality rate is 0%-
9%.  
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(d) Papillary carcinoma 
Papillary carcinoma is another verruciform tumour and accounts for 5%-15% of 
penile carcinomas. The HPV detection rate is low. Macroscopically, they are 
exophytic, large, and irregular. The cut surface shows an invasive papillary neoplasm 
with an irregular tumour front. Microscopically, the appearance is that of a low-grade 
papillary squamous neoplasm. There is hyperkeratosis and papillomatosis. The 
papillae are variable and complex, short or long, with or without a fibrovascular core. 
The tips are straight, undulated, spiky, or blunt. The tumour front is irregular and 
infiltrative. Koilocytic changes are absent. The differentiating features from verrucous 
and warty carcinomas are based on the heterogeneity of the papillae, the lack of 
koilocytosis, and the jagged irregular interface between the tumour and stroma. The 
latter feature is crucial to distinguish papillary from verrucous carcinoma. 
Differentiated PeIN and lichen sclerosus are frequently associated with this PeScc 
variant. The recurrence rate is low (12%), and inguinal nodal metastases are observed 
in 12% of all patients. The mortality rate is low (0%-6%). 
 
(e) Basaloid carcinoma 
Basaloid carcinoma is an aggressive HPV-related tumour, representing 4%-10% of all 
penile cancers. About 70%-80% of cases have evidence of HPV infection. 
Macroscopically, an ulcerated nonexophytic irregular mass is present. The cut surface 
reveals a tan, solid tumour, deeply invasive into the corpus spongiosum or 
cavernosum. Basaloid carcinoma limited to the lamina propria is exceedingly rare. 
Histologically, solid nests of small uniform basaloid cells are found, usually with 
central necrosis (comedo necrosis) or central abrupt keratinization. Nucleoli are 
inconspicuous, and apoptosis and mitoses abundant. Warty/basaloid PeIN is often 
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found in the epithelium adjacent to the invasive cancer. Local recurrences have been 
observed in up to one third of case and nodal metastasis in 50%-100% of cases. Up to 
one third of patients will die of systemic metastases, and 10-year survival rate is 76%. 
 
(f) Sarcomatoid carcinoma 
Sarcomatoid carcinoma accounts for 1%-3% of penile cancers. It is an aggressive 
neoplasm predominantly composed of spindle cells. HPV has been found in a few 
cases. Macroscopically, they appear as bulky, 5-10 cm, ulcerated or rounded polypoid 
masses. The cut surface almost invariably shows invasion deep into the corpus 
cavernosum. Microscopically, variable proportions of squamous cell and spindle cell 
carcinoma are present. The sarcomatoid component might mimic fibrous 
histiocytoma, leiomyosarcoma, fibrosarcoma, myxosarcoma, or angiosarcoma. 
Heterologous bone and cartilaginous formation might be focally observed. The 
differential diagnosis includes sarcoma or malignant melanoma. Inguinal nodal 
metastasis are seen in 75%-89% of cases, the mortality rate is high (40%-75%), local 
and systemic recurrences develop in up to two thirds of patients, and most die within 
1 year of diagnosis.  
 
(g) Carcinoma cuniculatum 
Carcinoma cuniculatum is an extremely unusual verruciform PeScc variant 
characterized by a burrowing growth pattern. No evidence of HPV infection has been 
found. Macroscopically, the tumours are white-to-grey and affect the glans, extending 
to the coronal sulcus and foreskin. Characteristically, on the cut surface, deep 
invaginations form irregular, narrow, and elongated neoplastic sinus tracts that 
connect the tumour surface to deep anatomic structures. Microscopically, it resembles 
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verrucous carcinoma, with a bulbous front of invasion. However, irregular foci of 
invasive PeScc (NOS) can be present. It should be distinguished from classic 
verrucous carcinoma, which rarely invades beyond the lamina propria. Despite deep 
penetration, none of the reported cases have shown groin metastases or systemic 
dissemination. 
 
(h) Pseudohyperplastic carcinoma 
Pseudohyperplastic carcinoma is a clinicopathologic entity represented by low grade, 
PeScc (NOS) preferentially affecting the foreskin of older patients (eighth decade) in 
association with lichen sclerosus. The tumour is not related to HPV infection. There is 
extreme differentiation and, in small biopsies, it can mimic pseudoepitheliomatous 
hyperplasia. It is often multicentric, and the second or third independent tumour might 
be verrucous. Macroscopically, they are flat or slightly elevated lesions measuring 
about 2 cm. Microscopically, keratinizing irregular nests of squamous cells are 
apparent, with minimal atypia, surrounded by reactive stroma that seems detached 
from the underlying epithelium and usually invades up to the preputial dartos. The 
prognosis is excellent, and none of the reported cases showed lymphatic or systemic 
dissemination. 
 
(i) Adenosquamous carcinoma 
Adenosquamous carcinoma is a rare tumour composed of squamous cells 
intermingled with areas of glandular differentiation. It is thought to arise from the 
epithelial surface of the glans. Macroscopically, a firm, granular, large neoplasm 
deeply invading the penile corpora is present. Microscopically, a mixed squamous cell 
mucin-producing adenocarcinoma pattern is seen. The squamous component 
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predominates. Glands stain with carcinoembryonic antigen. Adenosquamous 
carcinoma should be distinguished from mucoepidermoid, adenobasaloid, and 
pseudoglandular PeScc and from adenocarcinoma arising in the Littré glands. Local 
recurrences occur in upto 25% of cases. Inguinal node metastases appear in 50% of 
patients, however, the mortality rate is low (0%-14%). 
 
(j) Acantholytic carcinoma 
Acantholytic (adenoid, pseudoglandular) carcinoma is an unusual variant of PeScc 
characterized by prominent acantholysis and formation of pseudoglandular spaces. 
Macroscopically, the tumours are large, irregular masses involving multiple penile 
anatomic compartments and deeply invading into the corpora. Microscopically, the 
pseudoglandular spaces contain keratin, acantholytic cells, and necrotic debris. 
Carcinoembryonic antigen and mucin stains are negative. Compared PeScc (NOS), 
pseudoglandular variants show higher grade foci, invade deeper anatomic structures, 
and are associated with a greater incidence of regional metastases and mortality. 
 
3.2.3.3. Grading 
The “classical” grading system for PeScc described by Broder is based on the degree 
of cellular anaplasia present (Broders AC. 1921). Well differentiated (G1) squamous 
carcinoma retains the capability of keratinization with the production of typical 
keratin pearls. The characteristic intracellular bridges are clearly seen and the degree 
of anaplasia, as well as the number of mitotic figures are low. Moderately 
differentiated (G2) squamous carcinoma does not show keratin pearls but only single 
cell keratinization and a higher number of mitoses with anaplastic cells. Abundant 
mitoses, poor complete cell differentiation and the lack of keratinization are the 
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morphological hallmarks of poorly differentiated (G3) squamous carcinomas. 
Predominantly, a heterogeneous tumour is identified in 53% of cases (a combination 
of grade 2 and 3). Any proportion of grade 3 is associated with a significant risk of 
nodal metastasis, suggesting that any focus of grade 3 should be sufficient to grade 
the neoplasm as high grade. 
 
3.2.3.4. TNM Staging 
Historically, several staging systems have been used for PeScc. The Jackson system 
was introduced in 1966, and the TNM classification was introduced in 1968 and 
revised in 1978, 1987, 2004 and 2008 (Takayasu and Otaguro 1967; Wehnert, Lohse, 
and Gunther 1970; Lichtenauer et al. 1972; Chisholm et al. 1994; Leijte et al. 2008). 
The pT stage is based on the vertical invasion of the different anatomical structures 
(subepithelial connective tissue, corpus spongiosum or cavernosum, urethra, prostate, 
adjacent structures). Shortcomings have been observed in the various classifications, 
and a new clinical staging system was proposed in 1990, with better discrimination of 
survival rates according to the different stages. Locoregional disease can be 
subclassified by anatomical level with superficial echelon inguinal lymph nodes 
draining to deeper inguinal nodes before connecting to the pelvic lymphatics. Poorer 
survival outcomes are associated with: multiple, bilateral disease; deeper nodal 
involvement and extranodal extension. Disseminated metastases may be seen in 1-
10% of patients at presentation, commonly involving lung, liver, bone and brain. 
 
3.2.3.5. Measurements 
Macroscopic measurements of the tumour in three dimensions were recorded where 
possible. The location of the primary tumour was assessed and the extent of tumour 
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involvement evaluated with respect to unifocality or multifocality when several sites 
were affected. All microscopic measurements were calculated using a Vernier’s scale 
and specific distances recorded (Figure 3.1) included: 
i. Depth of invasion (mm) – measured from adjacent epithelial surface to 
the deepest infiltrating edge or nest of tumour cells. 
ii. Resection margins (mm) – measured for the deep resection and skin 
excision limits. Margins were inked prior to specimen processing for 
clarity. 
 
3.2.3.6. Immunohistochemistry 
Tissue sections prepared as described in section 3.2.1 with endothelial markers CD31 
and CD34, were carefully scrutinised for evidence of vascular invasion. This was 
defined by tumour thrombus within a vascular space and differentiated from retraction 
artefact.  
 
3.3. Results 
3.3.1. Clinicopathological information 
Clinical data for 141 patients diagnosed with carcinoma in situ (Cis) or invasive 
squamous carcinoma of the penis (PeScc) were entered into the study database. 
Patients with carcinoma in situ (n=12) or incomplete follow up data (n=11) were 
excluded from all analyses. Table 3.1 summarises the clinicopathological 
characteristics of the patients. The mean age of all patients at the time of diagnosis 
was 60.1 years (range 27 to 87 years).  
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The primary tumour was treated by local excision or circumcision in 27 cases, partial 
or total glans excision in 50 cases and partial or total penectomy in 49 cases. 3 cases 
were treated by total urethrectomy. Regional lymph node dissection (superficial +/- 
deep inguinal lymph nodes) was performed in 71 patients. Additionally, 25 patients 
were under active surveillance for more than two years and 20 patients for less than 2 
years. Furthermore, it was not possible to determine the lymph node status in a further 
2 patients. PeScc was staged according to 2004 TMN staging criteria and were 
classified as pT1 in 47% (n=60), pT2 in 43% (n=55), pT3 in 9% (n=12) and pT4 in 
1% (n=2). There were no superficial pTa lesions recorded in this series. A total of 37 
patients (29%) were diagnosed with positive inguinal lymph node involvement and 59 
patients (46%) classified as inguinal node negative. 33 patients (25%) remained 
unstaged (Nx) with respect to nodal status.  
 
At the time of diagnosis two patients had clinical or radiological evidence of distant 
metastases. Histological tumour types were grouped as PeScc: NOS (n=87), papillary 
(n=18), basaloid (n=7), warty/verrucous (n=6) and mixed/hybrid (n=11). Tumour 
grade was recorded as well differentiated (G1) in 26 patients, moderately 
differentiated (G2) in 54 patients and poorly differentiated (G3) in 49 patients. 
Overall, vascular invasion was identified in 28 cases (22%), BXO seen within 15 
specimens (12%) and 28 patients (22%) were classified with multifocal tumour 
patterns. 60 tumours (57%) were classified as greater than 2cm in size and overall 
distribution of the depth of invasion was less than 5mm (n=58), 5-10mm (n=27), 11-
20mm (n=13) and greater than 20mm (n=15). 
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3.3.2. DNA content and correlation to conventional tumour pathology 
DNA distribution histograms from 112 patients were classified as diploid in 41 cases 
(34%) and aneuploid in 71 cases (66%) based on the classification system outlined in 
section 2.7. The correlation of DNA content with available clinical data and tumour 
pathology is summarised in Table 3.2. Aneuploidy was significantly associated with 
increasing tumour anaplasia (p<0.0001) demonstrating a strong link between the loss 
of differentiation programmes and genomic instability. Interestingly, it was not 
possible to establish an association between aneuploidy and other traditional 
pathological factors. From these data, it is observed that DNA content can easily be 
measured in PeScc and may add independent information if included in diagnostic 
and prognostic algorithms. 
 
3.3.3. Correlation between histopathological factors, DNA content and 
lymph node involvement 
Accordingly, I sought to assess the univariate associations between tumour pathology 
variables (conventional histopathology and DNA content) and lymph node status 
(positive and negative) using a logistic regression model. Information for 96 men was 
entered into this analysis and univariate associations were calculated. Predictors 
which had statistically significant associations (at the 5% level) were investigated 
further using multivariable models (Table 3.3). Significant predictors of lymph node 
involvement (P<0.05) in this series include: grade, stage, aneuploidy and vascular 
invasion. Notably, a strong association between aneuploid tumours and distant 
metastases (metastases positive; p=0.04) was also observed. Multivariate analysis 
with backward elimination resulted in ploidy status and vascular invasion being 
dropped from the final model. Tumour grade and stage prove to be the strongest  
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independent predictors for lymph node positivity (Table 3.4).  The ROC area for this 
model was 0.78 (95% CI: 0.69 to 0.87). Given that the regression coefficients are 
simply the log of the odds ratios, it is possible to calculate the log-odds for an 
individual patient; thereby estimating their risk for lymph node metastases. Using the 
formula: 
 
log[p/(1-p)] = -3.410 + 1.569xGrade(2) + 2.628xGrade(3) 
+ 1.933xStage(2) + 0.842xStage(3) 
 
where p is the probability of lymph node disease. For example, a patient with PeScc 
(G3pT2) has log-odds -3.410 + 2.628 + 1.933 = 1.151.  This can then be transformed 
to the risk of node involvement in this patient of 76%. 
 
3.4. Discussion 
A number of potential clinical and pathological prognostic variables have been 
proposed in PeScc. Integrating these data generates a novel staging system for 
predicting locoregional involvement in patients with PeScc. Published nomograms 
incorporate the following information: clinical inguinal lymph node stage, pathologic 
tumour thickness, growth pattern, histologic grade, lymphatic and/or venous 
embolization, corpora cavernosa infiltration, corpus spongiosum, and/or urethral 
infiltration (Solsona et al. 2004; Ficarra et al. 2006; Kattan et al. 2006b; Kattan et al. 
2006a). I have shown through the work conducted in this chapter that many of these  
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variables are reproducible in this series. Additionally I have identified a novel 
discrete, binary variable that can be easily determined on initial pathological 
assessment. Ploidy status (diploid or aneuploid) determined by image cytometry 
offers novel, alternative information when staging penile cancer patients at an early 
stage in there overall treatment.  
 
Tissue DNA content can be assessed by either flow (FCM) or image (ICM) cytometry 
which detect gross genomic aberrations. A number of advantages have been proposed 
that support the use of ICM over FCM (Baretton et al. 1994a); however the two 
methods have shown high levels of concordance in various studies (Kachel et al. 
1979; Haroske et al. 2001; Bol et al. 2003; Friedrich et al. 2004; Wohlrab et al. 2005; 
Tarnok, Valet, and Emmrich 2006; Huang et al. 2008; Kilpatrick et al. 1994; Borgiani 
et al. 1994). It is understood that ICM offers increased sensitivity to detect 
aneuploidy, the presence of an internal reference standard, and the ability to generate 
quality histograms uncontaminated by debris and clumps of nuclei. FCM is limited by 
the potential for cell loss leading to erroneous aneuploidy measurements, does not 
permit morphological confirmation of measured objects and multinucleated 
histiocytes contribute both to high coefficients of variation (CV) and to the so-called 
"ripple effect”. Computed image cytometry offers an automated platform for analysis 
and is particularly useful for clarifying difficult areas in flow histograms - 
specifically, high coefficients of variation, high G2M phase, as well as possible near 
diploid aneuploidy and hypodiploidy. Finally, ICM has been successfully utilised in 
determining DNA content in a number of different solid tumours and linked to 
pathological and survival data (Theissig et al. 1991; Bottger et al. 1991; Bottger et al. 
1992; Steinbach et al. 1993; Baretton et al. 1994b; Baretton et al. 1995; Sampedro et 
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al. 1996; Schimming et al. 1998; Bottger et al. 1999; Riesener et al. 1999; Grote et al. 
2001; Raatz, Bocking, and Hauptmann 2004; Melegh et al. 2005; Lexander et al. 
2006; Cai et al. 2006; Yildirim-Assaf et al. 2007). The results presented in this 
chapter support the hypothesis that aneuploid tumours behave in a more aggressive 
fashion and are associated with locoregional and disseminated metastases in these 
patients. 
 
Currently, the impact of tumour ploidy status as a prognostic factor in PeScc is 
limited to a few small series and isolated case reports using FCM.  Masih et al 
described a diploid population of tumour cells in all verrucous carcinomas studied in 
their series. These tumours are known to be well differentiated and behave in an 
indolent biological fashion; supporting the finding of euploidy in this study. Ornellas 
et al performed FCM in 90 cases demonstrating that aneuploidy rates increased with 
tumour grade: well differentiated (5.5%), moderately differentiated (28.8%) and 
poorly differentiated (66.6%). Unfortunately, there were only 3 poorly differentiated 
tumours in this study, preventing formal analysis of aneuploidy as a prognostic factor. 
Nonetheless, there was a tendency towards high DNA content correlating with 
increased metastatic risk. Hall et al failed to demonstrate a prognostic predictive value 
in 46 men for ploidy determined by FCM above standard pathological parameters 
used at that time (Hall et al. 1998). No formal survival analysis was undertaken in this 
study and limitations with FCM methodology and histopathological assessment may 
account for differences seen against the results presented in this chapter. Winkler et al 
analysed 30 urethral squamous carcinomas by FCM and showed strong associations 
between aneuploidy and 5yr/10yr survival rates.  
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I have illustrated that aneuploidy is significantly associated with increasing tumour 
anaplasia in 112 cases of PeScc; demonstrating a strong link between the loss of 
differentiation programmes and genomic instability. In chapters five and six, I expand 
on these findings to link aneuploid states with cell cycle dysregulation and explore the 
utility of image cytometry as a prognostic tool in predicting survival outcomes in 
PeScc. 
 
Current EAU guidelines stratify the risk of lymph node involvement by the grade and 
stage of the tumour in conjunction with clinical nodal status. The results presented 
here, demonstrate that grade and stage remain powerful, independent predictive 
variables for lymph node disease. Unfortunately, given the retrospective nature of the 
study, it was not possible to incorporate some important variables such as clinical 
stage into this model. Prospective analysis including these variables with the 
additional information offered by image cytometry may provide improved power to 
the current integrated staging systems available. This will allow earlier risk 
stratification with improved counselling of patients and better allocation to 
surveillance or radical treatment programmes. 
 
3.5. Conclusion 
Image cytometry offers a novel and reproducible technique for determining the 
nuclear DNA content of tumour cells in patients with penile cancer. I have 
demonstrated that tumour ploidy status provides powerful prognostic information 
alongside conventional histopathology factors.  This novel approach may permit early 
stratification of patients for aggressive surgical and chemotherapeutic treatments. 
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Further large scale studies are warranted to support the careful incorporation of DNA 
aneuploidy into diagnostic and treatment guidelines for this unusual malignancy.  
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CHAPTER FOUR 
DEFINING NORMAL AND ABBERANT REGULATION 
OF THE DNA REPLICATION LICENSING SYSTEM IN  
PENILE SQUAMOUS CELL CARCINOMA 
 
4.1. Introduction 
The DNA replication licensing pathway has emerged as a powerful downstream 
mechanism for controlling the proliferative state of cells and ensures that DNA is 
replicated once and only once per cell cycle; thus maintaining genomic stability 
(Blow and Hodgson 2002a; Blow and Dutta 2005; Machida, Hamlin, and Dutta 2005; 
Jackson, Laskey, and Coleman 2013). Complex, multifunctional pathways are 
important in the coordinated growth of tissue systems in multicellular organisms. 
However, it has been shown that only a small proportion of cells are actively engaged 
in proliferative mechanisms within multicellular tissues. As described in detail in 
section 1.2, this observation has led to the identification of distinct cellular 
phenotypes relating to their respective withdrawal from the cell division cycle. Hence, 
cells may be either permanently or temporarily withdrawn from the cell cycle as a 
result of: terminal differentiation, quiescence or senescence (Hall and Watt 1989; 
Williams and Stoeber 2007). G0 represents a state when cells have reversibly 
withdrawn from the cell division cycle in response to high cell density or mitogen 
deprivation (Zetterberg 1985). A minority of cells are actively cycling (proliferating) 
and these are located mainly in the stem-transit amplifying compartments of self-
renewing tissues, such as epithelia and bone marrow (Potten and Loeffler 1990). 
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In section 1.4, I described the utility of RLFs as sensitive detectors for distinguishing 
cell cycle phase-specific cell populations. During late mitosis and early G1 phase, the 
replication licensing factors: ORC, Cdc6, Cdt1, and Mcm2-7 assemble into pre-
replicative complexes, which render replication origins “licensed” for DNA synthesis. 
During S phase, Cdc7 kinase and cyclin-dependent kinases induce a conformational 
change in the pre-replicative complex, resulting in recruitment of additional initiator 
proteins that collectively promote DNA unwinding and recruitment of DNA 
polymerases. During S-G2-M phases, the presence of the licensing repressor protein 
geminin prevents inappropriate re-initiation events at origins that have already been 
activated (Sclafani and Holzen 2007; Williams and Stoeber 2007; Blow and Gillespie 
2008).  
 
Mcm2-7 (MCM) proteins are expressed throughout the cell cycle (G1-S-G2-M) but 
are tightly downregulated during exit into out-of-cycle quiescent (G0), differentiated, 
or senescent states (Stoeber et al. 1998; Stoeber et al. 2001; Blow and Hodgson 
2002b; Eward et al. 2004; Kingsbury et al. 2005; Barkley et al. 2007; Williams and 
Stoeber 2007) [Figure 4.1]. Unlicensed replication origins and absence of CDK 
activity characterize these out-of-cycle states and therefore allow such cells to be 
clearly distinguished from cycling cells in complex and dynamic heterogeneous cell 
populations (Stoeber et al. 2001). Normal somatic cells demonstrate a key 
‘proliferation-differentiation’ switch which is responsible for the withdrawal of cells 
from the mitotic cell cycle. These mechanisms are essential for the fundamental and 
normal function of different cells types within a tissue system and contribute to the  
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Figure 4.1 
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loss of proliferative capacity as cells transit in to out of cycle states. Thus, the MCM 
proteins represent novel biomarkers of growth and have been confirmed as powerful 
markers for cancer detection and prognostication in a wide range of tumour types 
(Gonzalez et al. 2005; Williams and Stoeber 2007; Williams and Stoeber 2012; 
Jackson, Laskey, and Coleman 2013). Moreover, expression profiling of MCMs 
together with Ki67 (a standard proliferation marker) and geminin (biomarker of S-G2-
M progression) allows cells in out-of-cycle states to be distinguished from those 
residing in cycle and can assign cells to G1 and S-G2-M phases (Kulkarni et al. 2007; 
Loddo et al. 2009). Mcm2-7 protein expression also identifies non-cycling cells with 
proliferative potential (Figure 4.2). For example, in luminal breast epithelium of pre-
menopausal women, a large proportion of cells reside in a primed ‘replication 
licensed’ but non-proliferating state, characterised by expression of Mcm2 but 
absence of Ki67 and geminin (Williams et al. 1998; Stoeber et al. 1999; Stoeber et al. 
2001; Going et al. 2002; Shetty et al. 2005; Williams and Stoeber 2007). This 
phenomenon exemplifies the unique proliferative characteristics of these cells 
compared to tissues in the post-menopausal cohort. It is believed that this represents 
an evolutionary preserved mechanism allowing rapid cellular expansion secondary to 
hormonal fluctuations observed in pregnancy and lactation (Stoeber et al. 2001; Blow 
and Hodgson 2002b; Williams and Stoeber 2007; Loddo et al. 2009; Williams and 
Stoeber 2012) 
 
The ability of cells to re-enter the cell cycle after a period of non-proliferative 
activity, provides a crucial mechanism through which multicellular organisms can 
respond to mitogenic stimuli (i.e. tissue damage leading to healing and repair). The 
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Figure 4.2 
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relative ease in which cells are capable of making this transition has led to the 
classification of human tissues into three main groups. (1) Self-renewing tissues (e.g. 
skin, gastrointestinal mucosa and haematopoietic system) demonstrate rapid and 
continuous cell turnover. (2) Conditional renewal tissues (e.g. liver and thyroid) 
respond rapidly, as outlined above, to mitogenic stimuli with variable periods of 
stable inactivity. Finally, (3) Permanent tissues (e.g. nerve and skeletal muscle) are 
predominately composed of terminally differentiated cells and therefore lack the 
capacity for self-renewal.  
 
An in vivo, functional model demonstrating these processes is observed when the 
expression of MCM proteins are analysed in the human colonic crypt. As a self-
renewing tissue, normal colon shows the capacity for continuous cell turnover, 
through distinct proliferative compartments; thus maintaining the integrity and 
function of the terminally differentiated epithelial cells located at the luminal surface 
(Potten and Loeffler 1990). The highest level of MCM expression is observed in the 
transit amplifying population of cells. The level of MCM expression subsequently 
declines in the middle third of the crypt, becoming undetectable in surface terminally 
differentiated cells (Stoeber et al. 2001).  
 
Thus, combinatorial analysis of these important effectors of cellular growth and 
proliferation can provide an important insight into the cellular kinetics of different 
tissue systems. The Mcm2/Ki67 ratio defines the proportion of cells that are licensed 
to proliferate. Consequently, the higher the Mcm2/Ki67 ratio, the greater the 
proportion of cells that reside in a licensed non-cycling state (Dudderidge et al. 2005; 
Shetty et al. 2005; Kulkarni et al. 2007; Williams and Stoeber 2007; Loddo et al. 
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2009). Because Ki67 is present throughout the cell cycle in proliferating cells, the 
geminin/Ki67 ratio may be used as an indicator of the relative length of G1 phase and 
the rate of cell cycle progression (Dudderidge et al. 2005; Shetty et al. 2005; Kulkarni 
et al. 2007; Williams and Stoeber 2007; Loddo et al. 2009). Proliferating cells with a 
short G1 phase will approximate to a geminin/Ki67 ratio of ~1; whereas cells with a 
prolonged G1 phase will approximate to a ratio closer to 0 (Dudderidge et al. 2005; 
Obermann et al. 2005; Shetty et al. 2005; Dudderidge et al. 2007; Kulkarni et al. 
2007; Loddo et al. 2009)). Similarly, the Ki67-geminin labeling index (LI) can be 
used to identify the numbers of cells transiting G1 phase (Wharton et al. 2004; 
Dudderidge et al. 2005; Dudderidge et al. 2007). Importantly, studies show that this 
method of multiparameter analysis of RLFs translates into prognostic information 
with regards to patient survival in several tumour types (Dudderidge et al. 2005; 
Obermann et al. 2005; Shetty et al. 2005; Dudderidge et al. 2007; Kulkarni et al. 
2007; Loddo et al. 2009).  
 
Tumours acquire a growth advantage over normal tissues through a variety of 
mechanisms, including acquisition of aneuploidy and dysregulation of the 
mechanisms that control cellular proliferation. Complex signaling pathways 
interlinked with redundant growth-regulatory mechanisms contribute to the diverse 
and heterogeneous effects of oncogenic mutations observed in diverse tumour types. 
Dysregulation of replication licensing in early tumourigenesis may arise as a 
consequence of oncogene-induced cell proliferation, which can cause under 
replication or over replication of chromosomal DNA and therefore contribute to the 
development of aneuploidy commonly seen during multistep tumour progression to an 
aggressive cancer phenotype (Vaziri et al. 2003; Blow and Dutta 2005; Zhu and Dutta 
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2006; Lin and Dutta 2007). MCM proteins represent novel biomarkers of growth and 
have been confirmed as powerful markers for cancer detection and prognostication in 
a wide range of tumour types (Williams et al. 1998; Freeman et al. 1999; Stoeber et 
al. 1999; Going et al. 2002; Stoeber et al. 2002; Gonzalez et al. 2003; Williams et al. 
2004; Dudderidge et al. 2005; Obermann et al. 2005; Shetty et al. 2005; Dudderidge 
et al. 2007; Kulkarni et al. 2007; Scarpini et al. 2008; Loddo et al. 2009; Dudderidge 
et al. 2010; Kelly et al. 2012; Saeb-Parsy et al. 2012).  
 
Through greater understanding of the RLF pathway in malignancy, it has been shown 
that aberrant DNA licensing is a common finding in many solid tumours leading to an 
increased proliferative capacity in cells that would otherwise demonstrate down-
regulation of these key proteins. This event is thought to occur at an early point in 
tumourigenesis and provides insight into the mechanisms that may be involved in the 
malignant transformation of epithelial cells (Williams and Stoeber 2007; Blow and 
Gillespie 2008; Williams and Stoeber 2012; Jackson, Laskey, and Coleman 2013). 
Crucial understanding of these mechanisms remains to be explained in penile 
epithelium and the subsequent dysregualtion that may be observed in penile 
carcinoma evaluated.  In light of these observations, I have sought to investigate the 
dysregulation of RLFs, in order to elucidate their role in penile epithelial 
carcinogenesis. Furthermore, I have used multiparameter analysis of Mcm2, Ki67 and 
geminin in PeScc, to gain insight into the in vivo cell cycle kinetics of this 
heterogeneous and complex tumour type. 
 
 
4.2. Materials & Methods 
For a detailed methodological summary refer to the following subsections in chapter 
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two: Antibodies (2.3.1), Immunoblotting (2.3.2), Immunohistochemistry (2.3.3), 
Protein expression profile analysis (2.3.4), Cell culture and synchronisation (2.5.1), 
Preparation of total cell extracts (2.5.2), Statistical methods (2.6). 
 
4.3. Results 
4.3.1. Cell cycle phase specific expression of replication licensing factors 
Extensive characterisation of the RLF antibodies (section 2.3.1) used throughout these 
experiments has been undertaken and published widely. Detailed data recorded 
previously has been reconciled using both in vitro and in vivo systems with regard to 
protein monospecificity, immunolocalisation in conjunction with peptide blocking 
experiments. Initially, I sought to demonstrate the regulation of the DNA replication 
licensing system in different in vitro systems; thereby consolidating the work detailed 
above. Prior to investigation of these cell cycle regulators in synchronous cell 
extracts, the monospecificity of these antibodies against Mcm2, Cdt1, geminin was 
confirmed in asynchronous HeLa cells by detection of a single protein with a 
molecular mass consistent with the reported electrophoretic mobility of the 
corresponding human antigen (Figure 4.3). Similar data for Mcm2 and geminin has 
previously been described (Wharton et al. 2004). 
 
Subsequently, in order to further delineate the monospecificity of these antibodies, I 
performed Western blot analysis on extracts prepared from a synchronous cell 
populations using HeLa and SKOV-3 cells as described in sections 2.3.2, 2.4.1 & 
2.4.2. The aim of this series of experiments was to clarify the expression of RLFs with 
respect to normal cell cycle phase analysis. Technical support was gratefully received 
from Dr Sarah Kingsbury and Mr Marco Loddo with regards to acquiring these data. 
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Synchronized cycling cells were cultured and cell phase specificity determined using 
bivariate FACS (section 2.4.3). I proceeded to immunoblot protein extracts prepared 
from these cells with the monospecific antibodies listed in section 2.3.1 (Figure 4.4). I 
observed that Mcm2 levels did not vary significantly during passage through the cell 
cycle. These findings recapitulate the data from studies in budding yeast which 
demonstrate that MCM proteins attach and detach from chromatin but are not 
degraded.  Rather MCM complexes undergo exportation out of the nucleus in 
preference to overall inhibition (Siddiqui, On, and Diffley 2013).  
 
Geminin expression was restricted to S-G2-M phases of the cell cycle as reported 
previously (Wharton et al. 2004) . This is in keeping with geminin’s inhibitory role on 
Pre-RC assembly and is governed by its degradation in late mitosis and G1 by the 
ubiquitin-protein ligase APC. Levels of geminin are kept low in G1 thereby 
promoting the role of Cdt1 in Pre-RC assembly. I observed that Cdt1 levels began to 
rise at the end of mitosis, increased during G1 and fell abruptly at the start of S-phase. 
This highlights the critical interplay between rising geminin levels when the APC is 
inactivated and Cdt1 which is inhibited by geminin and degraded through targeted 
ubiquitination by SCF complex (a multi-protein E3 ubiquitin ligase complex) under 
CDK control (Siddiqui, On, and Diffley 2013). Actin levels were used as an internal 
control.  
 
Finally, further supportive data is gained from published immunoblots of total cell 
extracts for cells undergoing terminal differentiation (Barkley et al. 2007). In this 
HL60 cellular model, a clear down-regulation of Cdc6 is observed as an early event in 
this process occurring at 12h. Subsequent fall in other RLFs is noted as these cells 
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progress to a non-cycling population with a terminally differentiated phenotype at 144 
hours. Cdc6 expression appears to represent a rate-limiting step in this process. 
Conversely, cells re-entering the cell cycle from a quiescent state appear to up-
regulate the RLFs early in the transition from G0. Ectopic geminin can block re-
acquisition of DNA replication competence during re-entry into the cell cycle, 
indicating that geminin levels must be tightly down-regulated for escape from G0. 
 
In summary, these in vitro data recapitulate the published findings regarding the tight  
cell cycle phase-specific expression of RLFs. All antibodies, shown here, have a high 
level of monospecificity for their relative human antigen targets. Finally, it is 
observed that cells with intact “proliferation-differentiation” programmes can tightly 
regulate RLF expression to control exit to a G0 state. Subsequently, I will explore 
how RLF expression varies in different tumour groups in PeScc reflecting the loss of 
these important controls with increasing anaplasia when compared to the normal cell 
types studied here. 
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Figure 4.3 
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Figure 4.4 
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4.3.2. Regulation of the DNA licensing system in normal and dysplastic 
penile epithelium 
Next, I undertook further experiments using these monospecific antibodies to 
investigate the dysregulation of DNA replication licensing system in early, multistep 
progression of tumour development observed in normal and dysplastic penile 
epithelium. Here, I explore the protein expression profiles for Mcm2 and geminin, 
against the standard proliferation marker Ki67, in normal penile tissue alongside 
dysplastic epithelium and invasive PeScc. I sought to determine the spatiotemporal 
relationship of RLF and Ki67 expression using immunohistochemical staining in 
representative cases and to quantify the changes detected in normal, dysplastic and 
neoplastic penile epithelia. Furthermore, I investigated the relationship of 
dysregulated RLF expression with increasing anaplasia reflecting diminished cellular 
differentiation. 
 
4.3.2.1. Normal penile epithelium 
In normal penile squamous epithelium, RLF and Ki67 expression is restricted to the 
basal and suprabasal layers consistent with the transamplifying compartment (TAC) 
seen in other self-renewing systems (Freeman et al. 1999; Stoeber et al. 2001; 
Williams and Stoeber 2007; Jackson, Laskey, and Coleman 2013) [Figure 4.5]. Cells 
in the superficial layers demonstrate a fully differentiated phenotype with flattened 
morphology and stain negative for Mcm2, Ki67 and geminin expression. The level of 
RLF and Ki67 expression was extremely low (<4%) which is consistent with the 
previous finding that the loss of proliferative capacity which accompanies 
differentiation is coupled to down-regulation of the RLFs involved in origin licensing 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  162                                                                          
 
(Mcm2-7, Cdc6 and Cdt1) (Barkley et al. 2007; Williams and Stoeber 2007; Williams 
and Stoeber 2012).  
 
4.3.2.2. Dysplastic penile epithelium 
In contrast dysplastic lesions demonstrate high RLF and Ki67 expression reflecting 
discordant differentiation processes and an expanded proliferative compartment 
(Figure 4.5). It is observed that as tissues advance from mild or moderate dysplasia to 
full thickness dysplasia (carcinoma in-situ); there is a corresponding increase in the 
expression of Mcm2. These data mirror the findings observed in pre-malignant 
conditions of the uterine cervix, colon and oesophagus (Williams et al. 1998; Freeman 
et al. 1999; Going et al. 2002; Stoeber et al. 2002; Williams et al. 2004; Laskey 2005; 
Scott et al. 2006; Williams and Stoeber 2007; Williams and Stoeber 2012);  thereby 
underpinning the theoretical benefits of assessing Mcm2 levels in screening tests, 
currently under review in a number of international clinical trials (Siddiqui et al. 
2008; Tambouret, Misdraji, and Wilbur 2008; Wilbur et al. 2009; Depuydt et al. 
2011). These principles may be of clinical use in identifying severe dysplastic lesions 
on male genital epithelium.   
 
4.3.3. Regulation of the DNA licensing system in neoplastic penile 
epithelium 
RLF and Ki67 expression was significantly greater in malignant tissue compared to 
normal epithelium. Interestingly, I observed that biomarker immunostaining at the 
advancing tumour edge in low grade tumours (i.e. the proliferative compartment) 
recapitulates the findings demonstrated in the in vitro HL60 differentiation model 
(Musahl et al. 1998; Barkley et al. 2007). These tumours stained exclusively at the  
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Figure 4.6 
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peripheral tumour edge in keeping with a biologically active compartment. However, 
biomarker expression is sharply down-regulated as functional differentiation 
programmes are initiated towards the centre of these tumours. These cells appear to 
retain the capacity to differentiate and thus withdraw to a G0 state; reflecting a lower 
growth potential. In sharp contrast, there is a greater degree of biomarker staining 
throughout the tumour in high grade cancers; which reflects the loss of normal 
differentiation mechanisms, thereby retaining a larger proportion of cells in the cell 
division cycle (Figure 4.6). Furthermore, an increased expression of the S-G2-M 
phase-specific marker geminin with increasing anaplasia suggests that higher grade 
tumours yield greater proliferative fractions compared to low grade tumours. 
 
Analysis of the labelling indices (LI) [i.e. percentage of positively staining cells] 
(appendix B) revealed interesting characteristics with respect to biomarker expression 
against tumour grade. The distribution of LIs (median, inter-quartile range) for each 
biomarker is presented (Figure 4.7). Mcm2 protein expression (median LI) was 
greater than Ki67 expression (median LI), with both biomarkers mapped over a broad 
range. Mcm2 and Ki67 expression levels were significantly higher than geminin 
expression in these tumours, reflecting the lower growth fraction identified by 
geminin, which is exclusively expressed during the S-G2-M phases of the cell cycle. 
There exists a strong correlation between all biomarkers, highlighted by the high 
degree of concordance, from low to high scores, for Mcm2 and Ki67 (ρ=0.87), 
confirming the use of Mcm2 as a proliferation marker. 
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4.3.4. Dysregulation of RLF expression with increasing anaplasia in penile 
carcinoma 
I reviewed the protein expression profiling in PeScc specimens in order to better 
understand the changes observed when tissues lose their normal differentiation 
mechanisms in connection with increasing anaplasia. In well differentiated PeScc 
(grade 1), I observed that RLF and Ki67 expression is restricted to the peripheral zone 
of tumour nests. Central zones in these tumours stained negatively for all three 
biomarkers reflecting their non-cycling, non-proliferating state (Figure 4.6). This 
replicates the in vitro studies using the HL60 model as described earlier. It is likely 
that these cells are permanently withdrawn from the cell cycle and is coupled to 
reduced proliferative capacity. This recapitulates the proliferation-differentiation 
switch seen in normal, self-renewing tissues (Stoeber et al. 2001; Williams and 
Stoeber 2007; Williams and Stoeber 2012). In contrast, moderate and poorly 
differentiated PeScc (grades 2 and 3) demonstrate a greater degree of “maturation 
arrest” which is linked to a higher proportion of tumour cells being engaged in the cell 
division cycle (i.e. a higher growth fraction). Also, this recapitulates the high 
proliferation signature observed in full-thickness dysplastic lesions also showing 
maturation arrest (Figures 4.7 & 4.8). This is indicative of cell cycle engagement and 
an increase in proliferative capacity.  
 
I observed a significant correlation for increasing LI (p<0.0001) with increasing grade 
for all biomarkers (Figure 4.8; Table 4.1). It was also observed that when compared to 
other tissue types and specific cancers (Gonzalez et al. 2003; Wharton et al. 2004; 
Dudderidge et al. 2005; Obermann et al. 2005; Shetty et al. 2005; Mehrotra et al. 
2006; Dudderidge et al. 2007; Kulkarni et al. 2007; Loddo et al. 2009; Williams and 
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Stoeber 2012), the Ki67 expression almost matches Mcm2 expression in moderate 
and poorly differentiated tumours. This finding demonstrates that with increasing 
anaplasia, cells are licensed and cycling as seen in other squamous cell carcinomas 
(Williams et al. 1998; Kodani et al. 2001; Going et al. 2002; Chatrath et al. 2003; 
Williams et al. 2004; Gonzalez et al. 2005; Scott et al. 2006; Williams and Stoeber 
2007).  
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Figure 4.7 
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Figure 4.8 
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Figure 4.9 
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Table 4.1 
 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  172                                                                          
 
4.3.5. Cell cycle kinetics with increasing anaplasia in penile carcinoma  
The ‘Ki67-geminin’ score was associated with an increase in tumour grade (P < 
0.0001), indicative of an increase in the number of cells transiting G1 phase (Figure 
4.9). Thus, the proportion of tumour cells actively cycling increases with increasing 
grade. There was little evidence, however, of an increase in the geminin/Ki67 ratio 
with increasing grade. This ratio is an indicator of the relative length of G1 phase and 
the results suggest that increased recruitment of cells into the cell division cycle was 
not linked to accelerated cell cycle progression as seen in other tumour types (e.g., 
epithelial ovarian cancer) (Kulkarni et al. 2007). There was evidence of a trend for 
decreasing Mcm2/Ki67 ratio with increasing grade (P = 0.09); reflecting a shift in the 
proportion of non-proliferating cells that are licensed for DNA replication in well-
differentiated tumours to a population of actively cycling cells in poorly differentiated 
tumours (Dudderidge et al. 2005; Kulkarni et al. 2007; Loddo et al. 2009). 
 
4.4  Discussion 
Detection of Mcm 2-7 can help describe the proliferative state and growth fraction in 
dynamic cell populations (Stoeber et al. 2001; Williams and Stoeber 2007; Williams 
and Stoeber 2012). Repression of the DNA replication licensing machinery is a 
powerful mechanism through which cells can lower their proliferative capacity on 
exiting from the cell cycle in to a differentiated state. Here, I have clearly 
demonstrated that DNA replication licensing in normal penile epithelium conforms to 
the principles seen in other self-renewing tissues (Stoeber et al. 2001; Williams and 
Stoeber 2007; Williams and Stoeber 2012). The putative stem cell compartment in 
squamous epithelium may reside in the basal compartment from which proliferating 
cell colonies propagate according to Potten’s model (Potten and Loeffler 1990) 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  173                                                                          
 
outlined in chapetr 1. As, these cells enter the transamplification compartment (TAC) 
in penile squamous epithelium, they stain positively for Mcm2, Ki67 and geminin 
indicative of a fully proliferating cell. This effect is clearly observed in other 
squamous epithelium (e.g. oesophagus) and the colonic crypt (Stoeber et al. 2001). 
Early differentiating cellular populations demonstrate a subset of cells expressing 
Mcm2 alone, with Ki67 and geminin rapidly downregulated during the proliferation-
differentiation “molecular” switch. The inverse relationship between RLF expression 
and differentiation status recapitulates the findings in the in vitro HL60 
monocyte/macrophage differentiation model system (Barkley et al. 2007) and has 
been noted in several other malignancies (Williams et al. 1998; Freeman et al. 1999; 
Meng et al. 2001; Going et al. 2002; Chatrath et al. 2003; Gonzalez et al. 2003; 
Williams et al. 2004; Dudderidge et al. 2005; Obermann et al. 2005; Shetty et al. 
2005; Dudderidge et al. 2007; Kulkarni et al. 2007; Ayaru et al. 2008). Terminally 
differentiated cells reflect a complete withdrawal from the cell cycle and repression of 
origin licensing (Stoeber et al. 2001; Blow and Hodgson 2002b; Eward et al. 2004; 
Williams and Stoeber 2007). I have shown that cell systems in normal penile 
epithelium and PeScc, in which differentiation programmes remain functional, that 
transition to terminally differentiated “out of cycle” states is tightly coupled to early 
downregulation of RLFs which recapitulates what is seen in the HL60 systems 
(Musahl et al. 1998; Barkley et al. 2007). Ultimately, this reflects that the majority of 
the critical components of the RLF pathway are under E2F regulation (Fang and Han 
2006; Blow and Gillespie 2008; Tudzarova et al. 2010). Hence, the RLF pathway can 
be regulated at two levels: (1) at the transcription level, by E2F and growth-arresting 
signals, and (2) posttranscriptionally, by CDK phosphorylation, a step that is required 
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for eventual proteasome-mediated degradation of critical RLFs (Sclafani and Holzen 
2007; Blow and Gillespie 2008; Williams and Stoeber 2012). 
 
In contrast, higher grade cancers are characterised by uncontrolled growth with 
increased proliferation and abrogation of cell cycle checkpoints (Nurse 2002). In 
PeScc, this biological phenomenon is exemplified by high RLF and Ki67 expression 
indicative of cells failing to withdraw from the cell division cycle in keeping with a 
failure of the proliferation-differentiation switch and the onset of maturation arrest 
(i.e. a block to the differentiation programme). Furthermore, dysregulation of origin 
licensing and proliferative pathways with increasing anaplasia reflects the loss of 
normal somatic differentiation programmes and up-regulation of proliferation genes, 
notably Mcm 2-7 expression (Van't Veer and Bernards 2008). Crucially, cancers 
represent a heterogeneous population of cycling and non-cycling cells. As a tumour 
becomes more poorly differentiated there is a switch to a predominantly cycling and 
growing phenotype. In this study, it is observed that only a small fraction of cells may 
be cycling in well-differentiated, low-grade tumours; whilst the majority of cells 
reside in the fully differentiated ‘out-of-cycle’ state. Hence, these G1/S regulators of 
the cell cycle are critically involved in allowing cells to replicate and can sensitively 
predict cells residing “in cycle”.  
 
The HL60 monocyte/macrophage differentiation model system (Barkley et al. 2007) 
illustrates that loss of proliferative capacity and cell cycle withdrawal following 
engagement of the somatic differentiation program is tightly coupled to 
downregulation of core constituents of the DNA replication licensing machinery 
including the Mcm2-7 proteins. This coupling between loss of proliferative capacity, 
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cell cycle withdrawal, downregulation of the Mcm2-7 helicase complex, and 
differentiation has been observed in anal, bladder, cervical, colonic, esophageal, oral, 
pancreatic, and prostatic epithelia (Williams et al. 1998; Kodani et al. 2001; Williams 
et al. 2004; Scott et al. 2006; Ayaru et al. 2008; Scarpini et al. 2008; Dudderidge et al. 
2010). In normal stratified squamous penile epithelium, I observed downregulation of 
RLFs as cells exit the cell cycle and engage normal somatic differentiation programs. 
This seems to be a ubiquitous mechanism for lowering the proliferative capacity of 
cells in stem-transit–differentiating self-renewing tissue systems (Stoeber et al. 2001). 
In contrast, the block to normal differentiation programmes (i.e. arrested 
differentiation) that characterizes dysplastic (pre-invasive) lesions is associated with 
persistent expression of MCM proteins even in surface epithelial layers which is 
indicative of cells failing to withdraw from the cell cycle. As previously observed for 
dysplastic lesions of the cervix, esophagus, bladder, oral, and anal mucosa (Williams 
et al. 1998; Stoeber et al. 2002; Williams et al. 2004; Scott et al. 2006; Ayaru et al. 
2008; Scarpini et al. 2008; Dudderidge et al. 2010; Kelly et al. 2012), high-level 
MCM expression was detected in penile dysplasia. Interpreting these results, it would 
be possible to surface sample new or recurrent penile lesions (e.g. brush cytology) 
followed by immunoexpression analysis for MCM proteins in order to provide a rapid 
method for distinguishing benign hyperplastic lesions from dysplasia. This approach 
has already been exploited in screening for cervical cancer and detection of 
oesophageal, lung, bladder, anal, and oral dysplasia (Williams and Stoeber 2012; 
Jackson, Laskey, and Coleman 2013). 
 
Cell cycle phase analysis allows an accurate assessment of individual tumour kinetics 
(Figure 4.10) which imparts, not only important prognostic information, but also 
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predictive potential for response to phase specific drugs. The disappointing intent-to-
treat analyses of large, conventionally designed trials, such as TACT and tAnGo, 
suggests that further improvements in adjuvant treatment will require individualized 
therapeutic decisions (Wardley et al. 2008; Ellis et al. 2009). Cell cycle phase analysis 
of breast and ovarian cancers has shown that it is tumours displaying the accelerated 
cell cycle phenotype that are most likely to show a clinically relevant response to S- 
or M-phase-directed agents (Kulkarni et al. 2007; Williams and Stoeber 2007; 
Kulkarni et al. 2009; Loddo et al. 2009; Rodriguez-Acebes et al. 2010; Williams and 
Stoeber 2012). As non-proliferating cells are radiation-resistant, whereas cycling cells 
are most sensitive to radiation insult during transit through G2 and M phase, tumours 
displaying the accelerated cell cycle phenotype may also represent those that are most 
radiation-sensitive. 
 
Traditional methods of cell cycle assessment in tumour samples, including flow 
cytometry, have limitations. Clinical samples are often unsuitable for such techniques, 
in part due to fixation artefacts, inadequate amounts of tissue and interpretation 
difficulties due to contaminating stromal/benign cell populations (Williams and 
Stoeber 2007). The presence of cells derived from other contaminating tissues, such 
as blood vessels and lymphoid follicles, also complicates the analysis by adding large 
numbers of cells with additional complex cell cycle kinetics. By contrast, 
multiparameter analysis of G1/S cell cycle regulators can be applied directly to 
paraffin wax-embedded tissue sections using relatively simple immunohistochemical 
methods; thereby providing a detailed characterisation of tumour cell cycle state. 
Prognostic algorithms for many tumour types  
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include a crude measure of their proliferative state, often based on mitotic index 
and/or Ki67 count (e.g. Nottingham Prognostic Index for breast cancer, Federation 
Nationale des Centres de Lutte le Cancer grading system for soft tissue sarcoma) 
(Elston 2002; Coindre 2006). Notably, many of the neoadjuvant and adjuvant 
chemotherapeutic interventions approved for clinical use include agents targeting 
either replicating cells (in S phase) or dividing cells (M phase), and will therefore 
only be effective against cells progressing through the cell cycle. 
 
Interestingly, in PeScc the majority of tumours appear to exist in a “G1-arrested” 
state. This is characterised by an observed increase in the number of cells entering G1 
phase (high ‘Ki67 - geminin’ score) but failing to progress through the G1/S transition 
(low geminin) with prolonged length of G1 phase (low geminin/Ki67 ratio). 
Proliferating cells with a short G1 phase will approximate to a geminin/Ki67 ratio of 
~1, whereas cells with a prolonged G1 phase will approximate to a ratio closer to 0 
(section 1.4.4.3). In contrast, a subset of tumours may exhibit rapid growth potential; 
demonstrating high Mcm2 and geminin levels which are indicative of accelerated cell 
dynamics and a shortened G1 phase. These results point to a clear implication on the 
efficacy of traditional chemotherapy agents in this tumour type given this 
multiparameter analysis approach. Often cytostatic and cytotoxic drugs are used in 
combination to help circumvent a lack of effect but this occurs at the expense of 
unacceptable levels of toxicity to patients (hair loss, gastrointestinal disturbance, 
mucositits, neutropenic sepsis and death). Adopting a multiparametric approach 
(Figure 4.10) to analyse tumour cell kinetics and phase specific targeting; may 
improve therapeutic validation and stratify patients to radical chemotherapy more 
appropriately, thereby avoiding a non-targeted style approach which  
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Figure 4.10 
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is often conducted through clinical desperation and harbour little chance of 
therapeutic success.  
 
The inverse relationship between RLF expression and differentiation status 
recapitulates the findings witnessed in the in vitro HL60 monocyte/macrophage 
differentiation model system (Musahl et al. 1998; Barkley et al. 2007) and has been 
noted in several other malignancies (Going et al. 2002; Wharton et al. 2004; Kulkarni 
et al. 2007; Williams and Stoeber 2012). This relationship reflects the mutually 
antagonistic circuits that control cell proliferation and differentiation in human cells 
and highlights the potential clinical utility of RLFs for improving current tumour 
grading systems. These data show that analysis of RLFs alongside the ploidy status in 
primary biopsy material from PeScc can provide important additional prognostic 
information and identify those tumours with an aggressive cell cycle phenotype, the 
latter characterized by an increased growth fraction [i.e. an increase in the numbers of 
cells traversing G1 (Ki67-geminin score) and S-G2-M phases (geminin LI)] and 
accelerated cell cycle transit (geminin/Ki67 ratio). Notably, the aggressive tumour cell 
cycle phenotype is linked to general pathological features of aggressive disease, 
namely increasing: tumour size, stage, and depth of invasion as well as to 
morphologic subtypes associated with an adverse prognosis (e.g. basaloid). In the next 
chapter, I link this aggressive cell cycle phenotype to tumour ploidy status, suggesting 
that dysregulation of the DNA replication licensing pathway and cell cycle machinery 
is linked to the development of aneuploidy in PeScc. 
 
The importance of RLF expression as a prognostic factor alongside conventional 
pathological grading and staging systems, in overall survival of men with PeScc, will 
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be investigated further in the subsequent chapters. There appear to be a number of 
promising translational indications with regards to diagnostic, prognostic and 
therapeutic potential for patients with PeScc. Important information can be retrieved 
from cytological or biopsy specimens through to cell cycle phase analysis and 
monitoring response to treatments.  
 
4.5. Conclusion 
In summary, using highly specific antibodies against Mcm2, geminin and the 
conventional pan-cycle marker Ki67, I have shown that RLF expression is tightly 
regulated during normal proliferation-differentiation processes. In normal penile 
squamous epithelium there is tight control of RLF expression and sharp 
downregulation of RLFs as cells withdraw from the cell division cycle to a terminally 
differentiated state. Through, these findings it is possible to identify cell populations 
residing in both in- and out-of-cycle states within a normal tissue system. These data 
recapitulate the findings observed in the in vitro HL60 monocyte/macrophage 
differentiation model system. In malignant transformation the replication licensing 
pathway clearly becomes dysregulated with grossly aberrant processes involved in 
advanced anaplastic growth. There is marked increase in RLF expression with 
increasing anaplasia and I have illustrated a strong correlation between conventional 
grading systems with increased cell cycle kinetics and phase-specific analysis. The 
information presented in this chapter identifies novel aspects to PeScc biology which 
provides an intriguing opportunity to develop novel prognostic and therapeutic 
modalities for these patients. In Chapter 5, I explore the role of RLFs in linking the 
development of anaplasia and genomic instability with advanced tumour states.  
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CHAPTER FIVE 
 
REPLICATION LICENSING FACTORS 
CORRELATE WITH GENOMIC 
INSTABILITY REFLECTING 
AGGRESSIVE DISEASE PATTERNS 
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CHAPTER FIVE 
REPLICATION LICENSING FACTORS CORRELATE 
WITH GENOMIC INSTABILITY REFLECTING 
AGGRESSIVE DISEASE PATTERNS 
  
5.1. Introduction 
Penile cancer represents a heterogeneous pathological process which may manifest 
with a variety of clinical symptoms and signs. The absolute aetiology of this rare, 
genitourinary malignancy remains undetermined; however the hypothesis that 
tumorigenesis is multifactorial appears justified (Rubin 2001; Kayes 2007; Prowse 
2008; Andersson 2008). For clinicians, the identification of aggressive disease 
patterns is crucial in helping to stratify patients to specific treatment and surveillance 
options. This relies on accurate interpretation of important prognostic 
clinical/pathological variables which have now been identified through recent studies 
(Guimaraes et al. 2009; Cubilla 2009). A number of factors have been associated with 
aggressive disease states and guidelines based on the primary tumour grade and local 
stage have been published (Pizzocaro et al. 2010).  
 
However, identifying aggressive PeScc can be difficult using traditional 
clincopathological markers alone as highlighted in chapter 1 (Section 1.5.2 & 1.5.3; 
Figures 1.7, 1.8 & 1.9). Advanced PeScc can be defined as: all locally advanced 
tumours (pT3 or pT4), lymph node positivity (pN1 to pN3) or the presence of 
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metastatic dissemination (M1). Additionally, it is essential to identify tumours with 
aggressive biological intent earlier and thereby increase the chances of cure and/or 
disease control for these patients. Finally, identification of novel molecular targets 
and improvements in the understanding of why current chemotherapeutic agents are 
generally ineffective in advanced PeScc is urgently required. 
 
In section 1.5.4, I proposed a putative model for tumour progression in PeScc (Figure 
1.10), based on the molecular biological evidence for this rare tumour type available 
in the current literature. Broadly, tumorigenesis appears to follow either HPV 
dependent or HPV independent pathways with invasive carcinomas developing from 
in situ neoplastic lesions or de novo. The multi-step Vogelstein-Fearon model for 
colorectal cancer (Fearon and Vogelstein 1990) appears to share a similar platform of 
sequential genetic and epigenetic mutations leading to invasive cancer.  The distinct 
steps in this model include: initiation, promotion and progression. Therefore, it is 
possible to establish the successive genetic changes necessary to result in progression 
from an early cancer to an advanced and aggressive phenotype (i.e. anaplastic & 
higher stage with or without metastatic disease). Further work is required into the 
molecular mechanisms underpinning these biological events which tightly define each 
of these stages in PeScc. In this chapter, I aim to describe some of the core events in 
early and late tumorigenesis by analysing the dysregulation of the DNA replication 
licensing system and linking these data to the presence of chromosomal instability 
within these penile tumours. 
 
The development of chromosomal instability is linked to the pathogenesis and 
progression of multiple tumour types (Deliveliotis 2003; Raatz 2004; Bantis 2005; 
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Deliveliotis 2005; El-Rayes 2005; Pinto 2005; Saiz-Bustillo 2005; Kasprzyk 2006; 
Araujo 2007; Santagostino 2007; Susini 2007; Yildirim-Assaf 2007; Pinto 2008; 
Susini 2011); however, the debate as to whether aneuploidy is a cause or consequence 
of cancer remains unresolved (Rajagopalan 2004). In PeScc, a number of karyotpyes 
have been described which match the chromosomal changes seen in other distinctive 
squamous carcinomas (Poetsch et al. 2007). Fundamentally, early tumourigenesis has 
been linked to deletions of the short arm of chromosomes 3 and 9. Despite, 
understanding this basic cytogenetic information, it is currently impossible to fully 
elucidate the role of penile intraepithelial neoplasia (PIN) in tumour development and 
progression in PeScc. Clearer evidence is now coming to light to suggest that PIN 
also develops in an HPV dependent and independent fashion and gives rise to specific 
invasive PeScc subtypes through proposed molecular pathways (Bleeker et al. 2009; 
Kayes 2012). Later tumourigenic processes are linked with greater number of 
alterations involving chromosomes 5, 8, 11, 18 and 21 (Poetsch et al. 2007). Tumours 
which behave in an indolent and unaggressive manner are characterised by their 
diploid cellular populations (Ornellas et al. 2000). Notably, a putative balance 
between distinct RLFs appears essential for maintaining chromosomal integrity and 
re-replication errors incurred if geminin and Cdt1 levels disassociate (Saxena 2005). 
 
In previous chapters, I have described the validation of conventional 
clinicopathological features known to relate to aggressive oncogenic phenotypes in 
men with PeScc. I have also demonstrated that image cytometry offers an accurate 
and convenient method for analysing the DNA content of archival specimens and that 
aneuploidy is linked to locoregional disease. Furthermore, I have described the 
dysregulation of the DNA licensing system that occurs with neoplastic changes in 
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penile epithelium. In this chapter, I have sought to explore the link between these 
regulators of DNA replication with genomic instability as determined through ploidy 
studies. I have investigated the differences observed in RLF expression between 
diploid and aneuploid populations. Furthermore, I have analysed these factors 
alongside the tumour kinetics determined in chapter 4, in order to better understand 
the changes that occur between early and late tumorigenesis, reflecting a switch to 
more aggressive disease patterns. 
 
5.2. Materials and methods 
For Clinical data (2.2.1), Antibodies (2.3.1), Immunohistochemistry (2.3.3), Protein 
expression profile analysis (2.3.4), DNA ploidy analysis: image-based cytometry 
(2.5), Statistical methods (2.6) refer to Chapter Two.  
 
5.3. Results 
5.3.1. Dysregulation of the licensing machinery is linked to the 
development of genomic instability in PeScc 
I sought to investigate the relationship between RLF expression (sensitive biomarkers 
of proliferation), anaplasia (arrested differentiation) and tumour DNA ploidy 
(genomic instability) in this study cohort of PeScc. This was achieved through the in 
vivo analysis of the expression profiles for these proteins determined by 
immunohistochemistry in 141 cases of PeScc and correlated with ploidy status 
determined by image cytometry. In dysplastic cases (n=14), the majority of lesions 
were diploid (65%). There does not appear to be a key signature in RLF expression 
that defines diploid from aneuploid cell populations in pre-malignant lesions (Table 
5.1). Tumours showing increasing anaplasia also strongly exhibited aneuploidy  
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Table 5.1 
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(p<0.0001); suggesting that arrested differentiation and aneuploidy are linked in 
PeScc. Moreover, the subset of aneuploid tumours was significantly linked to 
increased Mcm2, geminin and Ki67 expression (p<0.01) (Table 5.1). A decreased 
Mcm2/Ki67 ratio (p=0.03) and increased Ki67-geminin score (p=0.01) were also 
associated with increased DNA content. These data indicate an increased proportion 
of cycling cells in aneuploid tumours compared with diploid tumours. These findings 
support a hypothesis that aneuploid cancers are associated with a hyperproliferative 
state when compared with diploid tumours in PeScc.  
 
5.3.2. DNA licensing factors are dysregulated during progression from 
indolent to aggressive disease 
In order to explore the associations between aberrant DNA replication licensing and 
aneuploidy within aggressive disease states, I analysed the expression profiles for 
these biomarkers against the pathological stage of the tumours determined by the 
2004 TMN staging system. Additionally, I analysed the correlation of RLF expression 
and DNA content with standard histopathological features of the primary tumour 
(Tables 5.2a & 5.2b). Aberrant RLF expression and aneuploidy are tightly correlated 
with increasing anaplasia as detailed in sections 3.3 and 4.3 Furthermore, a significant 
association between increased biomarker expression and geminin/Ki67 ratio with 
increasing tumour size and tumour subtype was observed. Previous research has 
shown that verrucous and warty tumours behave in a biologically indolent fashion 
with low risk for disease progression (Seixas et al. 1994) compared to aggressive 
variants, such as basaloid tumours which are associated with poorer clinical outcomes 
(Cubilla 2009). The innocuous clinical course observed with low risk tumours is 
reflected by the decreased growth potential and stable cell cycle dynamics witnessed 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  189                                                                          
 
when compared to more aggressive variants. As such, low risk tumours were 
associated with lower Ki67 and RLF expression with the lower geminin and Ki67-
geminin scores indicating smaller numbers of cells transiting S-G2-M and G1 phase 
respectively when compared with aggressive basaloid tumours (Tables 5.2a & 5.2b).  
 
The subtypes associated with poorer clinical outcome therefore displayed a more 
aggressive cell cycle phenotype. Elevated geminin expression and an increase in 
geminin/Ki67 ratio were significantly associated with increasing local tumour stage 
(geminin: p=0.05; geminin/Ki67: p=0.02) and increasing depth of invasion (geminin: 
p=0.02; geminin/Ki67: p=0.03) (Tables 5.2a & 5.2b). Higher tumour stage and 
increased depth of invasion appear to be features of aggressive cancers (Cubilla 2009; 
Pizzocaro et al. 2010). I have shown clearly that these tumours demonstrate an 
increased proliferative signature with aggressive tumours demonstrating accelerated 
cellular kinetics with shortened G1 phase times, as the geminin/Ki67 ratio 
approximates towards unity (see section 1.4.4.3 and 4.3.5). Interestingly, the positive 
correlation between geminin expression and increasing tumour anaplasia indicates 
that this licensing repressor does not behave as a tumour suppressor in PeScc and is in 
keeping with previous studies in other tumour types, which demonstrate the direct 
correlation between geminin expression and proliferation index (Wohlschlegel et al 
2002; Eward et al 2004; Wharton et al 2004; Dudderidge et al 2005; Obermann et al 
2005; Shetty et al 2005; Dudderidge et al 2007). Finally, I examined the critical 
associations between RLF expression, DNA content and the development of regional 
(inguinal and pelvic lymph nodes) and/or distant metastases. In univariate analysis, 
Mcm2 (P = 0.02), geminin (P = 0.02) and Ki67 (P = 0.03) expression were all 
significant predictors of nodal status (Table 5.3). As observed in section 3.3.3, tumour 
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grade (P = 0.02) and stage (P < 0.01), presence of vascular invasion (P = 0.04), and 
ploidy status (P = 0.03) were also predictive of nodal status; with poorly differentiated 
tumours [odds ratio (OR), 8.76; 95% CI, 1.80-42.73], high-stage disease (OR, 4.80; 
95% CI, 1.81-12.74), presence of vascular invasion (OR, 2.66; 95% CI, 1.04-6.75), 
and aneuploidy (OR, 2.96; 95% CI, 1.09-8.01) closely linked to advanced disease 
with regional lymph node involvement (Table 3.3).  
 
Multivariate analyses were used to construct a final model using these factors. After 
backward elimination, biomarker information (Mcm2, Ki67, or geminin LI), vascular 
invasion, and ploidy status were excluded from the final analysis. Tumour grade (P = 
0.006) and local stage (P = 0.003) were independent predictors of positive lymph 
node disease (Table 3.4). The area under the receiver operating characteristic curve 
for this model was 0.78 (95% CI, 0.69-0.87). Although all biomarkers were predictive 
markers in univariate analysis, no single biomarker was a significant predictor after 
adjustment for grade and stage. This is due, in part, to the significant associations 
between biomarker LI with tumour grade and stage, making it difficult to separate 
their independent effects. Finally, on further analysis, I observed a significant 
association between aneuploid tumours (p=0.03) and a trend for tumours showing 
increased Mcm2 expression (p=0.09) with the development of distant metastases; thus 
reflecting late cancer progression. These striking outcomes are explored in greater 
detail in chapter 6 in combination with overall survival data. 
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Table 5.2b 
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5.4. Discussion 
Evolutionary studies of human solid tumours provide not only a model of tumour 
progression, but potentially the means to identify distinct biological elements that 
might predict, detect, diagnose and treat human malignancy. Many cancers proceed 
through definitive stages that offer excellent opportunities to alter the course of 
disease; however, the inherent complexity of neoplasia and unique attributes of 
different tumour types dictate a multidimensional approach to identifying and 
evaluating molecular markers that incorporates knowledge of the stages and critical 
pathways involved in initiation and progression. The DNA replication licensing 
system lies at the convergent point of  upstream mitogenic signalling pathways 
(Williams and Stoeber 2007; Williams and Stoeber 2012; Jackson, Laskey, and 
Coleman 2013). Through understanding how this system is dysregulated in early and 
late carcinogenesis, it may be possible to target specific intracellular components for 
improved diagnosis, prognosis and treatment in men with PeScc and provide critical 
target validation for novel agents acting as new cancer therapeutics (Williams et al. 
1998; Freeman et al. 1999; Stoeber et al. 1999; Kodani et al. 2001; Stoeber et al. 
2002; Going et al. 2002; Williams et al. 2004; Laskey 2005; Gonzalez et al. 2005; 
Scott et al. 2006; Williams and Stoeber 2007; Scarpini et al. 2008; Siddiqui et al. 
2008; Ayaru et al. 2008; Kulkarni et al. 2009; Loddo et al. 2009; Rodriguez-Acebes et 
al. 2010; Dudderidge et al. 2010; Depuydt et al. 2011; Saeb-Parsy et al. 2012; 
Williams and Stoeber 2012; Kelly et al. 2012; Jackson, Laskey, and Coleman 2013).  
 
The multi-step tumourigenesis model for colorectal cancer (Fearon and Vogelstein 
1990) provides a basic template for the accumulation of genomic instability observed 
from cancer initiation through cancer progression. PeScc potentially represents a more 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  195                                                                          
 
heterogeneous and diverse pathology which may share key mechanistic events with 
other crucial urogenital and gynaecological tumours; specifically squamous cell 
carcinoma of the vulva (Longpre et al. 2012) and adenocarcinoma of the uterine 
cervix (Grulich et al. 2010; Wattleworth 2011). It has been demonstrated in principle 
that invasive carcinomas of the penis may arise from pre-malignant lesions or de novo 
and that the underlying forces driving carcinogenesis in these groups are remote from 
each other and possibly linked to HPV infection (Bleeker et al. 2009; Kayes 2012; 
Velazquez, Chaux, and Cubilla 2012).  
 
I sought to understand the relationship of origin licensing with genomic instability in 
penile intraepithelial neoplasia (PeIN) and invasive PeScc. The DNA replication 
licensing system appears to be highly dysregulated in pre-malignant lesions 
characterised by a high proliferative signature (i.e. high expression Mcm2; Ki67; 
geminin) in the context with full thickness dysplasia. Here, it is observed that these 
early events in PeScc carcinogenesis are usually associated with diploid DNA content 
of the dysplastic cells. This suggests that the replication licensing system is 
dysregulated at an early stage in PeScc, as observed in other tumour types (Williams 
et al. 1998; Freeman et al. 1999; Stoeber et al. 1999; Kodani et al. 2001; Going et al. 
2002; Stoeber et al. 2002; Williams et al. 2004; Gonzalez et al. 2005; Scott et al. 
2006; Williams and Stoeber 2007; Ayaru et al. 2008; Scarpini et al. 2008; Dudderidge 
et al. 2010; Kelly et al. 2012; Saeb-Parsy et al. 2012; Williams and Stoeber 2012; 
Jackson, Laskey, and Coleman 2013). Interestingly, it has been reported that between 
5-33% of PeIN will progress to invasive carcinoma (Bleeker et al. 2009) which may 
reflect the proportion of lesions with genomic instability in this dataset (35%). An 
alternative hypothesis could suggest that these aneuploid PeIN lesions may represent 
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a highly unstable epithelial precursor that may simply progress more rapidly if left 
untreated. 
 
Conversely, poorly differentiated, invasive carcinomas are significantly linked to 
elevated expression of all RLFs and are commonly aneuploid (Figure 5.1). 
Furthermore, aneuploid tumours are associated with a decreased Mcm2/Ki67 ratio (P 
= 0.03); and increased Ki67-geminin score (P = 0.01) indicating an increased 
proportion of actively cycling tumour cells in aneuploid tumours compared with 
diploid tumours. Importantly, these alterations in cell cycle regulation correlate with 
late carcinogenic events including: increasing tumour size, local invasion and 
development of regional and distant metastases. Geminin levels appear to be crucial 
in this process, promoting cell cycle progression in conjunction with dysregulation of 
normal cellular checkpoints. Several studies have reported the strong link between 
increased geminin expression and aggressive tumour factors (Shetty et al. 2005; 
Shrestha et al. 2007; Loddo et al. 2009; Nishihara et al. 2009; Kapoor 2012; Jackson, 
Laskey, and Coleman 2013). The proteins involved in DNA replication licensing 
appear to become increasingly dysregulated during the progression from low-grade, 
diploid tumours to aggressive high-grade, aneuploid tumours (Kulkarni et al. 2007; 
Loddo et al. 2009). This supports the hypothesis that not only may these proteins 
become dysregulated during the initiation of malignant potential but also that their 
continued aberrant regulation reflects tumour progression. 
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These data highlight an intriguing connection between chromosome replication 
initiation and polyploidy in cancer development and progression. The replication 
licensing pathway is integral to early tumour formation and is markedly dysregulated 
in late PeScc carcinogenesis as shown by the close correlation to aneuploidy 
progenies. Figure 5.1 attempts to further describe and develop the putative initiation 
and progression model originally discussed in chapter 1 (Figure 1.10). The role of 
HPV infection is critical to tumorigenesis for a subset of penile cancers 
(approximately 50%) (Della et al. 1992). This is important information for current 
WHO vaccination programmes (Crosignani et al. 2013) as the overall impact on the 
incidence of this rare tumour will remain small (Anderson 2012). The new model 
proposed in this section provides new, insight to distinct pathways involving 
potentially attractive molecular targets for novel therapeutic agents or prognostics 
tests.  
 
The targeting of upstream growth signalling pathways is often constrained by 
pathway redundancy (Williams and Stoeber 1999) or the development of growth-
independent (autonomous) cancer cell cycles (Williams and Stoeber 2007). Efficacy 
can be compromised through a variety of mechanisms, e.g. through overexpression of 
alternative receptor tyrosine kinases or development of new signalling pathways 
(Sierra, Cepero, and Giordano 2010). Therapeutic targeting of the DNA replication 
initiation machinery, which lies at the convergence point of growth signalling 
networks, is now emerging as a new concept promising to overcome the limitation of 
targeting more upstream pathways. Potent cancer cell-specific killing has been 
demonstrated in preclinical models after inhibition of origin licensing (Shreeram et al. 
2002) or, alternatively, origin activation through targeting Cdc7 kinase (Montagnoli et 
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al. 2004; Montagnoli et al. 2008; Kulkarni et al. 2009; Rodriguez-Acebes et al. 2010). 
Several studies have shown that following impairment of the DNA replication 
initiation machinery, normal cells arrest at the G1 –S boundary with unreplicated 
DNA, elevated p53 levels and induction of CDKI p21 (Shreeram et al. 2002; 
Montagnoli et al. 2004; Rodriguez-Acebes et al. 2010). This putative cell cycle 
checkpoint appears critically dependent on several tumour suppressor proteins, 
including p53, p21, Dkk3, ARF, Hdm2, FoxO3a, p15, p27 and RB (Tudzarova et al. 
2010). This suggests that inactivating mutations in checkpoint proteins, such as Rb 
and p53 which are commonly seen in penile cancer; will render these cells exquisitely 
sensitive to anti-cancer agents targeting the DNA replication initiation machinery 
(Tudzarova et al. 2010). 
 
Alternatively, translation of these results to clinical practice may represent an 
opportunity to effect changes to current grading systems (Broders AC. 1921; Maiche 
1991) given the highly significant association between these cell cycle regulators and 
tumour grade. These results have been consolidated in several other malignancies 
(Sudbo 2001; Wharton 2004; Shetty et al. 2005; Graafland 2011). “Molecular 
staging” based on a panel of molecular markers can complement current 
clinicopathological staging to accurately indicate the risk of disease progression 
through multi-parameter analysis exploring the cell cycle progression in PeScc. These 
findings are in keeping with similar analyses of RLFs in prostate, bladder, lung, breast 
and renal cell cancer (Freeman et al. 1999; Kodani et al. 2001; Meng 2001; Gonzalez 
2003; Wharton 2004; Dudderidge 2005; Gonzalez et al. 2005; Shetty et al. 2005; 
Dudderidge 2007; Kulkarni et al. 2007; Williams and Stoeber 2007; Loddo et al. 
2009; Williams and Stoeber 2012; Jackson, Laskey, and Coleman 2013). 
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Identification of specific molecular targets that may be more amenable to specific 
therapies would clearly be advantageous. These novel staging systems may then be 
used for administering targeted therapy, which can be individually tailored to meet a 
patient's molecular profile and projected response, thus decreasing morbidity (Figure 
5.2). 
 
5.5. Conclusion 
The data presented in this chapter provides important evidence supporting a link 
between aberrant regulation of the replication licensing system and the development 
of genomic instability in PeScc. As discussed in chapter 4, cell cycle phase analysis of 
these tumours helps to identify differential tumour cell populations which define early 
and later carcinogenic events, exemplified here by correlation to standard 
clinicopathological factors linked to advanced clinical disease. Expanding on the 
putative biological mechanisms that appear to drive tumour progression in PeScc, 
namely hyperproliferation and genomic instability; I subsequently explore whether 
these correlates provide realistic translation value for predicting survival in these men. 
In chapter 6, I link the RLF expression and DNA ploidy of these tumours to survival 
data and test the prognostic power of a new staging system to discriminate a patient’s 
risk for progression based on the pathological and molecular markers studied to date. 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  201                                                                          
 
Figure 5.2 
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CHAPTER SIX 
PROGNOSTIC INFORMATION FOR DNA REPLICATION 
LICENSING FACTORS AND ANEUPLOIDY  
IN PENILE CARCINOMA 
 
6.1. Introduction 
Advances in genomics, proteomics and molecular pathology have generated many 
candidate biomarkers with potential clinical value across different tumour types. 
However, translation from ‘bench to bedside’ outside of the research setting has 
proved difficult. There have been a lack of reliable, prospective studies and in many 
cases primary data is often statistically over-fitted leading to a lack of reproducibility. 
Five conceptual phases of biomarker development (Rifai 2006) have been proposed 
(Pepe 2001) :  
 
1. preclinical exploratory 
2. clinical assay and validation 
3. retrospective longitudinal 
4. prospective screening 
5. cancer control 
 
The process is fraught with difficulties and most candidate markers are still in the 
early phases of development. A new cancer biomarker under development is likely to 
have already encountered one or more of the following fatal features encountered by 
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prior markers: lack of clinical significance, hidden structure in the source data, a 
technically inadequate assay, inappropriate statistical methods, unmanageable 
domination of the data by normal variation, implausibility, deficiencies in the studied 
population or in the investigator system and its disproof or abandonment for cause by 
others (Rifai 2006). 
 
These processes are focussed on developing modern, personalised, tumour diagnostics 
and prognostics through combinatorial approaches of multiple biomarkers. Hopefully, 
this will obviate the heterogeneity seen in most tumours and guide diagnosis, 
treatment and follow up, especially in equivocal cases. Hence, future biomarkers 
should be able to reflect prognostic information set against disease free and overall 
survival data; as well as a predictive value to assess appropriate treatment responses 
(Williams 2007) .  
 
The formal TNM staging system is based almost exclusively on the anatomical extent 
of disease, which is assessed using a combination of tumour size or depth (T), lymph 
node spread (N), and presence or absence of metastases (M). Since its inception in 
1953, the TNM system has provided a standardized, anatomical basis for staging 
different malignancies (Denoix 1953). Less often, tumour grade, histological subtype 
or patient age has been added to TNM staging. Currently, none of the FDA approved 
biomarkers have been incorporated into current staging systems. Each anatomical site 
has its own histological grading system, designed to classify malignancies by degree 
of differentiation. 
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Low-grade, well-differentiated tumours are usually less aggressive and more 
favourable in prognosis than high-grade tumours, which tend to grow faster and 
metastasize earlier. However, tumour grade is only included in formal TNM staging, 
when intimately linked to prognosis, as it is for soft-tissue sarcomas, prostate cancer 
and primary brain malignancies (Wittekind 2002) . Assignment of grade is inherently 
subjective and dependent on the skill and experience of the reviewing pathologist. 
Biomarker expression can reliably score tumours according pathologist reported 
grades with additional potential for semi-automotive quantification which will permit 
fast and accurate diagnostics. 
 
Targeted therapies, which include monoclonal antibodies and small molecule 
inhibitors, have significantly changed the treatment of cancer over the past decade. 
Alongside standard chemotherapy (Table 6.1), these drugs are now more 
commonplace in the treatment of many common malignancies including: breast, 
colorectal, lung, and pancreatic cancers, as well as lymphoma, leukemia, and multiple 
myeloma (Table 6.2). However, these agents are effective only if their respective 
molecular markers are mutated or expressed at sufficient levels. The mechanisms of 
action and toxicities of targeted therapies differ from those of traditional cytotoxic 
chemotherapy. Targeted therapies are generally better tolerated than traditional 
chemotherapy but they are associated with several adverse effects such as acneiform 
rashes, cardiac dysfunction, thrombosis, hypertension, and proteinuria (de, Jr. 2006) . 
Small molecule inhibitors are metabolized by cytochrome P450 enzymes and are 
subject to multiple drug interactions. The use of targeted therapy has markedly 
changed outcomes for some cancers and has revolutionized treatment. In other 
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instances, the degree of clinical benefit is more modest. Before the advent of targeted 
therapies, patients with metastatic renal cell carcinoma treated with cytokines showed 
a median survival of 10 months (Motzer 1999) . However, newer agents including; 
sunitinib, sorafenib, and pazopanib, demonstrate efficacy and constitute the 
comparator arm in several ongoing studies. In patients with advanced renal cell 
carcinoma, the initial data for sunitinib against standard therapy in the form of 
immunotherapy (alpha-interferon) showed a real but modest increase in median 
survival from 21.8 to 26.4 weeks (Motzer 2007; Motzer 2009) . 
The process of PeScc carcinogenesis appears to be driven by a core number of 
oncogenic mutations which far out-strip the rudimentary algorithm proposed in 
sections 1.5.5 and 5.4. Hence, these epithelial tumours can present with variable 
clinical phenotypes underpinned by a diverse genological heritage and equivocal 
biological behaviour. The complexity of targeting upstream growth signalling 
pathways limits current therapeutic and prognostic modelling. In order to minimise 
the variability observed through the heterogeneous biology of most tumours, 
including PeScc, targeting the ubiquitously up-regulated cell proliferation powered by 
dysregulation of the cell cycle machinery appears to represent a core mechanism  
(Hanahan and Weinberg 2000; Evan and Vousden 2001; Jackson, Laskey, and 
Coleman 2013; Williams 2012). Ultimately, any oncogenic events upstream of the 
cell cycle machinery will be mirrored in the extent of its dysregulation.       
 
In this final chapter, I explore the early clinical data evaluating the impact of RLFs as 
novel prognostic indicators of disease progression and outcome in patients with 
PeScc.  Using the validated dataset presented in this thesis, I will aim to correlate RLF 
expression with traditional clinicopathological variables and ploidy status against 
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overall survival. Furthermore, using contemporary statistical techniques, I construct 
an innovative risk profile for these tumours to help stratify patients more succinctly 
into discrete categories in order to aid adjuvant therapies and surveillance 
programmes. 
    
6.2. Materials and methods 
For Clinical data (2.2.1), Antibodies (2.3.1), Immunohistochemistry (2.3.2), Protein 
expression profile analysis (2.3.4), DNA ploidy analysis: image-based cytometry 
(2.5), Statistical methods (2.6) refer to Chapter Two.  
 
6.3. Results 
6.3.1. RLF expression, DNA content, tumour characteristics and overall 
survival  
I investigated the survival time for patients with PeScc using Cox's proportional 
hazards model. The study group for the analysis included 118 men with a recorded 
survival time. Of these, 26 patients were dead (22%) and 92 were alive (78%) at the 
time of analysis. Univariate analysis (Table 6.3) showed that Mcm2 (P = 0.02), Ki67 
(P = 0.04) expression and Ki67-geminin score (P = 0.03) were all significantly 
associated with overall survival. Age (P = 0.002), tumour stage (P = 0.02), depth of 
invasion (P < 0.0001), tumour multifocality (P = 0.002), vascular invasion (P = 0.04), 
and ploidy status (P = 0.008) were also predictive of overall survival outcomes. 
Advanced age [hazard ratio (HR) 1.05 per year; 95% CI, 1.02-1.1], higher-stage 
tumours (HR 3.89; 95% CI, 1.52-9.99), multifocal tumours (HR 3.69; 95% CI, 1.63-
8.32), increased depth of invasion (HR 1.045; 95% CI, 1.025-1.064), presence of 
vascular invasion (HR 2.23; 95% CI, 1.02-4.87), and aneuploidy (HR 4.28; 95% CI, 
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1.46-12.58) were associated with a significantly shorter overall survival time. It was 
also noted that lymph node status (negative or positive) was an excellent prognostic 
factor on univariate analysis (HR, 11.07; 95% CI, 3.74-32.71) in keeping with 
previous reports. Notably, tumour grade failed to predict outcome in this series (P = 
0.28) emphasizing the limitations with current grading systems.  
 
Multivariate analyses were used to construct a final model involving 84 patients (76 
Alive; 18 Dead). Backward elimination resulted in the exclusion of biomarker 
information (Mcm2, Ki67, or geminin LI), vascular invasion, local tumour stage, and 
depth of invasion from the final model. However, age (P = 0.004), positive lymph 
node status (P < 0.001), tumour multifocality (P = 0.002), and aneuploidy (P = 0.03) 
were identified as independent predictors of overall survival (Table 6.4).  
 
6.3.2. Risk profiling in penile cancer 
I quantified the discriminatory ability of this model using Harrell's c-index (FE 
Harrell, Regression Modeling Strategies, Springer, 2001). This is analogous to the 
receiver operating characteristics (ROC) area and gives the probability that a 
randomly selected pair of patients has concordant predictions and survival times (i.e. 
the patient with the best prognosis also has the longer observed survival time).  The c-
index takes values between 0.5 (random predictions) to 1 (perfect concordance). In 
isolation, these predictors have c-index values of 0.77 (lymph node status), 0.68 (age), 
0.65 (aneuploidy), and 0.64 (multifocality). The multivariable model has a Harrell’s 
c-index of 0.88. Kaplan-Meier survival curves show the survival advantages for 
standard clincopathological variables (Figure 6.1 to 6.3), biomarker expression 
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(Figure 6.4) and ploidy status (Figure 6.5). In combination, these data suggest that the 
implementation of a ‘semi-automotive’ process to analyse tumours for aneuploid 
DNA content and increased RLF expression (Mcm2 and/or geminin) can provide 
important staging and prognostic information at an earlier stage of the disease and 
treatment process in these men. This further supports the rationale for developing a 
multiparameter test using this unique panel of biomarkers as previously outlined in 
section 5.4. This should allow improved prognostication compared to current standard 
histopathological assessment and can be performed on biopsy material alone in 
principle.  To illustrate the predicted survival based of this model, the patients were 
split into tertile groups and labelled as low, medium and high risk (Table 6.4). The 
model has the form: 
 
Prognostic Index (PI) = [2.14  Node (Positive)] + [1.58  Extent (Multifocal)]  
+ [1.43  Ploidy (Aneuploid)] + [0.0551  (Age)] 
 
For an individual patient it is possible to calculate their prognostic index (PI) and split 
the patients into tertile based on the PI score (low-risk: PI < 4.4, medium-risk: 4.4 < 
PI < 6.2, high-risk: PI > 6.2). Kaplan-Meier survival curves were constructed for these 
tertile risk groups derived by splitting the patients into equal-sized groups based on 
their predicted risk from the model (Table 6.5; Figure 6.6). Using this model, the 
overall survival rates observed at 3 years were 97%, 93%, and 27%, and 5-year 
survival figures of 97%, 72%, and 18% for low, moderate, and high risk men, 
respectively. This final risk profiling model will hopefully obviate the need for 
unnecessary surgery or radiological investigation in some patients, whilst highlighting 
high risk patients who may benefit from adjuvant therapies. 
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6.3. Discussion 
In this study, I have assessed the utility of Mcm2 and geminin, alongside DNA ploidy 
status as novel biological predictors of outcome in men with PeScc. My results show 
that Mcm2 and geminin labeling indices in conjunction with aneuploidy are powerful 
prognostic indicators of locoregional metastasis and overall survival. Predictive 
nomograms for lymph node involvement and cancer-specific survival in PeScc using 
traditional histopathologic information alone have been developed but require 
prospective validation (Ficarra 2006; Kattan 2006) . In this study: Mcm2 and Ki67 
LIs, Ki67-geminin score, age, tumour stage, depth of invasion, tumour 
extent/location, vascular invasion, lymph node status and ploidy status were all 
identified as predictors of overall survival; with lymph node status, tumour extent, and 
ploidy status identified as independent predictors of overall survival. Notably, I have 
shown that these parameters can be incorporated into a simple predictive model to 
stratify patients into high, intermediate, and low-risk groups for disease progression in 
PeScc. Crucially, the multivariable model suggests that low-risk patients are at 
minimal risk of disease progression compared with men assigned to moderate or high-
risk groups. This is highlighted by overall survival rates at 3 years of 97%, 93%, and 
27%, and 5-year survival figures of 97%, 72%, and 18%, for low, moderate, and high-
risk men, respectively. This provides a potentially powerful approach for early 
treatment stratification of patients, with low-risk patients assigned to surveillance 
programs whilst targeting high-risk patients with radical surgical and adjuvant 
chemotherapeutic interventions. Further studies in additional patient cohorts are now 
warranted to confirm the predictive power of this model in the risk stratification of 
PeScc.  
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Inhibition of the DNA replication initiation machinery has been shown to provoke a 
cancer cell–specific apoptotic response as a result of the loss or impairment of a 
putative checkpoint for replication-competent origins during tumourigenesis 
(Rodriguez-Acebes 2010; Tudzarova 2010). Potent cancer cell-specific killing has 
been demonstrated in preclinical models after inhibition of origin licensing (Shreeram 
2002) or, alternatively, origin activation through targeting Cdc7 kinase (Montagnoli 
2004; Montagnoli 2008). Tumour cell specificity is thought to result from transformed 
cells entering S phase with inadequate numbers of competent origins to complete 
chromosomal replication. This results in an abortive S phase with incompletely and/or 
abnormally replicated DNA. Tumour cells with a functional intra-S phase checkpoint 
appear to undergo rapid death after replication fork stalling/collapse, whereas more 
transformed cancer cells appear to survive longer but eventually face mitotic 
catastrophe as a result of partially replicated chromosomes (Montagnoli 2004; 
Montagnoli 2008; Shreeram 2002). In striking contrast, normal cells avoid entering S 
phase with a reduced number of replication-competent origins by engaging a recently 
described cell cycle checkpoint, the ‘origin activation checkpoint’. Several studies 
have shown that following impairment of the DNA replication initiation machinery, 
normal cells arrest at the G1–S boundary with unreplicated DNA, elevated p53 levels 
and induction of CDKI p21 (Montagnoli 2004; Shreeram 2002). We can therefore 
hypothesise that loss of the protective checkpoint mechanism through inactivating 
mutations in checkpoint proteins may render most common solid tumours sensitive to 
anti-cancer agents targeting the DNA replication initiation machinery.  
 
In summary, I have shown that increasing dysregulation of the DNA replication 
licensing pathway is linked to emergence of an aggressive cell cycle phenotype that 
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affects the in vivo behaviour of this tumour type. The DNA replication licensing 
pathway therefore also seems to be a potentially attractive therapeutic target in PeScc. 
The rationale and potential for developing novel Cdc7 kinase inhibitors is discussed 
further in the final chapter. 
 
6.4. Conclusion 
In summary, it is apparent that several of the proteins I have investigated are of 
important prognostic value as biomarkers in PeScc. Patient stratification for radical 
and adjuvant treatments will be aided by adopting this novel multiparameter analysis. 
Furthermore, it may be possible to implement these diagnostic and prognostic 
strategies at an earlier stage than current grading and staging algorithms. Finally, 
these data provide crucial target validation for developing novel small molecule 
therapeutics against the RLF machinery, as new and complimentary treatments in this 
highly complex malignancy. 
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CHAPTER SEVEN 
CONCLUDING REMARKS 
 
7.1. Conclusions 
PeScc is a rare and unusual genitourinary malignancy with a highly complex and 
heterogeneous heritage, reflected in the poorer overall outcomes and lack of 
efficacious first/second line chemotherapeutics in the management of advanced 
disease states (Hakenberg 2012). Classically, the progression to metastatic disease 
follows well-defined patterns of dissemination involving locoregional lymphatic 
spread to eventual distant metastases. It is not unusual for men to present with locally 
destructive lesions and the presence of inguinal deposits. Current surgical 
management strategies are often physically and psychologically debilitating. In 
contrast, men presenting with earlier disease offer a diagnostic and therapeutic 
dilemma, as current staging modalities lack the necessary sensitivity and specificity to 
stratify patients accurately to surveillance programmes versus adjuvant surgical and 
therapeutic regimes.  In order to impact on the poor survival rates seen in advanced 
PeScc, it is crucial to understand the mechanisms involved in malignant progression. 
This would enable prediction of those tumours at high risk of progression or relapse at 
diagnosis and identify those likely to benefit from specific therapies; thereby offering 
the opportunity to tailor management. The goal of achieving such personalised 
treatment has been the major focus of cancer research, across a broad range of 
malignancies. However to date, such success remains elusive in PeScc, not least due 
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to the rarity of the condition and also the complexity of the molecular events which 
occur during the transition from benign to malignant disease. 
 
Notably, expression arrays in a broad range of malignancies have identified 
‘proliferation signatures’, genes whose expression correlates with tumour grade, cell 
cycle status and doubling times (Ross 2000). This proliferation signature is one of the 
most prominent gene-expression patterns observed in tumour datasets and includes 
many cell cycle regulated genes, several of which have been shown to have a role in 
carcinogenesis. This is unsurprising when one considers the importance of the cell 
cycle machinery as a convergence point for upstream oncogenic signalling pathways 
(Evan 2001; Williams 2007; Jackson, Laskey, and Coleman 2013; Williams 2012). In 
the work of this thesis, I have focused on key G1/S cell cycle regulatory molecules 
which govern the DNA replication licensing system. Importantly, not only have these 
proteins been identified in several tumour types, including large-scale microarray 
datasets (Rhodes 2004; Whitfield 2002), as potential prognostic indicators, they are 
also attractive therapeutic targets and are therefore the focus of current drug 
development programmes (Jackson, Laskey, and Coleman 2013; Williams 2012). 
However there is a paucity of information regarding the role of these regulatory 
proteins in PeScc. In the work of this thesis, I have shown that there is aberrant 
regulation of the RLFs in PeScc. The broad utility of these proteins at various stages 
in the management of cancer, from population screening to tumour relapse, highlights 
several interesting prognostic and therapeutic avenues which arise from this work 
(Jackson, Laskey, and Coleman 2013; Williams 2012). 
 
Firstly, they may be used as proliferation markers with potential for further 
DNA replication licensing control and genomic instability in penile cancer                                           Oliver Kayes  
 
University College London  228                                                                          
 
improvements in the current grading system and as molecular markers of tumour 
stage allowing refinement of present surgical and radiological methods (Chapters 3 & 
4). Moreover, the observation that their expression does not fully distinguish between 
tumour grades demonstrates that traditional clinicopathological parameters do not 
always allow prediction of therapeutic response, supporting the concept of co-
evolution of biomarker and individualised targeted therapy. This has attractive 
implications for diagnosing and/or monitoring new and recurrent penile epithelial 
lesions without the need for repeated biopsy. This approach further exploits the 
surface sampling principles observed in other tumour types (Ayaru 2008; Dudderidge 
2010; Going 2002; Jackson, Laskey, and Coleman 2013; Kodani 2001; Scott 2006; 
Stoeber 2002; Williams 1998; Williams 2004; Williams 2007; Williams 2012) and 
which now form the basis of several, large FDA clinical trials (Depuydt 2011; 
Tambouret 2008). Furthermore, it may be possible to utilise the important prognostic 
information delivered through analysis of these biomarkers to deliver more 
appropriate treatments for men at an earlier stage of their clinical management  (i.e. 
on initial biopsy material). Hopefully, this will allow more men to receive effective 
adjuvant treatments without delay; whilst sparing low risk men from the notable side-
effects of contemporary surgical and chemotherapeutic treatments.  Secondly, the 
multiparameter analysis of RLFs provides insight into the cell cycle state of individual 
tumour samples (Chapter 4, 5 & 6). This form of analysis may be used in predictive 
testing for both cell-cycle phase specific chemotherapeutic drugs and novel small 
molecules targeting the cell cycle machinery or upstream growth signal transduction 
pathways that accelerate cell cycle progression. For example, tumours demonstrating 
high Mcm2 and Ki67 levels with low geminin co-expression, thus indicating an 
arrested or prolonged G1 phase (observed in PeScc), may be less likely to respond to 
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S or G2/M cell cycle phase-specific drugs.  
 
In this work, I have also demonstrated that there is an intricate link between 
dysregulation of these cell cycle regulatory proteins and the development of genomic 
instability and advanced disease states in PeScc (Chapter 5). Ploidy status provides 
important independent prognostic information but additionally the observed 
dysregulation of RLF expression presents further evidence that this pathway is a 
potentially important novel therapeutic target. Notably, in light of its kinase activity 
and amenability to small molecule inhibition, Cdc 7 has been shown to be a promising 
“anticancer” molecular switch (Montagnoli 2004; Williams 2012). Cdc7 is a highly 
conserved serine/threonine protein kinase and a core component of the licensing 
machinery required for origin unwinding of the DNA, and recruitment of DNA 
polymerases required for DNA synthesis (Tudzarova 2010; Williams 2012). Evidence 
suggests that in untransformed cells, inhibition of origin firing triggers the putative 
“licensing checkpoint”, leading to a block to DNA replication initiation and stable G1 
arrest (Montagnoli 2004; Rodriguez-Acebes 2010). It has been recently shown that 
this checkpoint response is critically dependent on several common tumour 
suppressor genes  including p53, p21, Dkk3, ARF,Hdm2, FoxO3a, p15, p27 and RB 
(Figure 7.1) (Tudzarova 2010). The checkpoint response is dependent on three axes 
coordinated through the transcription factor FoxO3a. In arrested cells, FoxO3a 
activates the ARF --∣ Hdm2 --∣ p53 → p21 pathway and mediates p15(INK4B) 
upregulation; p53 in turn activates expression of the Wnt/β-catenin signalling 
antagonist Dkk3, leading to Myc and cyclin D1 downregulation. The resulting loss of 
CDK activity inactivates the Rb-E2F pathway and overrides the G1-S transcriptional 
programme. Subsequently, E2F cannot then drive expression of replication factors:  
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Figure 7.1 
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Mcm2-7, Mcm10, geminin, Dbf4, Cdt1 and Cdc6 (Tudzarova 2010; Williams 2012); 
so origins become unlicensed, thus enforcing the observed G1 arrest. In contrast to 
untransformed cells, transformed cells are unable to trigger a checkpoint response due  
to inactivation of tumour suppressor genes. This results in transformed cells entering 
S phase with inadequate numbers of competent origins to complete chromosomal 
replication (Tudzarova 2010; Williams 2012). Insufficient Cdc7 availability required 
to trigger the 30,000 origins necessary to complete S phase in 6-8 hours, leads to fork 
stalling and collapse of replication forks, the induction of double-strand breaks and 
apoptosis in these cancer cells (Montagnoli 2008; Swords 2010). This results in an 
abortive S phase with incompletely and/or abnormally replicated DNA. Tumour cells 
with a functional intra-S phase checkpoint appear to undergo rapid death after 
replication fork stalling/collapse, whereas more transformed cancer cells appear to 
survive longer but eventually face mitotic catastrophe as a result of partially replicated 
chromosomes. Notably the checkpoint is critically dependent on both Rb and P53 
function. Importantly, these two tumour suppressor proteins are dysregulated in PeScc 
by HPV E6 and E7 (Figure 5.1); therefore PeScc represents an ideal tumour type to 
treat with a Cdc7 inhibitor and indeed mirrors the situation in ovarian cancer in which 
p53 and Rb are both inactivated and in which potent tumour cell killing has been 
observed following Cdc7 inhibition (Kulkarni 2009). The availability of Cdc7 small 
molecular inhibitors (SMI) now provides an exciting opportunity for this novel 
treatment paradigm to be tested (Koltun 2012; Natoni 2011; Swords 2010; Woods 
2012); (CRT: Cdc7 marketing information – Appendix F ). 
 
In conclusion, the work presented in this thesis provides a strong rationale for 
exploitation of the DNA replication licensing system alongside ploidy status as novel 
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prognostic/predictive biomarkers and molecular therapeutic targets in PeScc. The 
findings discussed above pave the way for future experimental work towards two 
major goals. Firstly, the prognostic value of these biomarkers highlights the need for 
large well-designed prospective, multicentre, international randomised controlled 
trials in PeScc, which can confirm their utility in predicting patient survival and 
tumour response to specific chemotherapeutic and biological therapies. The 
information obtained from such prospective studies could subsequently be used to 
tailor treatment options for patients based on the underlying biology of their tumour. 
This form of predictive testing would be invaluable in assisting decisions regarding 
the usage of cytotoxic drugs, with their associated toxicities, and biological agents in 
patients who may not benefit from such treatments. 
 
Secondly, the identification of Cdc7 kinase as a promising new therapeutic target may 
offer new treatment options in a variety of solid tumours but particularly in PeScc 
which is driven by HPV-dependent dysregulation of Rb and P53 pathways in certain 
patients. Importantly by targeting Cdc7 there appears to be minimal effects on normal 
cells, which has not been the case with the majority of other approaches to inhibition 
of the cell cycle. Thus, this approach potentially circumvents the cytotoxic side effects 
seen with traditional chemotherapeutic drugs, for example: hair loss, infertility and 
suppression of self-renewing tissues such as the haematopoietic and gastrointestinal 
systems. Low blood counts and gut-related symptoms, for example gastrointestinal 
haemorrhage, are rate-limiting toxicities for conventional cytotoxic agents. By 
contrast, cyclical treatment with a Cdc7 kinase inhibitor should have minimal effects 
on normal tissues and thus be associated with significantly fewer side effects. The 
main aim for future studies will therefore be to confirm the safety, efficacy and 
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tolerability of such an agent and assess translational molecular-based endpoints 
alongside survival and quality of life outcomes, thereby moving one step closer to the 
goal of personalised therapy in PeScc. 
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
1 17/01/1992 33 Lost to follow up Lost to follow up Cis WLE Cis Tis Nx 0
2 01/06/2001 74 ALIVE 58.3 Nos Glansectomy 1 1 0 0
3 05/12/1991 78 DEAD 14.5 Nos Total Penectomy 3 3 3 Mx
4 01/05/1998 66 Lost to follow up Lost to follow up Nos WLE 1 1 Nx Mx
5 02/04/2004 57 ALIVE 20.2 Cis WLE Cis Tis Nx 0
6 01/06/1997 65 ALIVE 101.3 Nos WLE 3 1 1 0
7 23/05/2000 43 ALIVE 66.9 Nos Glansectomy 1 2 1 0
8 01/05/2001 81 DEAD 48.1 Nos Total Penectomy 3 Tx 0 1
9 10/10/2002 48 ALIVE 37.9 Nos Total Penectomy 1 2 0 0
10 30/11/1992 43 DEAD 36.0 Nos Partial Penectomy 3 2 1 0
11 23/09/1994 73 Lost to follow up Lost to follow up Nos Total Penectomy 3 3 Nx Mx
12 20/04/1988 60 Lost to follow up Lost to follow up Nos Partial Penectomy 2 2 Nx Mx
13 22/07/1997 56 DEAD 15.8 Nos WLE 3 2 3 1
14 14/09/1999 69 ALIVE 62.8 Cis WLE Cis Tis 0 0
15 18/06/1999 68 ALIVE 80.7 Nos WLE 2 1 0 0
16 14/08/2003 73 ALIVE 28.7 Mixed Glansectomy 1 2 0 0
17 01/05/1993 28 ALIVE 156.2 Cis WLE Cis Tis 0 0
18 20/06/2003 50 ALIVE 35.7 Nos Glansectomy 1 1 0 0
19 01/07/2003 66 ALIVE 31.7 Nos WLE 2 2 2 1
20 01/04/2001 34 ALIVE 62.1 Nos Glansectomy 2 1 0 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
21 29/04/2002 41 ALIVE 42.3 Nos Partial Penectomy 3 3 0 0
22 01/08/1995 71 DEAD 13.9 Nos Partial Penectomy 2 1 3 0
23 05/07/1995 80 DEAD 14.9 Nos WLE 2 1 Nx Mx
24 09/08/1990 75 Lost to follow up Lost to follow up Papillary WLE 1 1 Nx Mx
25 14/11/1988 73 Lost to follow up Lost to follow up Nos Total Penectomy 1 2 Nx Mx
26 12/12/1997 71 ALIVE 97.7 Verrucous Partial Penectomy 1 1 0 0
27 02/12/1988 65 Lost to follow up Lost to follow up Nos WLE 1 2 Nx Mx
28 09/10/2000 47 ALIVE 64.2 Nos Total Penectomy 1 3 0 0
29 05/01/2000 64 ALIVE 67.6 Basaloid WLE 2 1 0 0
30 18/08/1998 55 Lost to follow up Lost to follow up Nos WLE 2 2 Nx Mx
31 03/12/2002 50 ALIVE 40.1 Basaloid Glansectomy 3 1 0 0
32 19/06/2001 66 ALIVE 55.7 Nos Total Penectomy 3 2 0 0
33 16/10/2003 75 ALIVE 25.5 Verrucous Glansectomy 1 1 0 0
34 15/01/2003 63 ALIVE 26.1 Basaloid Glansectomy 3 1 0 0
35 01/07/2003 57 ALIVE 31.5 Mixed Glansectomy 1 1 0 0
36 20/11/2003 69 DEAD 9.9 Mixed Partial Penectomy 3 2 3 0
37 15/01/2004 40 ALIVE 1.8 Cis WLE Cis Tis Nx 0
38 01/07/2004 57 ALIVE 18.4 Cis WLE Cis Tis Nx 0
39 11/07/1994 78 Lost to follow up Lost to follow up Nos Partial Penectomy 2 1 Nx Mx
40 26/10/1994 52 ALIVE 138.2 Nos WLE 2 1 0 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
41 17/11/1993 64 ALIVE 48.1 Nos Partial Penectomy 2 2 2 1
42 31/03/2004 43 ALIVE 22.7 Papillary Glansectomy 1 2 0 0
43 27/02/2004 65 ALIVE 23.0 Nos Glansectomy 2 1 Nx 0
44 10/06/2004 57 ALIVE 17.7 Nos WLE 2 1 Nx 0
45 01/02/2000 58 DEAD 9.1 Nos Total Penectomy 2 2 Nx 1
46 20/06/2003 62 DEAD 31.6 Papillary Glansectomy 2 1 0 0
47 14/08/2002 69 ALIVE 36.3 Nos Urethrectomy 1 Tx 0 0
48 01/04/1999 63 ALIVE 79.7 Nos Partial Penectomy 3 2 0 0
49 01/08/2001 56 ALIVE 57.1 Basaloid WLE 3 1 1 0
50 01/04/2002 39 ALIVE 50.1 Nos Glansectomy 3 1 0 0
51 01/09/2000 47 ALIVE 65.6 Papillary Urethrectomy 3 2 0 0
52 25/03/2002 70 ALIVE 47.4 Papillary Total Penectomy 3 2 2 1
53 22/10/2001 69 ALIVE 44.8 Nos Partial Penectomy 2 1 0 0
54 01/03/2000 55 ALIVE 1.3 Nos Glansectomy 2 2 Nx 0
55 07/03/2000 56 DEAD 11.8 Nos Total Penectomy 2 Tx 2 Mx
56 16/09/1993 39 DEAD 137.5 Mixed Glansectomy 2 2 1 1
57 18/01/2001 35 DEAD 20.2 Nos Partial Penectomy 2 2 3 1
58 21/04/2005 75 DEAD 1.1 Papillary Glansectomy 3 2 3 Mx
59 01/05/2002 39 ALIVE 45.5 Papillary Glansectomy 1 2 0 0
60 05/06/1991 33 Lost to follow up Lost to follow up Nos WLE 1 1 Nx 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
61 12/05/1988 81 DEAD 3.6 Nos Penectomy 2 2 Nx Mx
62 06/05/2004 72 ALIVE 25.1 Nos Glansectomy 2 1 0 0
63 19/12/1991 54 DEAD 5.0 Nos Total Penectomy 1 2 3 0
64 28/08/2002 77 DEAD 37.0 Nos Total Penectomy 3 3 2 0
65 23/01/2001 35 ALIVE 48.5 Nos Glansectomy 2 1 0 0
66 27/01/2005 71 ALIVE 12.4 Nos Glansectomy 3 1 Nx 0
67 10/10/2003 57 ALIVE 27.3 Mixed Glansectomy 1 1 0 0
68 19/02/2004 52 ALIVE 27.7 Cis WLE Cis Tis 0 0
69 16/05/2000 57 ALIVE 64.9 Verrucous Partial Penectomy 1 2 0 0
70 01/06/1992 54 Lost to follow up Lost to follow up Nos WLE 2 1 Nx Mx
71 22/10/1996 56 ALIVE 107.9 Nos WLE 3 1 0 Mx
72 19/02/1990 73 ALIVE 139.7 Basaloid WLE 3 1 0 Mx
73 01/02/1992 52 ALIVE 162.4 Nos WLE 2 1 0 Mx
74 30/07/2004 63 DEAD 3.0 Nos Partial Penectomy 3 2 2 1
75 20/01/2005 60 ALIVE 15.4 Nos Glansectomy 2 2 0 0
76 18/07/2000 56 ALIVE 64.4 Cis WLE Cis Tis 0 0
77 07/08/2002 45 ALIVE 42.9 Nos Partial Penectomy 3 1 2 0
78 10/12/2004 72 ALIVE 13.7 Nos Partial Penectomy 1 2 0 0
79 01/07/2003 55 ALIVE 28.1 Nos WLE 2 1 0 0
80 02/12/2004 63 ALIVE 18.0 Nos WLE 2 1 Nx 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
81 10/12/2004 74 ALIVE 17.8 Mixed Partial Penectomy 3 1 0 0
82 01/06/2003 54 ALIVE 33.2 Basaloid Glansectomy 3 2 0 0
83 13/10/1989 74 Lost to follow up Lost to follow up Cis WLE Cis Tis Nx 0
84 03/03/2004 79 ALIVE 23.0 Nos Glansectomy 3 1 0 0
85 15/04/2004 60 ALIVE 22.2 Nos Glansectomy 2 2 1 0
86 16/02/2000 47 ALIVE 67.4 Nos Total Penectomy 2 3 0 0
87 22/12/1994 57 ALIVE 133.6 Nos Partial Penectomy 1 1 0 0
88 15/05/2000 45 DEAD 32.2 Nos Urethrectomy 3 1 0 1
89 13/01/2005 38 ALIVE 12.9 Verrucous WLE 1 1 Nx 0
90 15/07/2005 80 ALIVE 7.6 Nos WLE 2 1 Nx 0
91 01/06/2005 79 ALIVE 7.5 Mixed WLE 3 1 0 0
92 08/03/2005 62 ALIVE 15.0 Nos WLE 3 1 3 1
93 17/08/2005 53 ALIVE 6.0 Mixed Partial Glansectomy 3 1 0 0
94 15/09/2005 59 ALIVE 2.3 Cis WLE Cis Tis Nx 0
95 01/09/2003 40 ALIVE 33.3 Papil lary Partial Penectomy 2 1 0 0
96 15/07/2004 39 ALIVE 21.8 Papil lary Glansectomy 2 2 0 0
97 14/02/2004 79 DEAD 19.0 Nos Partial Penectomy 2 2 2 1
98 30/11/1992 UKNOWN Lost to follow up Lost to follow up Nos WLE 2 1 Nx Mx
99 01/06/2005 61 ALIVE 8.3 Papillary Glansectomy 1 2 Nx 0
100 01/09/2005 63 DEAD 17.0 Mixed Partial Penectomy 2 3 Nx 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
101 09/03/2005 55 ALIVE 13.9 Nos Glansectomy 3 2 2 0
102 04/03/2005 59 ALIVE 13.0 Nos Glansectomy 3 2 2 0
103 01/06/2003 67 DEAD 21.8 Nos Partial Penectomy 2 2 1 0
104 15/02/2005 63 ALIVE 13.9 Papillary Glansectomy 2 1 Nx 0
105 28/01/2004 66 ALIVE 20.5 Papillary Total Penectomy 2 2 0 0
106 23/06/2005 42 ALIVE 9.6 Nos Total Penectomy 2 3 0 0
107 01/08/2003 75 ALIVE 30.2 Papil lary Partial Penectomy 3 3 1 0
108 22/07/2005 82 ALIVE 6.5 Nos Total Penectomy 3 3 2 1
109 02/05/2006 63 ALIVE 1.1 Mixed Total Penectomy 2 4 0 0
110 09/01/2006 70 ALIVE 2.8 Papil lary Glansectomy 2 2 0 0
111 01/12/2001 46 ALIVE 48.7 Nos Glansectomy 2 2 0 0
112 08/12/2005 69 ALIVE 2.0 Nos Glansectomy 2 1 Nx 0
113 23/10/2002 75 DEAD 15.0 Papil lary Partial Penectomy 3 1 2 1
114 13/01/2006 36 ALIVE 0.9 Cis Glansectomy Cis Tis Nx 0
115 01/02/2006 42 ALIVE 2.6 Nos Glansectomy 2 2 1 0
116 24/11/2005 71 ALIVE 3.0 Nos Glansectomy 2 1 Nx 0
117 24/11/2005 55 ALIVE 6.4 Nos Total Penectomy 3 3 0 1
118 04/05/2005 58 ALIVE 10.0 Nos Glansectomy 3 1 0 0
119 26/01/2006 28 ALIVE 3.8 Nos WLE 2 1 Nx 0
120 28/12/2005 60 ALIVE 4.2 Nos Glansectomy 2 1 Nx 0
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Case ID Date Diagnosis Age Dead or Alive Survival (months) Subtype Operation Grade T Stage N Stage M Stage
121 02/03/2005 61 DEAD 24.3 Nos Glansectomy 2 2 3 0
122 20/01/2006 55 ALIVE 3.5 Nos Glansectomy 3 3 0 0
123 02/12/2004 87 DEAD (NCR) 3.3 Nos Partial penectomy 1 2 0 0
124 18/01/2006 70 ALIVE 4.4 Nos Glansectomy 3 1 1 0
125 09/11/2005 77 ALIVE 6.2 Nos Partial Penectomy 3 2 0 0
126 30/08/2002 63 ALIVE 41.8 Papillary Partial Penectomy 3 2 0 0
127 27/10/2005 79 ALIVE 3.2 Mixed Glansectomy 3 2 Nx 0
128 27/04/2006 34 ALIVE 1.5 Nos Glansectomy 2 2 0 0
129 27/03/2006 70 ALIVE 2.5 Basaloid Glansectomy 3 2 Nx 0
130 19/05/2006 55 ALIVE 0.8 Nos Partial penectomy 1 2 Nx 0
131 22/03/2006 59 ALIVE 2.7 Warty WLE 2 2 Nx 0
132 01/04/2003 72 ALIVE 36.1 Papil lary Partial Penectomy 3 1 2 0
133 24/05/2006 59 ALIVE 6.4 Nos Glansectomy 3 2 1 0
134 02/06/2006 64 ALIVE 5.9 Nos Glansectomy 2 2 0 0
135 19/06/2006 72 ALIVE 4.4 Cis Circumcision Cis Tis 0 0
136 25/07/2006 47 ALIVE 3.4 Nos Glansectomy 3 2 1 0
137 18/09/2006 65 ALIVE 2.2 Nos Hemi-glansectomy 3 1 Nx 0
138 02/10/2006 76 ALIVE 3.9 Warty WLE 2 1 Nx 0
139 26/09/2006 38 ALIVE 3.3 Papil lary Glansectomy 2 1 0 0
140 30/09/2006 83 DEAD 2.5 Nos Total Penectomy 3 4 2 1
141 15/02/2006 85 DEAD 4.9 Nos Partial Penectomy 3 2 2 0
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Positive Negative LI (%) Positive Negative LI (%) Positive Negative LI (%)
1 1004 113 89.9 988 188 84.0 287 900 24.2 1.07 0.29 59.8 5.9 Diploid
2 372 113 76.7 508 234 68.5 79 402 16.4 1.12 0.24 52.0 8.2 Unknown
3 2063 84 96.1 1322 419 75.9 422 1331 24.1 1.27 0.32 51.9 20.2 Diploid
4 626 320 66.2 510 344 59.7 115 665 14.7 1.11 0.25 45.0 6.5 Diploid
5 2044 108 95.0 2029 140 93.5 385 1042 27.0 1.02 0.29 66.6 1.4 Diploid
6 1515 213 87.7 1207 208 85.3 304 1214 20.0 1.03 0.23 65.3 2.4 Diploid
7 543 414 56.7 545 400 57.7 167 591 22.0 0.98 0.38 35.6 -0.9 Diploid
8 657 136 82.8 690 99 87.5 180 373 32.5 0.95 0.37 54.9 -4.6 Aneuploid
9 1043 207 83.4 891 148 85.8 214 907 19.1 0.97 0.22 66.7 -2.3 Diploid
10 247 417 37.2 943 902 51.1 280 928 23.2 0.73 0.45 27.9 -13.9 Aneuploid
11 345 275 55.6 215 513 29.5 108 499 17.8 1.88 0.60 11.7 26.1 Aneuploid
12 785 116 87.1 785 203 79.4 222 808 21.6 1.10 0.27 57.9 7.7 Unknown
13 839 122 87.3 1293 218 85.6 511 1475 25.7 1.02 0.30 59.8 1.7 Aneuploid
14 1122 106 91.4 1135 225 83.5 208 906 18.7 1.09 0.22 64.8 7.9 Diploid
15 722 261 73.4 572 297 65.8 162 665 19.6 1.12 0.30 46.2 7.6 Diploid
16 942 195 82.8 581 483 54.6 190 683 21.8 1.52 0.40 32.8 28.2 Diploid
17 654 147 81.6 581 268 68.4 251 513 32.9 1.19 0.48 35.6 13.2 Unknown
18 1064 296 78.2 774 570 57.6 172 799 17.7 1.36 0.31 39.9 20.6 Diploid
19 2111 64 97.1 3037 130 95.9 488 1662 22.7 1.01 0.24 73.2 1.2 Aneuploid
20 1486 386 79.4 1570 317 83.2 328 1536 17.6 0.95 0.21 65.6 -3.8 Aneuploid
21 832 166 83.4 791 184 81.1 254 748 25.3 1.03 0.31 55.8 2.2 Aneuploid
22 445 327 57.6 728 394 64.9 234 872 21.2 0.89 0.33 43.7 -7.2 Aneuploid
23 875 146 85.7 708 342 67.4 127 748 14.5 1.27 0.22 52.9 18.3 Unknown
24 342 290 54.1 164 510 24.3 31 693 4.3 2.22 0.18 20.1 29.8 Diploid
25 229 247 48.1 164 339 32.6 23 465 4.7 1.48 0.14 27.9 15.5 Unknown
26 176 293 37.5 135 320 29.7 67 714 8.6 1.26 0.29 21.1 7.9 Diploid
27 446 372 54.5 354 650 35.3 87 880 9.0 1.55 0.26 26.3 19.3 Unknown
28 298 390 43.3 266 446 37.4 78 634 11.0 1.16 0.29 26.4 6.0 Diploid
29 1973 252 88.7 1483 393 79.1 479 1263 27.5 1.12 0.35 51.6 9.6 Diploid
30 781 425 64.8 811 1226 39.8 153 2987 4.9 1.63 0.12 34.9 24.9 Unknown
Mcm2-Ki67 PloidyCase ID
Mcm2 Ki-67 G95
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31 2383 12 99.5 2366 97 96.1 536 1608 25.0 1.04 0.26 71.1 3.4 Aneuploid
32 759 273 73.5 778 554 58.4 256 716 26.3 1.26 0.45 32.1 15.1 Diploid
33 258 509 33.6 210 573 26.8 35 710 4.7 1.25 0.18 22.1 6.8 Diploid
34 2942 111 96.4 2450 789 75.6 869 2186 28.4 1.27 0.38 47.2 20.7 Diploid
35 148 137 51.9 1304 1490 46.7 83 822 9.2 1.11 0.20 37.5 5.3 Diploid
36 2525 50 98.1 2577 124 95.4 994 1663 37.4 1.03 0.39 58.0 2.6 Aneuploid
37 916 28 97.0 668 71 90.4 233 1089 17.6 1.07 0.19 72.8 6.6 Diploid
38 1036 67 93.9 769 375 67.2 170 986 14.7 1.40 0.22 52.5 26.7 Unknown
39 1035 216 82.7 1020 240 81.0 360 1209 22.9 1.02 0.28 58.0 1.8 Diploid
40 546 94 85.3 404 157 72.0 66 659 9.1 1.18 0.13 62.9 13.3 Diploid
41 828 410 66.9 653 475 57.9 284 690 29.2 1.16 0.50 28.7 9.0 Unknown
42 1299 325 80.0 1082 297 78.5 287 873 24.7 1.02 0.32 53.7 1.5 Diploid
43 715 98 87.9 731 132 84.7 171 554 23.6 1.04 0.28 61.1 3.2 Diploid
44 2339 87 96.4 1869 412 81.9 570 2374 19.4 1.18 0.24 62.6 14.5 Aneuploid
45 862 153 84.9 992 200 83.2 213 666 24.2 1.02 0.29 59.0 1.7 Aneuploid
46 1054 192 84.6 1057 374 73.9 222 641 25.7 1.15 0.35 48.1 10.7 Aneuploid
47 541 179 75.1 400 187 68.1 111 394 22.0 1.10 0.32 46.2 7.0 Diploid
48 2030 29 98.6 1826 28 98.5 570 1425 28.6 1.00 0.29 69.9 0.1 Aneuploid
49 3141 9 99.7 2246 131 94.5 1041 1762 37.1 1.06 0.39 57.4 5.2 Aneuploid
50 167 22 88.4 315 75 80.8 68 298 18.6 1.09 0.23 62.2 7.6 Aneuploid
51 1923 23 98.8 1522 328 82.3 397 1567 20.2 1.20 0.25 62.1 16.5 Unknown
52 2893 57 98.1 2947 40 98.7 951 1700 35.9 0.99 0.36 62.8 -0.6 Aneuploid
53 1245 185 87.1 1147 247 82.3 411 1071 27.7 1.06 0.34 54.5 4.8 Aneuploid
54 3069 143 95.5 3242 211 93.9 824 2156 27.7 1.02 0.29 66.2 1.7 Diploid
55 1965 107 94.8 1771 207 89.5 591 1490 28.4 1.06 0.32 61.1 5.3 Aneuploid
56 819 730 52.9 1020 375 73.1 285 735 27.9 0.72 0.38 45.2 -20.2 Aneuploid
57 586 502 53.9 511 676 43.0 139 1315 9.6 1.25 0.22 33.5 10.8 Aneuploid
58 1877 121 93.9 1735 263 86.8 355 1790 16.6 1.08 0.19 70.3 7.1 Unknown
59 535 1873 22.2 396 1842 17.7 159 1678 8.7 1.26 0.49 9.0 4.5 Diploid
60 485 1062 31.4 296 1082 21.5 221 1114 16.6 1.46 0.77 4.9 9.9 Unknown
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61 588 120 83.1 430 89 82.9 174 596 22.6 1.00 0.27 60.3 0.2 Diploid
62 987 531 65.0 1130 511 68.9 215 1477 12.7 0.94 0.18 56.2 -3.8 Diploid
63 800 512 61.0 725 578 55.6 334 1164 22.3 1.10 0.40 33.3 5.3 Aneuploid
64 1782 382 82.3 1583 804 66.3 445 1815 19.7 1.24 0.30 46.6 16.0 Aneuploid
65 897 900 49.9 562 1602 26.0 108 1024 9.5 1.92 0.37 16.4 23.9 Diploid
66 461 437 51.3 278 268 50.9 178 838 17.5 1.01 0.34 33.4 0.4 Aneuploid
67 308 333 48.0 441 515 46.1 50 660 7.0 1.04 0.15 39.1 1.9 Diploid
68 202 66 75.4 124 119 51.0 28 222 11.2 1.48 0.22 39.8 24.3 Unknown
69 244 336 42.1 215 391 35.5 78 578 11.9 1.19 0.34 23.6 6.6 Diploid
70 1145 326 77.8 586 894 39.6 192 1211 13.7 1.97 0.35 25.9 38.2 Diploid
71 2056 378 84.5 1599 779 67.2 410 1636 20.0 1.26 0.30 47.2 17.2 Unknown
72 3261 80 97.6 1904 1053 64.4 607 3322 15.4 1.52 0.24 48.9 33.2 Aneuploid
73 841 1284 39.6 825 1210 40.5 180 660 21.4 0.98 0.53 19.1 -1.0 Diploid
74 472 165 74.1 516 324 61.4 84 769 9.8 1.21 0.16 51.6 12.7 Aneuploid
75 291 608 32.4 343 903 27.5 69 960 6.7 1.18 0.24 20.8 4.8 Unknown
76 715 63 91.9 826 445 65.0 121 694 14.8 1.41 0.23 50.1 26.9 Aneuploid
77 598 129 82.3 484 212 69.5 89 372 19.3 1.18 0.28 50.2 12.7 Diploid
78 376 265 58.7 427 355 54.6 106 539 16.4 1.07 0.30 38.2 4.1 Diploid
79 2183 120 94.8 2093 204 91.1 241 1663 12.7 1.04 0.14 78.5 3.7 Aneuploid
80 1768 76 95.9 1666 55 96.8 434 1232 26.1 0.99 0.27 70.8 -0.9 Diploid
81 891 263 77.2 767 441 63.5 150 757 16.5 1.22 0.26 47.0 13.7 Aneuploid
82 1746 148 92.2 1002 198 83.5 225 835 21.2 1.10 0.25 62.3 8.7 Aneuploid
83 1104 80 93.2 1159 155 88.2 319 1028 23.7 1.06 0.27 64.5 5.0 Aneuploid
84 2016 248 89.0 1994 120 94.3 430 1617 21.0 0.94 0.22 73.3 -5.3 Aneuploid
85 1831 1279 58.9 1453 1424 50.5 219 3005 6.8 1.17 0.13 43.7 8.4 Diploid
86 525 447 54.0 817 539 60.3 214 921 18.9 0.90 0.31 41.4 -6.2 Aneuploid
87 229 510 31.0 305 657 31.7 74 672 9.9 0.98 0.31 21.8 -0.7 Unknown
88 1035 680 60.3 1021 1010 50.3 290 1485 16.3 1.20 0.33 33.9 10.1 Aneuploid
89 280 1117 20.0 354 1133 23.8 43 1628 2.6 0.84 0.11 21.2 -3.8 Aneuploid
90 979 378 72.1 962 430 69.1 248 1137 17.9 1.04 0.26 51.2 3.0 Aneuploid
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91 2970 50 98.3 2970 243 92.4 353 2970 10.6 1.06 0.11 81.8 5.9 Aneuploid
92 1848 117 94.0 1243 845 59.5 455 1693 21.2 1.58 0.36 38.3 34.5 Unknown
93 1957 161 92.4 4312 452 90.5 721 4381 14.1 1.02 0.16 76.4 1.9 Aneuploid
94 817 233 77.8 771 485 61.4 85 832 9.3 1.27 0.15 52.1 16.4 Diploid
95 2114 110 95.1 2619 208 92.6 709 1816 28.1 1.03 0.30 64.6 2.4 Aneuploid
96 1527 356 81.1 1427 661 68.3 418 1600 20.7 1.19 0.30 47.6 12.8 Diploid
97 457 236 65.9 737 440 62.6 191 938 16.9 1.05 0.27 45.7 3.3 Diploid
98 633 217 74.5 837 617 57.6 133 1515 8.1 1.29 0.14 49.5 16.9 Aneuploid
99 990 718 58.0 493 1288 27.7 79 1638 4.6 2.09 0.17 23.1 30.3 Aneuploid
100 1406 237 85.6 1620 611 72.6 283 1497 15.9 1.18 0.22 56.7 13.0 Aneuploid
101 610 142 81.1 575 405 58.7 298 521 36.4 1.38 0.62 22.3 22.4 Aneuploid
102 575 112 83.7 471 168 73.7 205 489 29.5 1.14 0.40 44.2 10.0 Aneuploid
103 1618 96 94.4 1433 266 84.3 552 1305 29.7 1.12 0.35 54.6 10.1 Aneuploid
104 261 200 56.6 167 147 53.2 48 299 13.8 1.06 0.26 39.4 3.4 Aneuploid
105 1892 342 84.7 1897 492 79.4 570 1221 31.8 1.07 0.40 47.6 5.3 Diploid
106 741 251 74.7 667 147 81.9 212 620 25.5 0.91 0.31 56.5 -7.2 Aneuploid
107 1317 473 73.6 1014 394 72.0 380 1108 25.5 1.02 0.35 46.5 1.6 Aneuploid
108 932 623 59.9 625 557 52.9 224 1339 14.3 1.13 0.27 38.5 7.1 Unknown
109 520 121 81.1 422 211 66.7 138 535 20.5 1.22 0.31 46.2 14.4 Aneuploid
110 752 378 66.5 639 504 55.9 239 790 23.2 1.19 0.42 32.7 10.6 Aneuploid
111 1101 241 82.0 829 555 59.9 318 1000 24.1 1.37 0.40 35.8 22.1 Unknown
112 1834 18 99.0 1795 35 98.1 641 1232 34.2 1.01 0.35 63.9 0.9 Aneuploid
113 1472 75 95.2 1365 215 86.4 436 1040 29.5 1.10 0.34 56.9 8.8 Aneuploid
114 2400 12 99.5 2400 75 97.0 496 2006 19.8 1.03 0.20 77.1 2.5 Aneuploid
115 567 462 55.1 693 340 67.1 162 795 16.9 0.82 0.25 50.2 -12.0 Aneuploid
116 519 641 44.7 467 684 40.6 78 746 9.5 1.10 0.23 31.1 4.2 Aneuploid
117 605 96 86.3 741 190 79.6 234 443 34.6 1.08 0.43 45.0 6.7 Aneuploid
118 873 434 66.8 463 655 41.4 311 1315 19.1 1.61 0.46 22.3 25.4 Aneuploid
119 1433 284 83.5 1278 485 72.5 405 1110 26.7 1.15 0.37 45.8 11.0 Aneuploid
120 792 396 66.7 488 475 50.7 107 978 9.9 1.32 0.19 40.8 16.0 Aneuploid
Case ID
Mcm2 Ki-67 G95
Mcm2/Ki67 G95/Ki67 Ki67-G95 Mcm2-Ki67 Ploidy
U
niversity C
ollege London
D
N
A
 replication licensing control and genom
ic instability in penile cancer.                                  O
liver K
ayes
Positive Negative LI (%) Positive Negative LI (%) Positive Negative LI (%)
121 404 236 63.1 265 254 51.1 116 470 19.8 1.24 0.39 31.3 12.1 Aneuploid
122 1119 232 82.8 1126 360 75.8 407 850 32.4 1.09 0.43 43.4 7.1 Aneuploid
123 3595 880 80.3 563 1063 34.6 154 1321 10.4 2.32 0.30 24.2 45.7 Aneuploid
124 1111 77 93.5 1012 156 86.6 334 834 28.6 1.08 0.33 58.0 6.9 Aneuploid
125 988 56 94.6 957 96 90.9 499 570 46.7 1.04 0.51 44.2 3.8 Aneuploid
126 1243 42 96.7 1199 190 86.3 338 1049 24.4 1.12 0.28 62.0 10.4 Aneuploid
127 1290 25 98.1 1458 168 89.7 531 1330 28.5 1.09 0.32 61.1 8.4 Aneuploid
128 658 176 78.9 552 246 69.2 198 657 23.2 1.14 0.33 46.0 9.7 Diploid
129 768 89 89.6 552 363 60.3 66 699 8.6 1.49 0.14 51.7 29.3 Diploid
130 507 340 59.9 279 371 42.9 86 614 12.3 1.39 0.29 30.6 16.9 Diploid
131 1085 243 81.7 781 649 54.6 251 1019 19.8 1.50 0.36 34.9 27.1 Aneuploid
132 1350 99 93.2 1350 140 90.6 509 723 41.3 1.03 0.46 49.3 2.6 Unknown
133 2158 258 89.3 1869 423 81.5 251 2144 10.5 1.10 0.13 71.1 7.8 Aneuploid
134 310 727 29.9 310 923 25.1 23 1376 1.6 1.19 0.07 23.5 4.8 Aneuploid
135 2176 193 91.9 1896 479 79.8 360 2001 15.3 1.15 0.19 64.6 12.0 Aneuploid
136 1541 470 76.6 775 1358 36.3 700 1989 26.0 2.11 0.72 10.3 40.3 Aneuploid
137 1619 139 92.1 1565 537 74.6 238 1529 13.5 1.24 0.18 61.1 17.5 Aneuploid
138 1065 1028 50.9 873 1080 44.7 75 1700 4.3 1.14 0.10 40.4 6.2 Aneuploid
139 1033 78 93.0 1188 364 76.6 93 1356 6.4 1.21 0.08 70.1 16.4 Aneuploid
140 1798 440 80.3 468 972 32.5 181 1351 11.8 2.47 0.36 20.7 47.8 Aneuploid
141 815 198 87.9 831 232 84.7 260 643 23.6 1.04 0.28 61.1 3.2 Diploid
Ki67-G95 Mcm2-Ki67 PloidyCase ID
Mcm2 Ki-67 G95
Mcm2/Ki67 G95/Ki67
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APPENDIX  C 
Supportive documents 
 
 
(Form to be on headed paper) 
CONFIDENTIAL 
 
 
Centre Number:       UCLH Project ID 
number: 
Patient Identification Number for this study:    Form version: 1.1 
 
 
CONSENT FORM 
 
 
Prognostic Histopathological Features and Markers in 
Penile Cancer 
 
Principal investigator : 
 
The Institute of Urology and Nephrology, UCL, Middlesex Hospital, 48, Riding 
House Street, London W1W 7EY 
  
 
 
1. I confirm that I have read and understood the information sheet dated 
January 2004 (version 1.1) for the above study and have had the 
opportunity to ask questions. 
 
   
2.  I confirm that I have had sufficient time to consider whether or not want to 
be included in the study  
 
 
 
   
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
   
4. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from (company name) or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
 
   
 
5. 
 
I agree to take part in the above study. 
 
 
 
Continued on next page/ 
 
 
1 form for Patient;  
1 to be kept as part of the study documentation,   
1 to be kept with hospital notes 
 
Please initial box 
Page 1 of 2 
(Form to be on headed paper) 
 
 
 
Centre Number:       UCLH Project ID 
number: 
Patient Identification Number for this study:    Form version: 1.1 
 
 
CONSENT FORM 
 
 
Title of project: Prognostic Pathological Characteristics and Markers in Penile Cancer 
 
 
Principal Investigator : Mr S. Minhas 
 
 
__________________________ _________________   ________ 
Name of patient    Date     Signature 
 
 
 
 
________________________         _____________________  ________ 
Name of Person taking consent  Date     Signature 
(if different from researcher) 
 
 
 
Dr Oliver Kayes  Research fellow 
________________________    
Name of the researcher to be contacted if there are any problems    
      
 
 
Comments or concerns during the study  
 
If you have any comments or concerns you may discuss these with 
the investigator.   If you wish to go further and complain about any 
aspect of the way you have been approached or treated during the 
course of the study, you should write or get in touch with the 
Complaints Manager, UCL hospitals.  Please quote the UCLH 
project number at the top this consent form. 
 
 
 
 
1 form for Patient;  
1 to be kept as part of the study documentation,   
1 to be kept with hospital notes 
 
 
Page 2 of 2 
(Form to be on headed paper) 
CONFIDENTIAL 
 
 
Centre Number:      UCLH Project ID number: 
Patient Identification Number for this study:    Form version: 1.1 
            Date: Jan 2004 
 
PATIENT INFORMATION SHEET 
 
 
Prognostic Histopathological Features and Markers in 
Penile Cancer 
(A study on penile cancer tissue removed at operation) 
 
 
You are being invited to take part in a research study.   
Before you decide it is important for you to understand why the 
research is being done and what it will involve.   Please take time 
to read the following information carefully and discuss it with 
others if you wish.   Ask us if there is anything that is not clear or 
if you would like more information.   Take time to decide whether 
or not you wish to take part.    
 
 
What is the purpose of the study? 
 
Penile cancer is a relatively rare disease, in order to understand more about it we need 
to analyse as many samples as possible. The aim is to be able to predict the behaviour 
of the disease from looking at specimens under the microscope, this way we will be 
able to offer the right treatment to the right people. 
 
Why have I been chosen? 
 
Everyone with disease of the penis; which may be penis cancer, will be asked to take 
part. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.   If you do 
decide to take part you will be given this information sheet to 
keep and be asked to sign a consent form.  If you decide to take 
part you are still free to withdraw at any time and without giving a 
reason.   A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
 
What is involved in the study? 
 
If, as part of the treatment of your disease, you have an operation, we will want to 
study the tissue removed. 
 
 
It is important to realise that taking part in this study will not 
alter how you are treated in any way. 
 
The tests, treatments or operations and follow up visits to the hospital afterwards will 
be the same regardless of whether you take part or not. 
We will however collect data on who you are, the type of disease you have and the 
long term outcome of your disease. This will include collection of blood and urine 
samples. 
 
What are the possible benefits of taking part? 
 
There is no intended clinical benefit to you by taking part in this study, however the 
information we get from this study may help us to treat future patients with penile 
cancer better. 
 
The information held about you 
 
The study will involve holding information on your case, which will include your 
clinical details and the pathology results from the tissue analysed. UCLH will act as 
“data controller”, that is to say will collect, store, handle and process the data. The 
safety and security of the data will be the responsibility of the principal investigator, 
Mr S. Minhas, Senior Lecturer in Urology. Access to the data will be restricted to 
those directly involved in the study of penile cancer as approved by Mr S. Minhas.  
 
All information that is collected about you during the course of the 
study will be kept strictly confidential. 
 
Any information about you that leaves the hospital will have your name and address, 
date of birth and all identifiable information (including patient/hospital/NHS number) 
removed so that you cannot be recognised from it. The exception to this being that 
during the course of your treatment your GP will be informed as per normal practice 
of your progress. 
 
Tissue storage  
 
The sample donated will be considered a gift, and may be retained for future research.  
Any new research will be reviewed by a research ethics committee, but consent for 
future studies will only be required if the committee considers that the study is likely 
to substantially affect your interests.  
. 
Results of  the study 
 
You will receive the basic results of your tests (where the tissue is looked at under the 
microscope) should you wish to know them, in the same way that you normally 
would. The results from additional specialist tests on the tissue will not routinely be 
made known to you, unless there is clear evidence demonstrating its significance. 
The results will ultimately be published in a medical journal, and this is likely to be 
within the next couple of years (though of course you will not be identified in any 
report or publication). 
 
Research funding 
 
This study will be funded by a charitable organisation, called the St. Peters Urology 
Fund, and this fund will pay for including you in this study. No payment will be made 
to the doctors conducting the research for including you in this study. 
 
Withdrawal from the project 
 
Your participation in the trial is entirely voluntary.  You are free to decline to enter or 
to withdraw from the study any time without having to give a reason.   If you choose 
not to enter the trial, or to withdraw once entered, this will in no way affect your 
future medical care.  All information regarding your medical records will be treated as 
strictly confidential and will only be used for medical purposes.  Your medical 
records may be inspected by competent authorities and properly authorised persons, 
but if any information is released this will be done in a coded form so that 
confidentiality is strictly maintained.  Participation in this study will in no way affect 
your legal rights. 
 
 
Who has reviewed the study? 
 
This study has been reviewed by the Joint UCL/UCLH Committees on the ethics of 
human research which are administered by the UCLH Research & Development 
Directorate. 
 
Contact for further information  
 
If you have any further queries please contact Mr O J Kayes, Research fellow at the 
Andrology Department, The Institute of Urology and Nephrology, UCL, Middlesex 
Hospital, 48, Riding House Street, London W1W  
 
Finally, 
 
Thank-you for taking part in this study! 
 
You will be given a copy of this information sheet and a signed consent form to keep. 
 
 
 
 
PENILE CANCER PROFORMA
SITE
DATE SEEN BY
CONSULTANT
NAME
HOSPITAL NUMBER
DOB
AGE
ADDRESS
CONTACT TELEPHONE
REFERRING CENTRE
CO-MORBIDITY: RISK FACTORS: BXO □
STD □
UNCIRCUMCISED □
SMOKER □
PROFESSION:
SEXUAL ACTIVITY:
CLINICAL
Inguinal lymph nodes palpable? Y/N Site?
Please attach to patient's notes. ALL notes to be returned to St. Peters' Office Level 2  (C/o Mr Sux Minhas)
OPERATIVE HISTORY AND HISTOLOGY NAME:
BIOPSY Date Procedure
Surgeon
Centre
Complications
PRIMARY EXCISION
Date Procedure
Surgeon
Centre
Complications
RECURRENCE
Date Procedure
Surgeon
Centre
Complications
LYMPH NODES
Date: Palpable Y/N
R L NUMBER: TOTAL IP STAY:
INGUINAL PELVIC
SUPERFICIAL RADICAL COMPLICATIONS: COMMENTS:
FROZEN TIC
POSITIVE NEGATIVE DRAINS:
Date: Palpable Y/N
R L NUMBER: TOTAL IP STAY:
INGUINAL PELVIC
SUPERFICIAL RADICAL COMPLICATIONS: COMMENTS:
FROZEN TIC
POSITIVE NEGATIVE DRAINS:
Date: Palpable Y/N
R L NUMBER: TOTAL IP STAY:
INGUINAL PELVIC
SUPERFICIAL RADICAL COMPLICATIONS: COMMENTS:
FROZEN TIC
POSITIVE NEGATIVE DRAINS:
HISTOLOGY NAME:
SPECIMEN
SUBTYPE STANDARD SCC   BASALOID   VERRUCIFORM   PAPILLARY   SARCOMATOID   
GRADE 1  2   3 ▪ DIMENSIONS
STAGE X   0  1  2  3  4 ▪ DEPTH INVASION
▪ LIMITS
▪ VASCULAR INVASIONY/N
IMMUNO Y/N
NODES L R FROZEN
INGUINAL PELVIC NUMBER
SUPERFICIAL DEEP POSITIVE NEGATIVE
L R FROZEN
INGUINAL PELVIC NUMBER
SUPERFICIAL DEEP POSITIVE NEGATIVE
L R FROZEN
INGUINAL PELVIC NUMBER
SUPERFICIAL DEEP POSITIVE NEGATIVE
COMMENTS
IMAGING NAME:
MRI
DATE: PRIMARY/RECURRENCE/NODES
PGE-1 Y/N RESPONSE  
None/Poor/Good
SEQUENCE Tx - unassessable
T (Stage) X   0   1   2   3   4 T0 - no evidence of tumour
N (Nodes) X   0   1   2   3   T1 -  invades subepithelial 
connective tissue
Comments: T2 - invades corpus spongiosum
or corpus cavernosum
DATE: PRIMARY/RECURRENCE/NODES T3 - invades urethra or prostate
PGE-1 Y/N RESPONSE  T4 - invades adjacent structures
None/Poor/Good
SEQUENCE
T (Stage) X   0   1   2   3   4 Nx - unassessable
N (Nodes) X   0   1   2   3   N0 - no lymph node involvement
N1 - single inguinal lymph node
Comments: N2 - multiple or bilateral superficial
inguinal nodes
DATE: PRIMARY/RECURRENCE/NODES N3 - deep inguinal or pelvic nodes
PGE-1 Y/N RESPONSE  
None/Poor/Good
SEQUENCE
T (Stage) X   0   1   2   3   4
N (Nodes) X   0   1   2   3   
Comments:
PET Y/N Dates:
CT Y/N Dates:
USS/FNA Y/N Dates:
                PLEASE ATTACH ALL RADIOLOGY REPORTS
SENTINEL NODE NAME:
Intraoperative Counts
Injection site count :
Background count :
Residual groin post SLNB :
SN1 : Hot? : Gamma counts/sec : In Vivo :
Blue? : Strong Weak Ex Vivo :
Histology : Micromets Macromets Extracapsular Invasion
Notes : 
SN2 : Hot? : Gamma counts/sec : In Vivo :
Blue? : Strong Weak Ex Vivo :
Histology : Micromets Macromets Extracapsular Invasion
Notes :
SN3 : Hot? : Gamma counts/sec : In Vivo :
Blue? : Strong Weak Ex Vivo :
Histology : Micromets Macromets Extracapsular Invasion
Notes :
SN4 : Hot? : Gamma counts/sec : In Vivo :
Blue? : Strong Weak Ex Vivo :
Histology : Micromets Macromets Extracapsular Invasion
Notes :
SN5 : Hot? : Gamma counts/sec : Gamma counts  In Vivo :
Blue? : Strong Weak Ex Vivo :
Histology : Micromets Macromets Extracapsular Invasion
Notes :
OUTPATIENTS NAME
DATE
OUTPATIENTS NAME
DATE
OUTPATIENTS NAME
DATE
FOLLOW UP PROTOCOL
EAU follow up protocol (modified from Algaba et al 2002)
Year  1+2 
CONSERVATIVE + 
NODE SURVEILLANCE 
Year 3 
Year 4+5 
 2 monthly examination 
3 monthly examination 
6 monthly examination 
Year  1+2 
Year 3 
Year 4+5 
 4 monthly examination 
6 monthly examination 
Annual 
PARTIAL/TOTAL 
PENECTOMY or  
DNA replication licensing control and genomic instability in penile cancer Oliver Kayes  
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